• Accatino L, Figueroa C, Pizarro M, Solis N. Enhanced biliary excretion of canalicular membrane enzymes in estrogen-induced and obstructive cholestasis, and effects of different bile acids in the isolated perfused rat liver. J. Hepatol. 22: 658-670 (1995). *

• Accatino L, Pizarro M, Solis N, Koenig CS, Vollrath V, Chianale J. Modulation of hepatic content and biliary excretion of P-glycoproteins in hepatocellular and obstructive cholestasis in the rat. J. Hepatol. 25: 349-361 (1996). *

• Adachi M, Kurotani R, Morimura K, Shah Y, Sanford M, Madison BB, Gumucio DL, Marin HE, Peters JM, Young HA, Gonzalez FJ. PPARgamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 55: 1104-1113 (2006). *

• Adamopoulos AB. Inflammatory bowel disease (IBD) and the liver. Annals of Gastroenterology 19: 146-151 (2006). *

• Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW, Jeffrey GP. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin. Chem. 51: 1867-1873 (2005). *

• Adarichev VA, Vermes C, Hanyecz A, Ludanyi K, Tunyogi-Csapo M, Finnegan A, Mikecz K, Glant TT. Antigen-induced differential gene expression in lymphocytes and gene expression profile in synovium prior to the onset of arthritis. Autoimmunity 39: 663-673 (2006).

• Adjarov D, Popov S, Ivanov E. Studies on the mechanism of the changes in serum and liver gamma-glutamyl transpeptidase activity. I. Experimental extrahepatic cholestasis in rabbits. Enzyme 21: 1-7 (1976).

• Adler AI, Gunn E, Haworth CS, Bilton D. Characteristics of adults with and without cystic fibrosis-related diabetes. Diabet. Med. 24: 1143-1148 (2007). *

• Ahmad YA, Bruce IN. Genetic epidemiology: systemic lupus erythematosus. Arthritis Res. 3: 331-336 (2001). *

• Ahn KO, Lim SW, Yang HJ, Li C, Sugawara A, Ito S, Choi BS, Kim YS, Kim J, Yang CW. Induction of PPAR gamma mRNA and protein expression by rosiglitazone in chronic cyclosporine nephropathy in the rat. Yonsei. Med. J. 48: 308-316 (2007). *

• Aitola PT, Soppi ET, Halonen PJ, Laine ST, Matikainen MJ. The effect of proctocolectomy on serum antibody levels against cow's milk proteins in patients with chronic ulcerative colitis, with special reference to liver changes. Scand. J. Gastroenterol. 29: 646-650 (1994).

• Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, Glass CK, Brewer HB Jr, Gonzalez FJ. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell. Biol. 22: 2607-2619 (2002). *

• Al-Hathlol K, Al-Madani A, Al-Saif S, Abulaimoun B, Al-Tawil K, El-Demerdash A. Ursodeoxycholic acid therapy for intractable total parenteral nutrition-associated cholestasis in surgical very low birth weight infants. Singapore Med. J. 47: 147-151 (2006). *

• Alansari A, Gul A, Inanc M, Ordi J, Teh LS, Ollier WE, Gonzalez-Gay MA, Hajeer AH. Fc receptor gamma subunit polymorphisms and systemic lupus erythematosus. Saudi Med. J. 25: 1445-1448 (2004).

• Albrecht U, Yang X, Asselta R, Keitel V, Tenchini ML, Ludwig S, Heinrich PC, Haussinger D, Schaper F, Bode JG. Activation of NF-kappaB by IL-1beta blocks IL-6-induced sustained STAT3 activation and STAT3-dependent gene expression of the human gamma-fibrinogen gene. Cell. Signal. 19: 1866-1878 (2007). *

• Aldemir M, Faruk Gey I K M, Faruk Kokoglu O, Buyukbayram HI, Hosoglu SI, Yagmur Y. Effects of ursodeoxycholic acid, glutamine and polyclonal immunoglobulins on bacterial translocation in common bile duct ligated rats. ANZ J. Surg. 73: 722-726 (2003). *

• Allam G. Vasoactive intestinal peptide inhibits liver pathology in acute murine schistosomiasis mansoni and modulates IL-10, IL-12 and TNF-alpha production. Immunobiology 212: 603-612 (2007).

• Allred CD, Talbert DR, Southard RC, Wang X, Kilgore MW. PPARgamma1 as a molecular target of eicosapentaenoic acid in human colon cancer (HT-29) cells. J. Nutr. 138: 250-256 (2008). *

• Alonso EM, Snover DC, Montag A, Freese DK, Whitington PF. Histologic pathology of the liver in progressive familial intrahepatic cholestasis. J. Pediatr. Gastroenterol. Nutr. 18: 128-133 (1994).

• Alonzo ES, Gottschalk RA, Das J, Egawa T, Hobbs RM, Pandolfi PP, Pereira P, Nichols KE, Koretzky GA, Jordan MS, Sant'angelo DB. Development of promyelocytic zinc finger and ThPOK-expressing innate gammadelta T cells is controlled by strength of TCR signaling and Id3 3. J. Immunol. Dec 28 [Epub ahead of print] (2009).

• Alric L, Thebault S, Selves J, Peron JM, Mejdoubi S, Fortenfant F, Vinel JP. Characterization of overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis according to antimitochondrial antibodies status. Gastroenterol. Clin. Biol. 31: 11-16 (2007). *

• Alvarez F. Clinical and diagnostics aspects in children. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 87-88 (2004). *

• Alvaro D, Benedetti A, Marucci L, Delle Monache M, Monterubbianesi R, Di Cosimo E, Perego L, Macarri G, Glaser S, Le Sage G, Alpini G. The function of alkaline phosphatase in the liver: regulation of intrahepatic biliary epithelium secretory activities in the rat. Hepatology 32: 174-184 (2000). *

• Aman MJ, Tayebi N, Obiri NI, Puri RK, Modi WS, Leonard WJ. cDNA cloning and characterization of the human interleukin 13 receptor alpha chain. J. Biol. Chem. 271: 29265-29270 (1996). *

• Andersen S, Okkels H, Krarup H, Laurberg P. Geographical clustering and maintained health in individuals harbouring the mutation for Greenland familial cholestasis: a population-based study. Scand. J. Gastroenterol. 41: 445-450 (2006). *

• Andrade WA, Silva AM, Alves VS, Salgado AP, Melo MB, Andrade HM, Dall'orto FV, Garcia SA, Silveira TN, Gazzinelli RT. Early endosome localization and activity of RasGEF1b, a Toll-like receptor-inducible Ras guanine-nucleotide exchange factor. Genes Immun. Jan 21 [Epub ahead of print] (2010).

• Andrieu T, Thibault V, Malet I, Laporte J, Bauvois B, Agut H, Cahour A. Similar increased serum dipeptidyl peptidase IV activity in chronic hepatitis C and other viral infections. J. Clin. Virol. 27: 59-68 (2003).

• Andrulionyte L, Peltola P, Chiasson JL, Laakso M. Single nucleotide polymorphisms of PPARD in combination with the Gly482Ser substitution of PGC-1A and the Pro12Ala substitution of PPARG2 predict the conversion from impaired glucose tolerance to type 2 diabetes: the STOP-NIDDM trial. Diabetes 55: 2148-2152 (2006). *

• Anic K, Ivandic A, Peric L, Fijacko M, Volaric M, Bacun T, Kovacic D, Getto L. Isoenzymes of gammaglutamyltransferase in patients with obstructive and hepatocellular icterus. Wien. Med. Wochenschr. 149: 359-363 (1999).

• Antoniv TT, Ivashkiv LB. Dysregulation of interleukin-10-dependent gene expression in rheumatoid arthritis synovial macrophages. Arthritis Rheum. 54: 2711-2721 (2006). *

• Arai T, Michalski JP, McCombs CC, Elston RC, McCarthy CF, Stevens FM. T cell receptor gamma gene polymorphisms and class II human lymphocyte antigen genotypes in patients with celiac disease from the west of Ireland. Am. J. Med. Sci. 309: 171-178 (1995).

• Arakawa Y, Amaki S, Miyakawa H, Sakai T, Gotou I, Tanaka N, Moriyama M, Iwasaki A, Sugitani M, Arakawa Y. PBC-AIH overlap syndrome with concomitant ITP and Hashimoto's disease with positivity for anti-centromere antibody. J. Gastroenterol. 39: 490-495 (2004). *

• Arat M, Idilman R, Soydan EA, Soykan I, Erden E, Karayalcin S, Akan H. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver. Clin. Transplant. 19: 798-803 (2005). *

• Argikar UA, Senekeo-Effenberger K, Larson EE, Tukey RH, Remmel RP. Studies on induction of lamotrigine metabolism in transgenic UGT1 mice. Xenobiotica 39: 826-835 (2009).

• Argikar UA, Senekeo-Effenberger K, Larson EE, Tukey RH, Remmel RP. Studies on induction of lamotrigine metabolism in transgenic UGT1 mice. Xenobiotica Sep 29 [Epub ahead of print] (2009).

• Arrese M. Cholestasis during pregnancy: rare hepatic diseases unmasked by pregnancy. Ann. Hepatol. 5: 216-218 (2006). *

• Arrese M, Pizarro M, Solis N, Koenig C, Accatino L. Enhanced biliary excretion of canalicular membrane enzymes in ethynylestradiol-induced cholestasis. Effects of ursodeoxycholic acid administration. Biochem. Pharmacol. 50: 1223-1232 (1995).

• Arroyo M, Crawford JM. Hepatitic inherited metabolic disorders. Semin. Diagn. Pathol. 23: 182-189 (2006).

• Arslanoglu S, Moro GE, Tauschel HD, Boehm G. Ursodeoxycholic acid treatment in preterm infants: a pilot study for the prevention of cholestasis associated with total parenteral nutrition. J. Pediatr. Gastroenterol. Nutr. 46: 228-231 (2008). *

• Arundel C, Lewis JH. Drug-induced liver disease in 2006. Curr. Opin. Gastroenterol. 23: 244-254 (2007).

• Avezov SA, Mansurov FKh. Efficacy of combined administration of ursodeoxycholic acid and hepthral in the treatment of primary biliary cirrhosis. Klin. Med. (Mosk.) 82: 55-58 (2004).

• Avezov SA, Mansurova FKh. Efficacy of combined use of ursodeoxycholic acid and heptral in the treatment of primary biliary cirrhosis. Klin. Med. (Mosk.) 82: 46-49 (2004).

• Awad AS, Kamel R. Effect of rosuvastatin on cholestasis-induced hepatic injury in rat livers. J. Biochem. Mol. Toxicol. Feb 9 [Epub ahead of print] (2010). *

• Aygun C, Kocaman O, Gurbuz Y, Senturk O, Hulagu S. Clindamycin-induced acute cholestatic hepatitis. World J. Gastroenterol. 13: 5408-5410 (2007). *

• Azemoto N, Abe M, Murata Y, Hiasa Y, Hamada M, Matsuura B, Onji M. Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J. Gastroenterol. 44: 630-634 (2009). *

• Azer SA, Canfield PJ, Stacey NH. Hepatoprotection in ethinylestradiol-treated rats is provided by tauroursodeoxycholic acid, but not by ursodeoxycholic acid. J. Gastroenterol. Hepatol. 10: 261-269 (1995).

• Azzi A, Gysin R, Kempna P, Munteanu A, Negis Y, Villacorta L, Visarius T, Zingg JM. Vitamin E mediates cell signaling and regulation of gene expression. Ann. N. Y. Acad. Sci. 1031: 86-95 (2004). *

• Bachs L, Pares A, Elena M, Piera C, Rodes J. Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology 102: 2077-2080 (1992).

• Baines M. Clinical usefulness of the simultaneous localisation of the isoenzymes of alkaline phosphate and gamma-glutamyl transferase. Ann. Clin. Biochem. 17: 20-25 (1980).

• Balada E, Villarreal-Tolchinsky J, Ordi-Ros J, Labrador M, Serrano-Acedo S, Martinez-Lostao L, Vilardell-Tarres M. Multiplex family-based study in systemic lupus erythematosus: association between the R620W polymorphism of PTPN22 and the FcgammaRIIa (CD32A) R131 allele. Tissue Antigens 68: 432-438 (2006). *

• Balistreri WF. Genetic liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).

• Balistreri WF. Bile acid therapy in pediatric hepatobiliary disease: the role of ursodeoxycholic acid. J. Pediatr. Gastroenterol. Nutr. 24: 573-589 (1997). *

• Barbier O, Villeneuve L, Bocher V, Fontaine C, Torra IP, Duhem C, Kosykh V, Fruchart JC, Guillemette C, Staels B. The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J. Biol. Chem. 278: 13975-13983 (2003). *

• Barisani D, Ceroni S, Meneveri R, Cesana BM, Bardella MT. IL-10 polymorphisms are associated with early-onset celiac disease and severe mucosal damage in patients of Caucasian origin. Genet. Med. 8: 169-174 (2006).

• Barnes DS. Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm (2002). *

• Barrera G, Toaldo C, Pizzimenti S, Cerbone A, Pettazzoni P, Dianzani MU, Ferretti C. The role of PPAR ligands in controlling growth-related gene expression and their interaction with lipoperoxidation products. PPAR Res. 2008: 524671 (2008). *

• Barton CC, Ganey PE, Roth RA. Lipopolysaccharide augments aflatoxin B(1)-induced liver injury through neutrophil-dependent and -independent mechanisms. Toxicol. Sci. 58: 208-215 (2000). *

• Barton CC, Hill DA, Yee SB, Barton EX, Ganey PE, Roth RA. Bacterial lipopolysaccharide exposure augments aflatoxin B(1)-induced liver injury. Toxicol. Sci. 55: 444-452 (2000). *

• Basarir Ozkan T, Mistik R, Dikici B, Ozturk Nazlioglu H. Antiviral therapy in neonatal cholestatic cytomegalovirus hepatitis. BMC Gastroenterol. 7: 9 (2007). *

• Bastida G, Nos P, Aguas M, Beltran B, Rubin A, Dasi F, Ponce J. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 22: 775-782 (2005). *

• Batt AM, Ferrari L. Manifestations of chemically induced liver damage. Clin. Chem. 41: 1882-1887 (1995). *

• Battezzati PM, Podda M, Bianchi FB, Naccarato R, Orlandi F, Surrenti C, Pagliaro L, Manenti F. Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. Italian Multicenter Group for the Study of UDCA in PBC. J. Hepatol. 17: 332-338 (1993).

• Bauerova K, Paulovicova E, Mihalova D, Svik K, Ponist S. Study of new ways of supplementary and combinatory therapy of rheumatoid arthritis with immunomodulators. Glucomannan and Imunoglukan(R) in adjuvant arthritis. Toxicol. Ind. Health 25: 329-335 (2009).

• Bauerova K, Ponist S, Ondrejickova O, Komendova D, Mihalova D. Association between tissue gamma-glutamyl-transferase and clinical markers of adjuvant arthritis in Lewis rats. Neuro. Endocrinol. Lett. 27: S172-S175 (2006).

• Baumgart DC, Lowder JN, Targan SR, Sandborn WJ, Frankel MB. Transient cytokine-Induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am. J. Gastroenterol. 104: 868-876 (2009). *

• Beagley KW, Fujihashi K, Lagoo AS, Lagoo-Deenadaylan S, Black CA, Murray AM, Sharmanov AT, Yamamoto M, McGhee JR, Elson CO, et al. Differences in intraepithelial lymphocyte T cell subsets isolated from murine small versus large intestine. J. Immunol. 154: 5611-5619 (1995).

• Beath SV. Hepatic function and physiology in the newborn. Semin. Neonatol. 8: 337-346 (2003).

• Beau P, Labat-Labourdette J, Ingrand P, Beauchant M. Is ursodeoxycholic acid an effective therapy for total parenteral nutrition-related liver disease? J. Hepatol. 20: 240-244 (1994).

• Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 42: 44-52 (2005). *

• Begg GE, Holman SR, Stokes PH, Matthews JM, Graham RM, Iismaa SE. Mutation of a critical GTP-binding arginine in transglutaminase 2 disinhibits intracellular crosslinking activity. J. Biol. Chem. 281: 12603-12609 (2006). *

• Bell H, Tallaksen C, Sjaheim T, Weberg R, Raknerud N, Orjasaeter H, Try K, Haug E. Serum carbohydrate-deficient transferrin as a marker of alcohol consumption in patients with chronic liver diseases. Alcohol Clin. Exp. Res. 17: 246-252 (1993).

• Bellentani S, Podda M, Tiribelli C, Callea F, Marazzi M, Sodde M, Merlini R, Batezzati PM, Crosignani A, Zuin M, et al. Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial. J. Hepatol. 19: 459-464 (1993).

• Bellentani S, Tabarroni G, Barchi T, Ferretti I, Fratti N, Villa E, Manenti F. Effect of ursodeoxycholic acid treatment on alanine aminotransferase and gamma-glutamyltranspeptidase serum levels in patients with hypertransaminasemia. Results from a double-blind controlled trial. J. Hepatol. 8: 7-12 (1989).

• Bellomo-Brandao MA, Arnaut LT, Tommaso AM, Hessel G. Differential diagnosis of neonatal cholestasis: clinical and laboratory parameters. J. Pediatr. (Rio J.) 86: 40-44 (2010).

• Ben-Ari Z, Dhillon AP, Sherlock S. Autoimmune cholangiopathy: part of the spectrum of autoimmune chronic active hepatitis. Hepatology 18: 10-15 (1993).

• Ben-Ari Z, Weiss-Schmilovitz H, Sulkes J, Brown M, Bar-Nathan N, Shaharabani E, Yussim A, Shapira Z, Tur-Kaspa R, Mor E. Serum cholestasis markers as predictors of early outcome after liver transplantation. Clin. Transplant. 18: 130-136 (2004).

• Benlloch M, Ortega A, Ferrer P, Segarra R, Obrador E, Asensi M, Carretero J, Estrela JM. Acceleration of glutathione efflux and inhibition of gamma-glutamyl transpeptidase sensitize metastatic B16 melanoma cells to endothelium-induced cytotoxicity. J. Biol. Chem. 280: 6950-6959 (2005). *

• Berchtold CM, Wu ZH, Huang TT, Miyamoto S. Calcium-dependent regulation of NEMO nuclear export in response to genotoxic stimuli. Mol. Cell. Biol. 27: 497-509 (2007). *

• Bergamini G, Cigana C, Sorio C, Della Peruta M, Pompella A, Corti A, Huaux FA, Leal T, Assael BM, Melotti P. Effects of azithromycin (AZM) on glutathione-S-transferases (GST)s in cystic fibrosis airway cells. Am. J. Respir. Cell. Mol. Biol. 41: 199-206 (2009). *

• Bergeron R, Yao J, Woods JW, Zycband EI, Liu C, Li Z, Adams A, Berger JP, Zhang BB, Moller DE, Doebber TW. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in ZDF rats: a comparison to PPARgamma agonism. Endocrinology 147: 4252-4262 (2006). *

• Bertrand L, Arnefaux J. Gamma-glutamyl transpeptidase values in liver and bile duct diseases. Clinical observations and experimental trials. Ann. Med. Interne. (Paris) 124: 173-180 (1973).

• Bettinardi N, Felicetta I, Tomasi PA, Colombo C. Carbohydrate 19-9 antigen is not a marker of liver disease in patients with cystic fibrosis. Clin. Chem. Lab. Med. 41: 311-316 (2003).

• Beuers U, Spengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W, Weinzierl M, Pape GR, Sauerbruch T, Paumgartner G. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 16: 707-714 (1992).

• Bhadauria M, Nirala SK, Shrivastava S, Sharma A, Johri S, Chandan BK, Singh B, Saxena AK, Shukla S. Emodin reverses CCl(4) induced hepatic cytochrome P450 (CYP) enzymatic and ultrastructural changes: the in vivo evidence. Hepatol. Res. 39: 290-300 (2009). *

• Bhat M, Guindi M, Heathcote EJ, Hirschfield GM. Transient development of anti-mitochondrial antibodies accompanies autoimmune hepatitis-sclerosing cholangitis overlap. Gut 58: 152-153 (2009).

• Bhavsar MD, Amiji MM. Oral IL-10 gene delivery in a microsphere-based formulation for local transfection and therapeutic efficacy in inflammatory bowel disease. Gene Ther. 15: 1200-1209 (2008).

• Bidel S, Silventoinen K, Hu G, Lee DH, Kaprio J, Tuomilehto J. Coffee consumption, serum gamma-glutamyltransferase and risk of type II diabetes. Eur. J. Clin. Nutr. 62: 178-185 (2008). *

• Blumerman SL, Herzig CT, Wang F, Coussens PM, Baldwin CL. Comparison of gene expression by co-cultured WC1(+) gammadelta and CD4(+) alphabeta T cells exhibiting a recall response to bacterial antigen. Mol. Immunol. 44: 2033-2045 (2007). *

• Boelsterli UA, Rakhit G, Balazs T. Modulation by S-adenosyl-L-methionine of hepatic Na+,K+-ATPase, membrane fluidity, and bile flow in rats with ethinyl estradiol-induced cholestasis. Hepatology 3: 12-17 (1983).

• Bogdanovic M, Bulat P. Biliary function in workers occupationally exposed to aluminium dust and fumes. Arh. Hig. Rada. Toksikol. 59: 135-139 (2008).

• Bohme M, Nitz I, Doring F, Klapper M. Analysis of the transcriptional regulation of the FABP2 promoter haplotypes by PPARgamma/RXRalpha and Oct-1. Biochim. Biophys. Acta 1779: 616-621 (2008). *

• Boki KA, Dourakis SP. Polymyositis associated with primary biliary cirrhosis. Clin. Rheumatol. 14: 375-378 (1995).

• Bongartz T, Coras B, Vogt T, Scholmerich J, Muller-Ladner U. Treatment of active psoriatic arthritis with the PPARgamma ligand pioglitazone: an open-label pilot study. Rheumatology (Oxford) 44: 126-129 (2005). *

• Bonkowsky JL, Bohnsack JF, Pennington MJ, Viskochil D, Thompson JA. Leukoencephalopathy, arthritis, colitis, and hypogammaglobulinemia (LACH) in two brothers: a novel syndrome? Am. J. Med. Genet. 128A: 52-56 (2004). *

• Bosse Y, Weisnagel SJ, Bouchard C, Despres JP, Perusse L, Vohl MC. Combined effects of PPARgamma2 P12A and PPARalpha L162V polymorphisms on glucose and insulin homeostasis: the Quebec Family Study. J. Hum. Genet. 48: 614-621 (2003). *

• Bouchra A, Benbouazza K, Hajjaj-Hassouni N. Guillain-Barre in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy. Clin. Rheumatol. 28 Suppl. 1: S53-S55 (2009). *

• Bourke B, Goggin N, Walsh D, Kennedy S, Setchell KD, Drumm B. Byler-like familial cholestasis in an extended kindred. Arch. Dis. Child. 75: 223-227 (1996).

• Boyer JL. Nuclear receptor ligands: rational and effective therapy for chronic cholestatic liver disease? Gastroenterology 129: 735-740 (2005). *

• Boykinova OB, Stoilova YD, Tsvetkova TZ, Baltadjiev IG. Epidemiological, immunological and clinical characteristics of acute hepatitis C. Folia Med. (Plovdiv.) 51: 61-69 (2009).

• Boyton RJ, Reynolds C, Wahid FN, Jones MG, Ozerovitch L, Ahmad T, Chaudhry A, Jewell DP, Kon OM, Smith J, Rose M, Newman-Taylor AJ, Cole P, Wilson R, Altmann DM. IFNgamma and CXCR-1 gene polymorphisms in idiopathic bronchiectasis. Tissue Antigens 68: 325-330 (2006). *

• Braaten DC, McClellan JS, Messaoudi I, Tibbetts SA, McClellan KB, Nikolich-Zugich J, Virgin HW. Effective control of chronic gamma-herpesvirus infection by unconventional MHC class Ia-independent CD8 T cells. PLoS Pathog. 2: e37 (2006). *

• Braier J, Ciocca M, Latella A, de Davila MG, Drajer M, Imventarza O. Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell histiocytosis. Med. Pediatr. Oncol. 38: 178-182 (2002). *

• Brailski Kh, Damianov B. Primary biliary cirrhosis. Vutr. Boles. 22: 27-37 (1983).

• Brant PE, Kopke-Aguiar L, Shigueoka DC, Sales D, D'Ippolito G, Kouyoumdjian M, Borges DR. Anicteric cholangiopathy in schistosomiasis patients. Acta Trop. 108: 218-221 (2008).

• Braun A, Gessner JE, Varga-Szabo D, Syed SN, Konrad S, Stegner D, Vogtle T, Schmidt RE, Nieswandt B. STIM1 is essential for Fcgamma receptor activation and autoimmune inflammation. Blood 113: 1097-1104 (2009). *

• Breitling LP, Raum E, Muller H, Rothenbacher D, Brenner H. Synergism between smoking and alcohol consumption with respect to serum gamma-glutamyltransferase. Hepatology 49: 802-808 (2009). *

• Brites D. Intrahepatic cholestasis of pregnancy: changes in maternal-fetal bile acid balance and improvement by ursodeoxycholic acid. Ann. Hepatol. 1: 20-28 (2002). *

• Brock DJ, Clarke HA, Barron L. Prenatal diagnosis of cystic fibrosis by microvillar enzyme assay on a sequence of 258 pregnancies. Hum. Genet. 78: 271-275 (1988).

• Brockmann JG, August C, Wolters HH, Homme R, Palmes D, Baba H, Spiegel HU, Dietl KH. Sequence of reperfusion influences ischemia/reperfusion injury and primary graft function following porcine liver transplantation. Liver Transpl. 11: 1214-1222 (2005). *

• Brody F, Hill S, Celenski S, Kar R, Kluk B, Pinzone J, Fu S. Expression of ectonucleotide pyrophosphate phosphodiesterase and peroxisome proliferator activated receptor gamma in morbidly obese patients. Surg. Endosc. 21: 941-944 (2007). *

• Brohult J, Fridell E, Sundblad L. Studies on alkaline phosphatase isoenzymes. Relation to gamma-glutamyltransferase and lactate dehydrogenase isoenzymes. Clin. Chim. Acta 76: 205-211 (1977).

• Brooling JT, Campbell JS, Mitchell C, Yeoh GC, Fausto N. Differential regulation of rodent hepatocyte and oval cell proliferation by interferon gamma. Hepatology 41: 906-915 (2005). *

• Brostoff JM, Rashid S, McCrea D. Primary biliary cirrhosis with a normal alkaline phosphatase: a case report. Cases J. 1: 33 (2008). *

• Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I, Kliewer SA, Lehmann JM, Lenhard JM, Harrington WW, Novak PJ, Faison W, Binz JG, Hashim MA, Oliver WO, Brown HR, Parks DJ, Plunket KD, Tong WQ, Menius JA, Adkison K, Noble SA, Willson TM. A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. Diabetes 48: 1415-1424 (1999). *

• Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol. Rev. 214: 73-91 (2006). *

• Buckingham RE. Thiazolidinediones: pleiotropic drugs with potent anti-inflammatory properties for tissue protection. Hepatol. Res. 33: 167-170 (2005).

• Buetler TM. Identification of glutathione S-transferase isozymes and gamma-glutamylcysteine synthetase as negative acute-phase proteins in rat liver. Hepatology 28: 1551-1560 (1998). *

• Bugge A, Grontved L, Aagaard MM, Borup R, Mandrup S. The PPARgamma2 A/B-domain plays a gene specific role in transactivation and co-factor recruitment. Mol. Endocrinol. 23: 794-808 (2009). *

• Bulle F, Mavier P, Zafrani ES, Preaux AM, Lescs MC, Siegrist S, Dhumeaux D, Guellaen G. Mechanism of gamma-glutamyl transpeptidase release in serum during intrahepatic and extrahepatic cholestasis in the rat: a histochemical, biochemical and molecular approach. Hepatology 11: 545-550 (1990).

• Burlina A, Bugiardini R. Studies on alkaline phosphatase isoenzymes in hepatic diseases. Relation to gamma-glutamyltransferase. Clin. Chim. Acta 85: 49-54 (1978).

• Buscher HP, Zietzschmann Y, Gerok W. Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently to ursodeoxycholic acid alone. J. Hepatol. 18: 9-14 (1993).

• Bush CR, Havens JM, Necela BM, Su W, Chen L, Yanagisawa M, Anastasiadis PZ, Guerra R, Luxon BA, Thompson EA. Functional genomic analysis reveals crosstalk between peroxisome proliferator-activated receptor gamma (PPAR-gamma) and calcium signaling in human colorectal cancer cells. J. Biol. Chem. 282: 23387-23401 (2007). *

• Buzzetti R, Petrone A, Ribaudo MC, Alemanno I, Zavarella S, Mein CA, Maiani F, Tiberti C, Baroni MG, Vecci E, Arca M, Leonetti F, Mario UD. The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity. Eur. J. Hum. Genet. 12: 1050-1054 (2004). *

• Caballeria L, Pares A, Rodes J. Treatment of primary biliary cirrhosis. Contributions to Science 1: 79-85 (1999). *

• Cabibi D, Tarantino G, Barbaria F, Campione M, Craxi A, Di Marco V. Intrahepatic IgG/IgM plasma cells ratio helps in classifying autoimmune liver diseases. Dig. Liver Dis. Jan 6 [Epub ahead of print] (2010).

• Cabrera-Abreu JC, Green A. Gamma-glutamyltransferase: value of its measurement in paediatrics. Ann. Clin. Biochem. 39: 22-25 (2002).

• Cai Q, Du X, Zhou B, Cai C, Kermany MH, Yoo T. Induction of tolerance by oral administration of beta-tubulin in an animal model of autoimmune inner ear disease. ORL J. Otorhinolaryngol. Relat. Spec. 71: 135-141 (2009).

• Calderon B, Suri A, Pan XO, Mills JC, Unanue ER. IFN-gamma-dependent regulatory circuits in immune inflammation highlighted in diabetes. J. Immunol. 181: 6964-6974 (2008). *

• Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, Gallois Y, Ternisien C, Chevailler A, Lunel F. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42: 1373-1381 (2005). *

• Canbakan B, Akin H, Tahan G, Tarcin O, Eren F, Atug O, Tahan V, Imeryuz N, Yapicier O, Avsar E, Tozun N. The effects of pegylated interferon alpha 2b on bile-duct ligation induced liver fibrosis in rats. Ann. Hepatol. 8: 234-240 (2009).

• Cancado EL, Leitao RM, Carrilho FJ, Laudanna AA. Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of gamma-glutamyl transpeptidase. Am. J. Gastroenterol. 93: 1510-1517 (1998). *

• Castro-e-Silva Junior O, Franco CF, Souza ME, Picinato MA, Santos JS, Ceneviva R. Serum gamma-glutamyl transpeptidase in chronic extrahepatic cholestasis. Braz. J. Med. Biol. Res. 23: 515-518 (1990).

• Cavalcanti YV, Pereira VR, Reis LC, Ramos AL, Luna CF, Nascimento EJ, Lucena-Silva N. Evaluation of memory immune response to mycobacterium extract among household contact of tuberculosis cases. J. Clin. Lab. Anal. 23: 57-62 (2009). *

• Cecil JE, Watt P, Palmer CN, Hetherington M. Energy balance and food intake: the role of PPARgamma gene polymorphisms. Physiol. Behav. 88: 227-233 (2006). *

• Chamuleau RA, Diekman MJ, Bos PJ, Smitt JH, Bosma A, Schellekens PT. Reappearance of vanished bile ducts. Hepatogastroenterology 39: 523-524 (1992).

• Chaouni I, Lefranc MP, d'Angeac AD, Zanin C, Pellet F, Clot J, Combe B, Sany J, Reme T. T cell receptor gamma variable gene locus polymorphism in patients with rheumatoid arthritis. Arthritis Rheum. 35: 756-760 (1992).

• Chapman RW. The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17 (2003).

• Chaturvedi RK, Adhihetty P, Shukla S, Hennessy T, Calingasan N, Yang L, Starkov A, Kiaei M, Cannella M, Sassone J, Ciammola A, Squitieri F, Beal MF. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum. Mol. Genet. 18: 3048-3065 (2009).

• Chazouilleres O, Poupon R, Capron JP, Metman EH, Dhumeaux D, Amouretti M, Couzigou P, Labayle D, Trinchet JC. Ursodeoxycholic acid for primary sclerosing cholangitis. J. Hepatol. 11: 120-123 (1990).

• Chen HL, Chang PS, Hsu HC, Lee JH, Ni YH, Hsu HY, Jeng YM, Chang MH. Progressive familial intrahepatic cholestasis with high gamma-glutamyltranspeptidase levels in Taiwanese infants: role of MDR3 gene defect? Pediatr. Res. 50: 50-55 (2001). *

• Chen HL, Liu YJ, Su YN, Wang NY, Wu SH, Ni YH, Hsu HY, Wu TC, Chang MH. Diagnosis of BSEP/ABCB11 mutations in Asian patients with cholestasis using denaturing high performance liquid chromatography. J. Pediatr. 153: 825-832.e2 (2008). *

• Chen J, Raymond K. Treatment effect of rifampicin on cholestasis. The Internet Journal of Pharmacology Vol. 4 (http://www.ispub.com/ostia/index.php?xmlFilePath=journals/ijpharm/vol4n2/colestasis.xml) (2006). *

• Chen L, Necela BM, Su W, Yanagisawa M, Anastasiadis PZ, Fields AP, Thompson EA. Peroxisome proliferator-activated receptor-gamma promotes epithelial to mesenchymal transformation by Rho GTPase activation of ERK1/2. J. Biol. Chem. 281: 24575-24587 (2006). *

• Chen N, Bezzina R, Hinch E, Lewandowski PA, Cameron-Smith D, Mathai ML, Jois M, Sinclair AJ, Begg DP, Wark JD, Weisinger HS, Weisinger RS. Green tea, black tea, and epigallocatechin modify body composition, improve glucose tolerance, and differentially alter metabolic gene expression in rats fed a high-fat diet. Nutr. Res. 29: 784-793 (2009).

• Chen TM, Subeq YM, Lee RP, Chiou TW, Hsu BG. Single dose intravenous thioacetamide administration as a model of acute liver damage in rats. Int. J. Exp. Pathol. 89: 223-231 (2008). *

• Chen W, Gluud C. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 2: CD003626 (2003). *

• Cheng S, Afif H, Martel-Pelletier J, Benderdour M, Pelletier JP, Hilal G, Haraoui P, Raynauld JP, Choquette D, Fahmi H. Association of polymorphisms in the peroxisome proliferator-activated receptor gamma gene and osteoarthritis of the knee. Ann. Rheum. Dis. 65: 1394-1397 (2006). *

• Cheong JY, Cho SW, Chung SG, Lee JA, Yeo M, Wang HJ, Lee JE, Hahm KB, Kim JH. Genetic polymorphism of interferon-gamma, interferon-gamma receptor, and interferon regulatory factor-1 genes in patients with hepatitis B virus infection. Biochem. Genet. 44: 246-255 (2006). *

• Chicharro M, Guarner L, Vilaseca J, Planas M, Malagelada J. Does cyclosporin A worsen liver function in patients with inflammatory bowel disease and total parenteral nutrition? Rev. Esp. Enferm. Dig. 92: 68-77 (2000).

• Chida K. Histochemical and immunohistochemical study on the expression of alkaline phosphatase, gamma-glutamyl transpeptidase and alpha-fetoprotein during the process of rat hepatocyte proliferation. Kitasato Arch. Exp. Med. 63: 91-98 (1990).

• Chien RN, Sheen IS, Chen TJ, Liaw YF. A clinicopathological study in primary biliary cirrhosis. J. Formos. Med. Assoc. 91 Suppl. 2: S117-S121 (1992).

• Chira EC, McMillen TS, Wang S, Haw A 3rd, O'Brien KD, Wight TN, Chait A. Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. Atherosclerosis 195: 100-109 (2007).

• Choi J, Park JK, Lee KT, Park KK, Kim WB, Lee JH, Jung HJ, Park HJ. In vivo antihepatotoxic effects of Ligularia fischeri var. spiciformis and the identification of the active component, 3,4-dicaffeoylquinic acid. J. Med. Food 8: 348-352 (2005).

• Chu CQ, Swart D, Alcorn D, Tocker J, Elkon KB. Interferon-gamma regulates susceptibility to collagen-induced arthritis through suppression of interleukin-17. Arthritis Rheum. 56: 1145-1151 (2007). *

• Chun JN, Song IS, Kang DH, Song HJ, Kim HI, Suh JW, Lee KJ, Kim J, Kang SW. A splice variant of the C2H2-type zinc finger protein, ZNF268s, regulates NF-kappaB activation by TNF-alpha. Mol. Cells 26: 175-180 (2008).

• Cicero AF, Derosa G, Miconi A, Laghi L, Nascetti S, Gaddi A. Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates. Biomed. Pharmacother. 59: 312-317 (2005).

• Cindoruk M, Kerem M, Karakan T, Salman B, Akin O, Alper M, Erdem O, Unal S. Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study. BMC Gastroenterol. 7: 44 (2007). *

• Claessen H, Brenner H, Drath C, Arndt V. Gamma-glutamyltransferase and disability pension: a cohort study of construction workers in Germany. Hepatology 51: 482-490 (2010).

• Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, Padula SJ. The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J. Immunol. 164: 1364-1371 (2000). *

• Clayton PT, Mills KA, Johnson AW, Barabino A, Marazzi MG. Delta 4-3-oxosteroid 5 beta-reductase deficiency: failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid. Gut 38: 623-628 (1996). *

• Coban S, Yildiz F, Terzi A, Al B, Aksoy N, Bitiren M, Celik H. The effects of Nigella sativa on bile duct ligation induced-liver injury in rats. Cell. Biochem. Funct. 28: 83-88 (2009). *

• Colina F, Pinedo F, Solis JA, Moreno D, Nevado M. Nodular regenerative hyperplasia of the liver in early histological stages of primary biliary cirrhosis. Gastroenterology 102: 1319-1324 (1992).

• Colombo C, Battezzati PM, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis. Hepatology 23: 1484-1490 (1996). *

• Colombo C, Okolicsanyi L, Strazzabosco M. Advances in familial and congenital cholestatic diseases. Clinical and diagnostic implications. Dig. Liver Dis. 32: 152-159 (2000).

• Colombo C, Setchell KD, Podda M, Crosignani A, Roda A, Curcio L, Ronchi M, Giunta A. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J. Pediatr. 117: 482-489 (1990).

• Cone RE, Li X, Sharafieh R, O'Rourke J, Vella AT. The suppression of delayed-type hypersensitivity by CD8 regulatory T cells requires interferon-gamma. Immunology 120: 112-119 (2007). *

• Connolly AK, Price SC, Connelly JC, Hinton RH. Early changes in bile duct lining cells and hepatocytes in rats treated with alpha-naphthylisothiocyanate. Toxicol. Appl. Pharmacol. 93: 208-219 (1988).

• Cornelis T, Claes K, Gillard P, Nijs E, Roskams T, Lombaerts R, Nevens F, Cassiman D. Cholestatic liver disease in long-term infantile nephropathic cystinosis. J. Gastroenterol. Hepatol. 23: e428-e431 (2008). *

• Courtois G, Israel A. Human pathologies associated with NF-kappaB defects. J. Soc. Biol. 198: 93-96 (2004).

• Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 27: 580-583 (1998). *

• Crippa G, Cagnoni C, Castelli A, Concesi C, Girometta S, Pancotti D, Sverzellati E, Tacchini G, Pierfranceschi MG, Carrara GC. Prolonged treatment with ursodeoxycholic acid for primary biliary cirrhosis. Clin. Ter. 146: 367-372 (1995).

• Cuevas MJ, Almar M, Gonzalez-Gallego J. Effects of epomediol on ethinyloestradiol-induced changes in glutathione homeostasis in the rat. Pharmacol. Toxicol. 90: 121-126 (2002). *

• Cui R, He J, Zhang F, Wang B, Ding H, Shen H, Li Y, Chen X. Diagnostic value of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary to alpha-fetoprotein. Br. J. Cancer 88: 1878-1882 (2003). *

• Cui Y, Kang L, Cui L, He W. Human gamma/delta T cell recognition of lipid A is predominately presented by CD1b or CD1c on dendritic cells. Biol. Direct 4: 47 (2009). *

• Culafic D, Perisic M, Boricic I, Culafic-Vojinovic V, Vukcevic M. Primary amyloidosis presenting with cholestasis and hyperkinetic portal hypertension. J. Gastrointestin. Liver Dis. 16: 201-204 (2007). *

• Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective? J. Hepatol. 48: 792-800 (2008). *

• Cutillo L, Najimi M, Smets F, Janssen M, Reding R, de Goyet Jde V, Sokal EM. Safety of living-related liver transplantation for progressive familial intrahepatic cholestasis. Pediatr. Transplant. 10: 570-574 (2006). *

• Czaja AJ. Autoimmune hepatitis - approach to diagnosis. MedGenMed. 8: 55 (2006). *

• Dahlgren J, Takhar H, Anderson-Mahoney P, Kotlerman J, Tarr J, Warshaw R. Cluster of systemic lupus erythematosus (SLE) associated with an oil field waste site: a cross sectional study. Environ. Health 6: 8 (2007). *

• Dai W, Gupta SL. Regulation of indoleamine 2,3-dioxygenase gene expression in human fibroblasts by interferon-gamma. Upstream control region discriminates between interferon-gamma and interferon-alpha. J. Biol. Chem. 265: 19871-19877 (1990). *

• Dai Y, Liang YH, Xie PY, Chen BW, Liu XG. Clinical analysis of primary biliary cirrhosis: a report of 42 cases. Beijing Da Xue Xue Bao 37: 410-414 (2005).

• Dann AT, Kenyon AP, Seed PT, Poston L, Shennan AH, Tribe RM. Glutathione S-transferase and liver function in intrahepatic cholestasis of pregnancy and pruritus gravidarum. Hepatology 40: 1406-1414 (2004). *

• Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Barbasso Helmers S, Elvin K, Crow MK, Nennesmo I, Lundberg IE. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann. Rheum. Dis. 67: 1670-1677 (2008).

• Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J. Pediatr. Gastroenterol. Nutr. 47: 61-67 (2008). *

• Davies YK, Cox KM, Abdullah BA, Terry AB, Cox KL. Oral vancomycin: treatment of primary sclerosing cholangitis in children. J. Pediatr. Gastroenterol. Nutr. 37: 345-346 (2003). *

• Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J. Rare Dis. 4: 1 (2009). *

• Day AP, Feher MD, Chopra R, Mayne PD. The effect of bezafibrate treatment on serum alkaline phosphatase isoenzyme activities. Metabolism 42: 839-842 (1993).

• Day C, Patel R, Guillen C, Wardlaw AJ. The chemokine CXCL16 is highly and constitutively expressed by human bronchial epithelial cells. Exp. Lung Res. 35: 272-283 (2009).

• De Broe ME, Borgers M, Wieme RJ. The separation and characterization of liver plasma membrane fragments circulating in the blood of patients with cholestasis. Clin. Chim. Acta 59: 369-372 (1975).

• De Hertogh G, Geboes K. Crohn's disease and infections: a complex relationship. MedGenMed. 6: 14 (2004). *

• de J Ribeiro P, Narciso JL, de Toledo CF, Borges DR. gamma-Glutamyltransferase decreases in patients with the chronic form of Schistosomiasis mansoni treated with ursodeoxycholic acid. J. Clin. Pathol. 58: 783-784 (2005). *

• de Kort S, Hokken-Koelega A. The PPAR-gamma Pro12Ala polymorphism associates with weight gain during GH-treatment in short children born small for gestational age. Eur. J. Endocrinol. 162: 49-52 (2010).

• de Oliveira CP, Stefano JT, de Siqueira ER, Silva LS, de Campos Mazo DF, Lima VM, Furuya CK, Mello ES, Souza FG, Rabello F, Santos TE, Nogueira MA, Caldwell SH, Alves VA, Carrilho FJ. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol. Res. 38: 159-165 (2008). *

• de Oliveira e Silva A, dos Santos TE, Cardoso ES, de Melo CR, Santo GC, dos Santos Junior ED, Cavichio MW, Kuramochi CA, Mattar RH, Teixeira AC, Leite CJ, D'Albuquerque LA. Primary sclerosing cholangitis in children and adolescents. Arq. Gastroenterol. 35: 267-273 (1998).

• de Oliveira Silva-Junior G, da Silva Torres T, de Souza Mendonca L, Alberto Mandarim-de-Lacerda C. Rosiglitazone (peroxisome proliferator-activated receptor-gamma) counters hypertension and adverse cardiac and vascular remodeling in 2K1C hypertensive rats. Exp. Toxicol. Pathol. Sep 21 [Epub ahead of print] (2009). *

• de Vree JM, Jacquemin E, Sturm E, Cresteil D, Bosma PJ, Aten J, Deleuze JF, Desrochers M, Burdelski M, Bernard O, Oude Elferink RP, Hadchouel M. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc. Natl. Acad. Sci. U.S.A. 95: 282-287 (1998). *

• Debray D, Pariente D, Urvoas E, Hadchouel M, Bernard O. Sclerosing cholangitis in children. J. Pediatr. 124: 49-56 (1994).

• Degiorgio D, Colombo C, Seia M, Porcaro L, Costantino L, Zazzeron L, Bordo D, Coviello DA. Molecular characterization and structural implications of 25 new ABCB4 mutations in progressive familial intrahepatic cholestasis type 3 (PFIC3). Eur. J. Hum. Genet. 15: 1230-1238 (2007). *

• Deleuze JF, Jacquemin E, Dubuisson C, Cresteil D, Dumont M, Erlinger S, Bernard O, Hadchouel M. Defect of multidrug-resistance 3 gene expression in a subtype of progressive familial intrahepatic cholestasis. Hepatology 23: 904-908 (1996). *

• Demirag MD, Onen HI, Karaoguz MY, Dogan I, Karakan T, Ekmekci A, Guz G. Apolipoprotein E gene polymorphism in nonalcoholic fatty liver disease. Dig. Dis. Sci. 52: 3399-3403 (2007). *

• Demirbilek S, Tas E, Gurunluoglu K, Akin M, Aksoy RT, Emre MH, Aydin NE, Ay S, Ozatay N. Fluvastatin reduced liver injury in rat model of extrahepatic cholestasis. Pediatr. Surg. Int. 23: 155-162 (2007). *

• Deng T, Shan S, Li ZB, Wu ZW, Liao CZ, Ko B, Lu XP, Cheng J, Ning ZQ. A new retinoid-like compound that activates peroxisome proliferator-activated receptors and lowers blood glucose in diabetic mice. Biol. Pharm. Bull. 28: 1192-1196 (2005). *

• Dervieux T, Wessels JA, van der Straaten T, Penrod N, Moore JH, Guchelaar HJ, Kremer JM. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. Pharmacogenet. Genomics Oct 24 [Epub ahead of print] (2009).

• Desmond CP, Wilson J, Bailey M, Clark D, Roberts SK. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid. Liver Int. 27: 1402-1408 (2007). *

• Desvergne B, IJpenberg A, Devchand PR, Wahli W. The peroxisome proliferator-activated receptors at the cross-road of diet and hormonal signalling. J. Steroid Biochem. Mol. Biol. 65: 65-74 (1998).

• Devaraj S, Leonard S, Traber MG, Jialal I. Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. Free Radic. Biol. Med. 44: 1203-1208 (2008).

• Diaferia A, Nicastri PL, Tartagni M, Loizzi P, Iacovizzi C, Di Leo A. Ursodeoxycholic acid therapy in pregnant women with cholestasis. Int. J. Gynaecol. Obstet. 52: 133-140 (1996).

• Dietrich M, Do TA, Schmid RD, Pleiss J, Urlacher VB. Altering the regioselectivity of the subterminal fatty acid hydroxylase P450 BM-3 towards gamma- and delta-positions. J. Biotechnol. 139: 115-117 (2009). *

• Diks SH, Kok K, O'Toole T, Hommes DW, Van Dijken P, Joore J, Peppelenbosch MP. Kinome profiling for studying lipopolysaccharide signal transduction in human peripheral blood mononuclear cells. J. Biol. Chem. 279: 49206-49213 (2004). *

• Ding SY, Tigno XT, Braileanu GT, Ito K, Hansen BC. A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist ameliorates dyslipidemia and insulin resistance in prediabetic rhesus monkeys. Metabolism 56: 1334-1339 (2007). *

• Ding X, Lichti K, Kim I, Gonzalez FJ, Staudinger JL. Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha. J. Biol. Chem. 281: 26540-26551 (2006). *

• Ding Y, Zhao L, Mei H, Huang ZH, Zhang SL. Alterations of biliary biochemical constituents and cytokines in infantile hepatitis syndrome. World J. Gastroenterol. 12: 7038-7041 (2006). *

• Ding Y, Zhao L, Mei H, Zhang SL, Huang ZH, Duan YY, Ye P. Exploration of Emodin to treat alpha-naphthylisothiocyanate-induced cholestatic hepatitis via anti-inflammatory pathway. Eur. J. Pharmacol. 590: 377-386 (2008).

• Dinler G, Kocak N, Ozen H, Yuce A, Gurakan F. Ursodeoxycholic acid treatment in children with Byler disease. Pediatr. Int. 41: 662-665 (1999).

• Dinler G, Kocak N, Yuce A, Gurakan F, Ozen H. Ursodeoxycholic acid therapy in children with cholestatic liver disease. Turk. J. Pediatr. 41: 91-98 (1999).

• Dirix CE, Kester AD, Hornstra G. Associations between term birth dimensions and prenatal exposure to essential and trans fatty acids. Early Hum. Dev. 85: 525-530 (2009).

• Dixon PH, Weerasekera N, Linton KJ, Donaldson O, Chambers J, Egginton E, Weaver J, Nelson-Piercy C, de Swiet M, Warnes G, Elias E, Higgins CF, Johnston DG, McCarthy MI, Williamson C. Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum. Mol. Genet. 9: 1209-1217 (2000). *

• Dong C, He L, Li J, Ye F, He M, Wang Y. Association of the Pro12Ala and C1431T polymorphism of the PPAR gamma2 gene and their haplotypes with obesity and type 2 diabetes. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 25: 447-451 (2008).

• Dongxia L, Qi H, Lisong L, Jincheng G. Association of peroxisome proliferator-activated receptor-gamma gene Pro12Ala and C161T polymorphisms with metabolic syndrome. Circ. J. 72: 551-557 (2008). *

• Doodes PD, Cao Y, Hamel KM, Wang Y, Rodeghero RL, Mikecz K, Glant TT, Iwakura Y, Finnegan A. IFN-gamma regulates the requirement for IL-17 in proteoglycan-induced arthritis. J. Immunol. Dec 18 [Epub ahead of print] (2009).

• Drivdal M, Trydal T, Hagve TA, Bergstad I, Aagenaes O. Prognosis, with evaluation of general biochemistry, of liver disease in lymphoedema cholestasis syndrome 1 (LCS1/Aagenaes syndrome). Scand. J. Gastroenterol. 41: 465-471 (2006). *

• Du MX, Sotero-Esteva WD, Taylor MW. Analysis of transcription factors regulating induction of indoleamine 2,3-dioxygenase by IFN-gamma. J. Interferon Cytokine Res. 20: 133-142 (2000).

• Dubeykovskiy A, McWhinney C, Robishaw JD. Runx-dependent regulation of G-protein gamma3 expression in T-cells. Cell. Immunol. 240: 86-95 (2006). *

• Dubner SE, Shults J, Baldassano RN, Zemel BS, Thayu M, Burnham JM, Herskovitz RM, Howard KM, Leonard MB. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease. Gastroenterology 136: 123-130 (2009). *

• Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. II. Recommendations for use of laboratory tests in screening, diagnosis, and monitoring. Clin. Chem. 46: 2050-2068 (2000). *

• Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin. Chem. 46: 2027-2049 (2000). *

• Dumasia R, Eagle KA, Kline-Rogers E, May N, Cho L, Mukherjee D. Role of PPAR- gamma agonist thiazolidinediones in treatment of pre-diabetic and diabetic individuals: a cardiovascular perspective. Curr. Drug Targets Cardiovasc. Haemato. Disord. 5: 377-386 (2005).

• Dunn W, Angulo P, Sanderson S, Jamil LH, Stadheim L, Rosen C, Malinchoc M, Kamath PS, Shah VH. Utility of a new model to diagnose an alcohol basis for steatohepatitis. Gastroenterology 131: 1057-1063 (2006). *

• Durazzo M, Niro G, Premoli A, Morello E, Rizzotto ER, Gambino R, Bo S, Musso G, Cassader M, Pagano G, Floreani A. Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression? J. Gastroenterol. 44: 476-482 (2009). *

• Eastham LL, Mills CN, Niles RM. PPARalpha/gamma expression and activity in mouse and human melanocytes and melanoma cells. Pharm. Res. 25: 1327-1333 (2008). *

• Ebbeson RL, Schreiber RA. Diagnosing autoimmune hepatitis in children: is the International Autoimmune Hepatitis Group scoring system useful? Clin. Gastroenterol. Hepatol. 2: 935-940 (2004). *

• Ebert EC, Groh V. Dissection of spontaneous cytotoxicity by human intestinal intraepithelial lymphocytes: MIC on colon cancer triggers NKG2D-mediated lysis through Fas ligand. Immunology 124: 33-41 (2008). *

• Eisenbach C, Goeggelmann C, Flechtenmacher C, Stremmel W, Encke J. Severe cholestatic hepatitis caused by azathioprine. Immunopharmacol. Immunotoxicol. 27: 77-83 (2005).

• Ekong UD, Melin-Aldana H, Seshadri R, Lokar J, Harris D, Whitington PF, Alonso EM. Graft histology characteristics in long-term survivors of pediatric liver transplantation. Liver Transpl. 14: 1582-1587 (2008). *

• El-Beshbishy HA. Aqueous garlic extract attenuates hepatitis and oxidative stress induced by galactosamine/lipoploysaccharide in rats. Phytother. Res. 22: 1372-1379 (2008).

• El-Karaksy HM, El-Koofy NM, Okasha H, Kamal NM, Naga M. A comparative study of endoscopic ultrasonography versus endoscopic retrograde cholangiopancreatography in children with chronic liver disease. Indian J. Med. Sci. 62: 345-353 (2008). *

• Elisaf M. Effects of fibrates on serum metabolic parameters. Curr. Med. Res. Opin. 18: 269-276 (2002).

• Ellis G, Worthy E, Goldberg DM. Lack of value of serum gamma-glutamyl transferase in the diagnosis of hepatobiliary disease. Clin. Biochem. 12: 142-145 (1979).

• Elsurer R, Tatar G, Simsek H, Balaban YH, Aydinli M, Sokmensuer C. Celiac disease in the Turkish population. Dig. Dis. Sci. 50: 136-142 (2005). *

• Enjoji M, Yada R, Fujino T, Yoshimoto T, Yada M, Harada N, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nakashima M, Kotoh K, Nakamuta M. The state of cholesterol metabolism in the liver of patients with primary biliary cirrhosis: the role of MDR3 expression. Hepatol. Int. Jun 16 [Epub ahead of print] (2009). *

• Ereqat S, Nasereddin A, Azmi K, Abdeen Z, Amin R. Impact of the Pro12Ala polymorphism of the PPAR-gamma 2 gene on metabolic and clinical characteristics in the Palestinian type 2 diabetic patients. PPAR Res. 2009: 874126 (2009). *

• Erickson RP, Bhattacharyya A, Hunter RJ, Heidenreich RA, Cherrington NJ. Liver disease with altered bile acid transport in Niemann-Pick C mice on a high fat, 1% cholesterol diet. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G300-G307 (2005). *

• Ersoz G, Gunsar F, Karasu Z, Akay S, Batur Y, Akarca US. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment. Turk. J. Gastroenterol. 16: 124-128 (2005). *

• European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. J. Hepatol. 51: 237-267 (2009). *

• Ewald N, Marzeion AM, Bretzel RG, Kloer HU, Hardt PD. Endoscopic sphincterotomy in patients with stenosis of ampulla of Vater: three-year follow-up of exocrine pancreatic function and clinical symptoms. World J. Gastroenterol. 13: 901-905 (2007). *

• Eyre-Walker A, Woolfit M, Phelps T. The distribution of fitness effects of new deleterious amino acid mutations in humans. Genetics 173: 891-900 (2006). *

• Fae KC, da Silva DD, Oshiro SE, Tanaka AC, Pomerantzeff PM, Douay C, Charron D, Toubert A, Cunningham MW, Kalil J, Guilherme L. Mimicry in recognition of cardiac myosin peptides by heart-intralesional T cell clones from rheumatic heart disease. J. Immunol. 176: 5662-5670 (2006). *

• Fagerberg B, Schuster H, Birketvedt GS, Tonstad S, Ohman KP, Gause-Nilsson I; On Behalf Of The Sir Study Group. Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARa/g agonist, tesaglitazar. Diab. Vasc. Dis. Res. 4: 174-180 (2007).

• Fagundes ED, Roquete ML, Penna FJ, Reis FJ, Duque CG. Diagnostic screening of liver disease in cystic fibrosis. J. Pediatr. (Rio J.) 78: 389-396 (2002).

• Falasca K, Ucciferri C, Mancino P, Vitacolonna E, De Tullio D, Pizzigallo E, Conti P, Vecchiet J. Treatment with silybin-vitamin E-phospholipid complex in patients with hepatitis C infection. J. Med. Virol. 80: 1900-1906 (2008).

• Farkkila M, Karvonen AL, Nurmi H, Nuutinen H, Taavitsainen M, Pikkarainen P, Karkkainen P. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 40: 1379-1386 (2004). *

• Farver DK, Lavin MN. Quinine-induced hepatotoxicity. Ann. Pharmacother. 33: 32-34 (1999).

• Faust D, Akoglu B, Ristic G, Milovic V. Ursodeoxycholic acid for treatment of cholestasis in patients with hepatic amyloidosis. Vojnosanit. Pregl. 66: 482-486 (2009).

• Fazle Akbar SM, Furukawa S, Nakanishi S, Abe M, Horiike N, Onji M. Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis. J. Gastroenterol. 40: 157-163 (2005). *

• Feigelson J, Anagnostopoulos C, Poquet M, Pecau Y, Munck A, Navarro J. Liver cirrhosis in cystic fibrosis - therapeutic implications and long term follow up. Arch. Dis. Child. 68: 653-657 (1993).

• Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 38: 210-217 (2003). *

• Feng CG, Zheng L, Jankovic D, Báfica A, Cannons JL, Watford WT, Chaussabel D, Hieny S, Caspar P, Schwartzberg PL, Lenardo MJ, Sher A. The immunity-related GTPase Irgm1 promotes the expansion of activated CD4(+) T cell populations by preventing interferon-gamma-induced cell death. Nat. Immunol. 9: 1279-1287 (2008). *

• Ferenci P, Dragosics B, Pesendorfer FX, Schubert H. Gamma-glutamyl-transpeptidase in alcoholic liver diseases. Acta Med. Austriaca 3: 50-54 (1976).

• Fernandez-Martinez E, Perez-Hernandez N, Muriel P, Perez-Alvarez V, Shibayama M, Tsutsumi V. The thalidomide analog 3-phthalimido-3-(3,4-dimethoxyphenyl)-propanoic acid improves the biliary cirrhosis in the rat. Exp. Toxicol. Pathol. 61: 471-479 (2009). *

• Ferrari R, Pappas G, Agostinelli D, Muratori P, Muratori L, Lenzi M, Verucchi G, Cassani F, Chiodo F, Bianchi FB. Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type. QJM 97: 407-412 (2004). *

• Fesinmeyer MD, Stanford JL, Brentnall TA, Mandelson MT, Farin FM, Srinouanprachanh S, Afsharinejad Z, Goodman GE, Barnett MJ, Austin MA. Association between the peroxisome proliferator-activated receptor gamma Pro12Ala variant and haplotype and pancreatic cancer in a high-risk cohort of smokers: a pilot study. Pancreas 38: 631-637 (2009).

• Filipe-Santos O, Bustamante J, Chapgier A, Vogt G, de Beaucoudrey L, Feinberg J, Jouanguy E, Boisson-Dupuis S, Fieschi C, Picard C, Casanova JL. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin. Immunol. 18: 347-361 (2006). *

• Filipovic B, Opric M, Milicic A, Paranos S. Primary biliary cirrhosis. Srp. Arh. Celok. Lek. 130: 213-216 (2002).

• Finck BN, Kelly DP. Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) regulatory cascade in cardiac physiology and disease. Circulation 115: 2540-2548 (2007). *

• Fisher L, Byrnes E, Fisher AA. Prevalence of vitamin K and vitamin D deficiency in patients with hepatobiliary and pancreatic disorders. Nutr. Res. 29: 676-683 (2009). *

• Floreani A, Baragiotta A, Leone MG, Baldo V, Naccarato R. Primary biliary cirrhosis and hepatitis C virus infection. Am. J. Gastroenterol. 98: 2757-2762 (2003). *

• Floreani A, Baragiotta A, Martines D, Naccarato R, D'odorico A. Plasma antioxidant levels in chronic cholestatic liver diseases. Aliment. Pharmacol. Ther. 14: 353-358 (2000). *

• Floreani A, Carderi I, Paternoster D, Soardo G, Azzaroli F, Esposito W, Montagnani M, Marchesoni D, Variola A, Rosa Rizzotto E, Braghin C, Mazzella G. Hepatobiliary phospholipid transporter ABCB4, MDR3 gene variants in a large cohort of Italian women with intrahepatic cholestasis of pregnancy. Dig. Liver Dis. 40: 366-370 (2008).

• Floreani A, Niro G, Rosa Rizzotto E, Antoniazzi S, Ferrara F, Carderi I, Baldo V, Premoli A, Olivero F, Morello E, Durazzo M. Type I autoimmune hepatitis: clinical course and outcome in an Italian multicentre study. Aliment. Pharmacol. Ther. 24: 1051-1057 (2006).

• Floreani A, Variola A, Niro G, Premoli A, Baldo V, Gambino R, Musso G, Cassader M, Bo S, Ferrara F, Caroli D, Rizzotto ER, Durazzo M. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am. J. Gastroenterol. 103: 1959-1965 (2008). *

• Floyd ZE, Wang ZQ, Kilroy G, Cefalu WT. Modulation of peroxisome proliferator-activated receptor gamma stability and transcriptional activity in adipocytes by resveratrol. Metabolism 57: S32-S38 (2008). *

• Foley KF, Pantano C, Ciolino A, Mawe GM. IFN-gamma and TNF-alpha decrease serotonin transporter function and expression in intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G779-G784 (2007). *

• Forlani G, Di Bonito P, Mannucci E, Capaldo B, Genovese S, Orrasch M, Scaldaferri L, Di Bartolo P, Melandri P, Dei Cas A, Zavaroni I, Marchesini G. Prevalence of elevated liver enzymes in type 2 diabetes mellitus and its association with the metabolic syndrome. J. Endocrinol. Invest. 31: 146-152 (2008).

• Fraser A, Ebrahim S, Davey Smith G, Lawlor DA. A comparison of associations of alanine aminotransferase and gamma-glutamyltransferase with fasting glucose, fasting insulin, and glycated hemoglobin in women with and without diabetes. Hepatology 46: 158-165 (2007). *

• Fraser A, Thinggaard M, Christensen K, Lawlor DA. Alanine aminotransferase, gamma-glutamyltransferase (GGT) and all-cause mortality: results from a population-based Danish twins study alanine aminotransferase, GGT and mortality in elderly twins. Liver Int. 29: 1494-1499 (2009). *

• Frezza EE, Gerunda GE, Plebani M, Galligioni A, Giacomini A, Neri D, Faccioli AM, Tiribelli C. Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rat. Dig. Dis. Sci. 38: 1291-1296 (1993).

• Frezza M. A meta-analysis of therapeutic trials with ademetionine in the treatment of intrahepatic cholestasis. Ann. Ital. Med. Int. 8 Suppl.: 48S-51S (1993).

• Fried RH, Murakami CS, Fisher LD, Willson RA, Sullivan KM, McDonald GB. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann. Intern. Med. 116: 624-629 (1992).

• Fukuo Y, Kitami T, Nomoto T, Terashi A. A lipid lowering drug (bezafibrate) has a favorable effect on liver enzymes (Al-P and gamma-GTP). Nippon Ika Daigaku Zasshi 63: 424-430 (1996).

• Fuleihan RL. The hyper IgM syndrome. Curr. Allergy Asthma Rep. 1: 445-450 (2001).

• Futter M, Diekmann H, Schoenmakers E, Sadiq O, Chatterjee K, Rubinsztein DC. Wild-type but not mutant huntingtin modulates the transcriptional activity of liver X receptors. J. Med. Genet. 46: 438-446 (2009). *

• Galan AI, Munoz ME, Jimenez R. S-Adenosylmethionine protects against cyclosporin A-induced alterations in rat liver plasma membrane fluidity and functions. J. Pharmacol. Exp. Ther. 290: 774-781 (1999). *

• Galimberti D, Scalabrini D, Fenoglio C, Comi C, De Riz M, Venturelli E, Lovati C, Mariani C, Monaco F, Bresolin N, Scarpini E. CXCL10 haplotypes and multiple sclerosis: association and correlation with clinical course. Eur. J. Neurol. 14: 162-167 (2007).

• Galle PR, Theilmann L, Raedsch R, Otto G, Stiehl A. Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes. Hepatology 12: 486-491 (1990).

• Gao N, Qiao HL, Jia LJ, Tian X, Zhang YW. Relationships between specific serum IgE, IgG, IFN-gamma level and IFN-gamma, IFNR1 polymorphisms in patients with penicillin allergy. Eur. J. Clin. Pharmacol. 64: 971-977 (2008). *

• Gao QJ, Liu DW, Zhang SY, Jia M, Wang LM, Wu LH, Wang SY, Tong LX. Polymorphisms of some cytokines and chronic hepatitis B and C virus infection. World J. Gastroenterol. 15: 5610-5619 (2009). *

• Garcia-Dominguez J, Aller MA, Garcia C, de Vicente F, Corcuera MT, Gomez-Aguado F, Alonso MJ, Vara E, Arias J. Splanchnic Th(2) and Th(1) cytokine redistribution in microsurgical cholestatic rats. J. Surg. Res. Nov 11 [Epub ahead of print] (2009). *

• Garzon L, Ledo A, Cubells E, Saenz P, Vento M. Cholestasis associated with prolonged parenteral nutrition in neonates: the role of ursodeoxycholic acid. An. Pediatr. (Barc.) 70: 547-552 (2009).

• Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J, Brouns G, Schmidt M, Von Kalle C, Barington T, Jakobsen MA, Christensen HO, Al Ghonaium A, White HN, Smith JL, Levinsky RJ, Ali RR, Kinnon C, Thrasher AJ. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 364: 2181-2187 (2004). *

• Gatmaitan ZC, Nies AT, Arias IM. Regulation and translocation of ATP-dependent apical membrane proteins in rat liver. Am. J. Physiol. 272: G1041-G1049 (1997).

• Gauthier-Villars M, Franchi S, Gauthier F, Fabre M, Pariente D, Bernard O. Cholestasis in children with portal vein obstruction. J. Pediatr. 146: 568-573 (2005). *

• Gayathri SB, Radha V, Vimaleswaran KS, Mohan V. Association of the PPARGC1A gene polymorphism with diabetic nephropathy in an Asian Indian population (CURES-41). Metab. Syndr. Relat. Disord. Nov 9 [Epub ahead of print] (2009).

• Gentile V, Cooper AJ. Transglutaminases - possible drug targets in human diseases. Curr. Drug Target CNS Neurol. Disord. 3: 99-104 (2004).

• Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J. Gastrointestin. Liver Dis. 16: 39-46 (2007). *

• Geuken E, Visser D, Kuipers F, Blokzijl H, Leuvenink HG, de Jong KP, Peeters PM, Jansen PL, Slooff MJ, Gouw AS, Porte RJ. Rapid increase of bile salt secretion is associated with bile duct injury after human liver transplantation. J. Hepatol. 41: 1017-1025 (2004). *

• Gheorghe L, Iacob S, Bolog N, Stoicescu A, Parvulescu I, Popescu I. Overlap syndrome between autoimmune hepatitis and primary biliary cirrhosis complicated by hepatocellular carcinoma. Case report. Rom. J. Gastroenterol. 13: 33-38 (2004).

• Giannini E, Borro P, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Risso D, Lantieri PB, Antonucci A, Boccato M, Milone S, Testa R. Cholestasis is the main determinant of abnormal CA 19-9 levels in patients with liver cirrhosis. Int. J. Biol. Markers 15: 226-230 (2000).

• Gibson PR. Increased gut permeability in Crohn's disease: is TNF the link? Gut 53: 1724-1725 (2004). *

• Gidwani P, Segal E, Shanske A, Driscoll C. Chorea associated with antiphospholipid antibodies in a patient with Kabuki syndrome. Am. J. Med. Genet. A. 143: 1338-1341 (2007).

• Gilger MA, Gann ME, Opekun AR, Gleason WA Jr. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children. J. Pediatr. Gastroenterol. Nutr. 31: 136-141 (2000). *

• Gindro T, Arrigoni A, Martinasso G, Rosina F, Perardi S, Cappello N, Benedetti P, Actis GC, Verme G, Rizzetto M. Monoethyl glycine xylidide (MEGX) test evaluation in primary biliary cirrhosis: comparison with Mayo score. Eur. J. Gastroenterol. Hepatol. 9: 1155-1159 (1997).

• Gisbert JP, Luna M, Gonzalez-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Mate J. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm. Bowel Dis. 13: 1106-1114 (2007). *

• Gizard F, Bruemmer D. Transcriptional control of vascular smooth muscle cell proliferation by peroxisome proliferator-activated receptor-gamma: therapeutic implications for cardiovascular diseases. PPAR Res. 2008: 429123 (2008). *

• Glas J, Torok HP, Tonenchi L, Kapser J, Schiemann U, Muller-Myhsok B, Folwaczny M, Folwaczny C. Association of polymorphisms in the interleukin-18 gene in patients with Crohn's disease depending on the CARD15/NOD2 genotype. Inflamm. Bowel Dis. 11: 1031-1037 (2005). *

• Godsland IF, Johnston DG. Co-associations between insulin sensitivity and measures of liver function, subclinical inflammation, and hematology. Metabolism 57: 1190-1197 (2008). *

• Gogos CA, Nikolopoulou V, Zolota V, Siampi V, Vagenakis A. Autoimmune cholangitis in a patient with celiac disease: a case report and review of the literature. J. Hepatol. 30: 321-324 (1999). *

• Gohlke F, Lohse AW, Dienes HP, Lohr H, Marker-Hermann E, Gerken G, Meyer zum Buschenfelde KH. Evidence for an overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis. J. Hepatol. 24: 699-705 (1996). *

• Golovnova EV, Il'chenko LIu, Tsaregorodtseva TM, Serova TI, Gudkova RV, Shepeleva SD, Tkachev VD. Primary biliary cirrhosis: 12-year experience in observation. Ter. Arkh. 75: 26-30 (2003).

• Gong Z, Huang C, Sheng X, Zhang Y, Li Q, Wang MW, Peng L, Zang YQ. The role of tanshinone IIA in the treatment of obesity through peroxisome proliferator-activated receptor gamma antagonism. Endocrinology 150: 104-113 (2009). *

• Goyenechea E, Dolores Parra M, Alfredo Martinez J. Weight regain after slimming induced by an energy-restricted diet depends on interleukin-6 and peroxisome-proliferator-activated-receptor-gamma2 gene polymorphisms. Br. J. Nutr. 96: 965-972 (2006). *

• Grau T, Bonet A, Rubio M, Mateo D, Farre M, Acosta JA, Blesa A, Montejo JC, Garcia de Lorenzo A, Mesejo A. Liver dysfunction associated with artificial nutrition in critically ill patients. Crit. Care 11: R10 (2007). *

• Griffin JM, Blossom SJ, Jackson SK, Gilbert KM, Pumford NR. Trichloroethylene accelerates an autoimmune response by Th1 T cell activation in MRL +/+ mice. Immunopharmacology 46: 123-137 (2000).

• Grodzicki M, Pawlak J, Chrzanowska A, Porembska Z, Krawczyk M. Arginase activity concentration marking in monitoring of hepatocytes function after orthotopic liver transplantation - preliminary report. Ann. Transplant. 9: 54-57 (2004).

• Grogan PM, Katz JS. Inflammatory myopathies. Curr. Treat. Options Neurol. 6: 155-161 (2004).

• Grunewald RW, Fiedler GM, Stockmann F, Schauer A, Muller GA. Unusual diagnosis in recurrent arthritis, erythema nodosum and arrhythmia. Dtsch. Med. Wochenschr. 122: 1516-1520 (1997).

• Gruppioni E, Vasuri F, Fiorentino M, Capizzi E, Altimari A, Pirini MG, Grazi GL, Malvi D, Grigioni WF, D'errico-Grigioni A. Real-time quantitative assay for routine testing HCV RNA in formalin-fixed, paraffin-embedded liver samples. Diagn. Mol. Pathol. 18: 232-238 (2009).

• Gu EL, Yao GB. The clinical characteristics of primary biliary cirrhosis in China: a systimatic review. Zhonghua Gan Zang Bing Za Zhi 17: 861-866 (2009).

• Guattery JM, Faloon WW. Effect of estradiol upon serum enzymes in primary biliary cirrhosis. Hepatology 7: 737-742 (1987).

• Guettier JM, Park JY, Cochran EK, Poitou C, Basdevant A, Meier M, Clement K, Magre J, Gorden P. Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation. Clin. Endocrinol. (Oxf.) 68: 547-554 (2008). *

• Guilherme A, Tesz GJ, Guntur KV, Czech MP. Tumor necrosis factor-alpha induces caspase-mediated cleavage of peroxisome proliferator-activated receptor gamma in adipocytes. J. Biol. Chem. 284: 17082-17091 (2009). *

• Gunsar F, Akarca US, Ersoz G, Karasu Z, Yuce G, Batur Y. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Hepatogastroenterology 49: 1195-1200 (2002).

• Guo X, Barroso L, Becker SM, Lyerly DM, Vedvick TS, Reed SG, Petri WA Jr, Houpt ER. Protection against intestinal amebiasis by a recombinant vaccine is transferable by T cells and mediated by IFN-gamma. Infect. Immun. 77: 3909-3918 (2009). *

• Gupta D, Jetton TL, Mortensen RM, Zhong Duan S, Peshavaria M, Leahy JL. In vivo and in vitro studies of a functional peroxisome proliferator-activated receptor gamma response element in the mouse PDX-1 promoter. J. Biol. Chem. 283: 32462-32470 (2008). *

• Guslandi M. Treatment of chronic liver disease with ursodeoxycholic acid. J. Int. Med. Res. 18: 497-505 (1990).

• Habermehl D, Kempna P, Azzi A, Zingg JM. Recombinant SEC14-like proteins (TAP) possess GTPase activity. Biochem. Biophys. Res. Commun. 326: 254-259 (2005). *

• Hajdu D, Aiglova K, Vinklerova I, Urbanek K. Acute cholestatic hepatitis induced by fenofibrate. J. Clin. Pharm. Ther. 34: 599-602 (2009). *

• Hamada T, Kotani K, Tsuzaki K, Sano Y, Murata T, Tabata M, Sato S, Sakane N. Association of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma2 gene with small dense low-density lipoprotein in the general population. Metabolism 56: 1345-1349 (2007). *

• Hanik L, Eriksson S. Presymptomatic primary biliary cirrhosis. Acta Med. Scand. 202: 277-281 (1977).

• Haratake J, Kasai T, Makino H. Diffuse mucosal carcinoma of intrahepatic and extrahepatic bile ducts including gallbladder. Pathol. Int. 52: 784-788 (2002). *

• Haring R, Wallaschofski H, Nauck M, Dorr M, Baumeister SE, Volzke H. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 50: 1403-1411 (2009).

• Harrington WW, S Britt C, G Wilson J, O Milliken N, G Binz J, C Lobe D, R Oliver W, C Lewis M, M Ignar D. The effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan agonists on body weight, body mass, and serum lipid profiles in diet-induced obese AKR/J mice. PPAR Res. 2007: 97125 (2007). *

• Hart CM, Roman J, Reddy R, Sime PJ. PPARgamma: a novel molecular target in lung disease. J. Investig. Med. 56: 515-517 (2008).

• Hawkins PT, Stephens LR. PI3Kgamma is a key regulator of inflammatory responses and cardiovascular homeostasis. Science 318: 64-66 (2007). *

• Hazzan R, Tur-Kaspa R. Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J. Clin. Gastroenterol. Oct 29 [Epub ahead of print] (2009).

• He YW, Beers C, Deftos ML, Ojala EW, Forbush KA, Bevan MJ. Down-regulation of the orphan nuclear receptor ROR gamma t is essential for T lymphocyte maturation. J. Immunol. 164: 5668-5674 (2000). *

• Heikkinen J, Maentausta O, Ylostalo P, Janne O. Serum bile acid levels in intrahepatic cholestasis of pregnancy during treatment with phenobarbital or cholestyramine. Eur. J. Obstet. Gynecol. Reprod. Biol. 14: 153-162 (1982).

• Helliwell C. Immunology primer. Immunology news: a new type of T cell is discovered (http://www.acnr.co.uk/JF07/ACNR_JF07_immunology.pdf). ACNR 6: 8-9 (2007). *

• Hendrickse MT, Rigney E, Giaffer MH, Soomro I, Triger DR, Underwood JC, Gleeson D. Low-dose methotrexate is ineffective in primary biliary cirrhosis: long-term results of a placebo-controlled trial. Gastroenterology 117: 400-407 (1999). *

• Henke BR, Blanchard SG, Brackeen MF, Brown KK, Cobb JE, Collins JL, Harrington WW Jr, Hashim MA, Hull-Ryde EA, Kaldor I, Kliewer SA, Lake DH, Leesnitzer LM, Lehmann JM, Lenhard JM, Orband-Miller LA, Miller JF, Mook RA Jr, Noble SA, Oliver W Jr, et al. N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem. 41: 5020-5036 (1998). *

• Hering NA, Schulzke JD. Therapeutic options to modulate barrier defects in inflammatory bowel disease. Dig. Dis. 27: 450-454 (2009).

• Herrine SK. Drug-induced liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases (2003).

• Herszenyi L, Szalay L, Schaff Z, Gergely P, Feher J. Ursodeoxycholic acid therapy in biliary cirrhosis. Orv. Hetil. 134: 2085-2089 (1993).

• Heurgue A, Vitry F, Diebold MD, Yaziji N, Bernard-Chabert B, Pennaforte JL, Picot R, Louvet H, Fremond L, Geoffroy P, Schmit JL, Cadiot G, Thiefin G. Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a retrospective study of 115 cases of autoimmune liver disease. Gastroenterol. Clin. Biol. 31: 17-25 (2007). *

• Hidaka M, Iwasaki S, Matsui T, Kawakita T, Inoue Y, Sakai T, Harada N, Takemoto S, Nagakura S, Kiyokawa T, Takahashi M, Saibara T, Onishi S, Kawano F. Efficacy of bezafibrate for chronic GVHD of the liver after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. Oct 5 [Epub ahead of print] (2009).

• Higuchi T, Hishida N, Isomura T, Takeshima H, Hayashi H. The effectual level of ursodeoxycholic acid in therapy for non-advanced chronic cholestasis is fifty percent of total serum bile acids. Gastroenterol. Jpn. 27: 222-229 (1992).

• Ho CY, Kuo TH, Chen TS, Tsay SH, Chang FY, Lee SD. Fenofibrate-induced acute cholestatic hepatitis. J. Chin. Med. Assoc. 67: 245-247 (2004). *

• Hoffmann TW, Halimi JM, Buchler M, Velge-Roussel F, Al-Najjar A, Marliere JF, Lebranchu Y, Baron C. Impact of a polymorphism in the IL-12p40 gene on the outcome of kidney transplantation. Transplant. Proc. 41: 654-656 (2009). *

• Hoffmann TW, Halimi JM, Buchler M, Velge-Roussel F, Goudeau A, Najjar AA, Boulanger MD, Houssaini TS, Marliere JF, Lebranchu Y, Baron C. Association between a polymorphism in the IL-12p40 gene and cytomegalovirus reactivation after kidney transplantation. Transplantation 85: 1406-1411 (2008).

• Hohenester S, Oude-Elferink RP, Beuers U. Primary biliary cirrhosis. Semin. Immunopathol. 31: 283-307 (2009). *

• Hokari A, Zeniya M, Esumi H, Kawabe T, Gershwin ME, Toda G. Detection of serum nitrite and nitrate in primary biliary cirrhosis: possible role of nitric oxide in bile duct injury. J. Gastroenterol. Hepatol. 17: 308-315 (2002). *

• Hollingshead HE, Morimura K, Adachi M, Kennett MJ, Billin AN, Willson TM, Gonzalez FJ, Peters JM. PPARbeta/delta protects against experimental colitis through a ligand-independent mechanism. Dig. Dis. Sci. 52: 2912-2919 (2007). *

• Hontecillas R, O'Shea M, Einerhand A, Diguardo M, Bassaganya-Riera J. Activation of PPAR gamma and alpha by punicic acid ameliorates glucose tolerance and suppresses obesity-related inflammation. J. Am. Coll. Nutr. 28: 184-195 (2009). *

• Horie Y, Kitaichi N, Takemoto Y, Namba K, Yoshida K, Hirose S, Hasumi Y, Ota M, Inoko H, Mizuki N, Ohno S. Polymorphism of IFN-gamma gene and Vogt-Koyanagi-Harada disease. Mol. Vis. 13: 2334-2338 (2007). *

• Horvat-Karajz K, Csepregi A, Nemesanszky E, Tulassay Z, Selmeci L, Szalay F. Activity of neutral endopeptidase in serum of patients with primary biliary cirrhosis. Orv. Hetil. 141: 963-965 (2000).

• Housley WJ, O'Conor CA, Nichols F, Puddington L, Lingenheld EG, Zhu L, Clark RB. PPARgamma regulates retinoic acid-mediated DC induction of Tregs. J. Leukoc. Biol. 86: 293-301 (2009). *

• Howard M, Fischer H, Roux J, Santos BC, Gullans SR, Yancey PH, Welch WJ. Mammalian osmolytes and S-nitrosoglutathione promote Delta F508 cystic fibrosis transmembrane conductance regulator (CFTR) protein maturation and function. J. Biol. Chem. 278: 35159-35167 (2003). *

• Hsieh JC, Nakajima S, Galligan MA, Jurutka PW, Haussler CA, Whitfield GK, Haussler MR. Receptor mediated genomic action of the 1,25(OH)2D3 hormone: expression of the human vitamin D receptor in E. coli. J. Steroid Biochem. Mol. Biol. 53: 583-594 (1995).

• Hsu YC, Chen HL, Wu MZ, Liu YJ, Lee PH, Sheu JC, Chen CH. Adult progressive intrahepatic cholestasis associated with genetic variations in ATP8B1 and ABCB11. Hepatol. Res. 39: 625-631 (2009). *

• Hu G, Tuomilehto J, Pukkala E, Hakulinen T, Antikainen R, Vartiainen E, Jousilahti P. Joint effects of coffee consumption and serum gamma-glutamyltransferase on the risk of liver cancer. Hepatology 48: 129-136 (2008). *

• Hu X, Feng Y, Shen Y, Zhao XF, Yu JH, Yang YS, Leng Y. Antidiabetic effect of a novel non-thiazolidinedione PPAR gamma/alpha agonist on ob/ob mice. Acta Pharmacol. Sin. 27: 1346-1352 (2006).

• Huang W, Eum SY, Andras IE, Hennig B, Toborek M. PPARalpha and PPARgamma attenuate HIV-induced dysregulation of tight junction proteins by modulations of matrix metalloproteinase and proteasome activities. FASEB J. 23: 1596-1606 (2009). *

• Huang W, Rha GB, Han MJ, Eum SY, Andras IE, Zhong Y, Hennig B, Toborek M. PPARalpha and PPARgamma effectively protect against HIV-induced inflammatory responses in brain endothelial cells. J. Neurochem. 107: 497-509 (2008).

• Hudcovic T, Kozakova H, Kolínska J, Stepankova R, Hrncír T, Tlaskalova-Hogenova H. Monocolonization with Bacteroides ovatus protects immunodeficient SCID mice from mortality in chronic intestinal inflammation caused by long-lasting dextran sodium sulfate treatment. Physiol. Res. 58: 101-110 (2009). *

• Hui Y, Yu-Yuan L, Yu-Qiang N, Wei-Hong S, Yan-Lei D, Xiao-Bo L, Yong-Jian Z. Effect of peroxisome proliferator-activated receptors-gamma and co-activator-1alpha genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people. Liver Int. 28: 385-392 (2008). *

• Hull M, Berger M, Heneka M. Disease-modifying therapies in Alzheimer's disease: how far have we come? Drugs 66: 2075-2093 (2006).

• Hwang SJ, Chan CY, Lee SD, Wu JC, Tsay SH, Lo KJ. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up. J. Gastroenterol. Hepatol. 8: 217-223 (1993).

• Ichikawa T, Sato H, Kaira K, Oh-I S, Kakizaki S, Sato K, Takagi H, Mori M. Prolonged intrahepatic cholestasis after exposure to loxoprofen. Clin. Ther. 30: 2402-2406 (2008).

• Ikeda T, Tozuka S, Noguchi O, Kobayashi F, Sakamoto S, Marumo F, Sato C. Effects of additional administration of colchicine in ursodeoxycholic acid-treated patients with primary biliary cirrhosis: a prospective randomized study. J. Hepatol. 24: 88-94 (1996). *

• Ilan Y, Shouval D. Primary biliary cirrhosis in Israel. Isr. J. Med. Sci. 28: 683-687 (1992).

• Imai N, Ikeda H, Tawara I, Wang L, Wang L, Nishikawa H, Kato T, Shiku H. Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8+ T cells with tumor regression. Cancer Sci. 100: 1317-1325 (2009). *

• Inoue K, Matsumoto M, Miyoshi Y, Kobayashi Y. Elevated liver enzymes in women with a family history of diabetes. Diabetes Res. Clin. Pract. 79: e4-e7 (2008).

• Ioannou GN. Cholelithiasis, cholecystectomy, and liver disease. Am. J. Gastroenterol. Jan 12 [Epub ahead of print] (2010). *

• Irie M, Suzuki N, Sohda T, Anan A, Iwata K, Takeyama Y, Watanabe H, Fischer P, Scherberich JE, Sakisaka S. Hepatic expression of gamma-glutamyltranspeptidase in the human liver of patients with alcoholic liver disease. Hepatol. Res. 37: 966-973 (2007). *

• Isenberg JN, L'Heureux PR, Warwick WJ, Sharp HL. Clinical observations on the biliary system in cystic fibrosis. Am. J. Gastroenterol. 65: 134-141 (1976).

• Ishibashi H, Komori A, Shimoda S, Gershwin ME. Guidelines for therapy of autoimmune liver disease. Semin. Liver Dis. 27: 214-226 (2007). *

• Ishihara K, Katsutani N, Asai N, Inomata A, Uemura Y, Suganuma A, Sawada K, Yokoi T, Aoki T. Identification of urinary biomarkers useful for distinguishing a difference in mechanism of toxicity in rat model of cholestasis. Basic Clin. Pharmacol. Toxicol. 105: 156-166 (2009).

• Ishikawa H, Naito T, Iwanaga T, Takahashi-Iwanaga H, Suematsu M, Hibi T, Nanno M. Curriculum vitae of intestinal intraepithelial T cells: their developmental and behavioral characteristics. Immunol. Rev. 215: 154-165 (2007). *

• Ishizu T, Osoegawa M, Mei FJ, Kikuchi H, Tanaka M, Takakura Y, Minohara M, Murai H, Mihara F, Taniwaki T, Kira J. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 128: 988-1002 (2005). *

• Ishizuka Y, Moriwaki S, Kawahara-Hanaoka M, Uemura Y, Serizawa I, Miyauchi M, Shibata S, Kanaya T, Takata T, Taniguchi N, Niida S. Treatment with anti-gamma-glutamyl transpeptidase antibody attenuates osteolysis in the collagen-induced arthritis mice. J. Bone Miner. Res. 22: 1933-1942 (2007). *

• Ismail H, Kalicinski P, Markiewicz M, Jankowska I, Pawlowska J, Kluge P, Eliadou E, Kaminski A, Szymczak M, Drewniak T, Revillon Y. Treatment of progressive familial intrahepatic cholestasis: liver transplantation or partial external biliary diversion. Pediatr. Transplant. 3: 219-224 (1999).

• Itakura J, Izumi N, Nishimura Y, Inoue K, Ueda K, Nakanishi H, Tsuchiya K, Hamano K, Asahina Y, Kurosaki M, Uchihara M, Miyake S. Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis. Hepatol. Res. 29: 216-222 (2004).

• Ito S, Yukawa T, Uetake S, Yamauchi M. Serum intercellular adhesion molecule-1 in patients with nonalcoholic steatohepatitis: comparison with alcoholic hepatitis. Alcohol Clin. Exp. Res. 31: S83-S87 (2007). *

• Iwai M, Jo M, Ishii M, Mori T, Harada Y. Comparison of clinical features and liver histology in acute and chronic autoimmune hepatitis. Hepatol. Res. 38: 784-789 (2008). *

• Iwasaki S, Tsuda K, Ueta H, Aono R, Ono M, Saibara T, Maeda T, Onishi S. Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis. Hepatol. Res. 16: 12-18 (1999).

• Jacquemin E. Progressive familial intrahepatic cholestasis and hereditary anomalies of hepatocellular metabolism of bile acids. Arch. Pediatr. 5: 45-53 (1998).

• Jacquemin E, Hermans D, Myara A, Habes D, Debray D, Hadchouel M, Sokal EM, Bernard O. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 25: 519-523 (1997). *

• Jacquemin E, Setchell KD, O'Connell NC, Estrada A, Maggiore G, Schmitz J, Hadchouel M, Bernard O. A new cause of progressive intrahepatic cholestasis: 3 beta-hydroxy-C27-steroid dehydrogenase/isomerase deficiency. J. Pediatr. 125: 379-384 (1994).

• Jaffe R. Liver involvement in the histiocytic disorders of childhood. Pediatr. Dev. Pathol. 7: 214-225 (2004). *

• Jagiello P, Wieczorek S, Yu P, Csernok E, Gross WL, Epplen JT. Association study with Wegener granulomatosis of the human phospholipase Cgamma2 gene. J. Negat. Results Biomed. 4: 1 (2005). *

• Jansen PL, Muller M. Genetic cholestasis: lessons from the molecular physiology of bile formation. Can. J. Gastroenterol. 14: 233-238 (2000). *

• Jansen PL, Strautnieks SS, Jacquemin E, Hadchouel M, Sokal EM, Hooiveld GJ, Koning JH, De Jager-Krikken A, Kuipers F, Stellaard F, Bijleveld CM, Gouw A, Van Goor H, Thompson RJ, Muller M. Hepatocanalicular bile salt export pump deficiency in patients with progressive familial intrahepatic cholestasis. Gastroenterology 117: 1370-1379 (1999). *

• Jansen PL, Sturm E. Genetic cholestasis, causes and consequences for hepatobiliary transport. Liver Int. 23: 315-322 (2003). *

• Jazia EB, Khalifa M, Abdelkader AB, Kaabia N, Ghannouchi N, Braham A, Letaief A, Bahri F. A case of primary biliary cirrhosis associated with pernicious anemia: a case report. Cases J. 3: 11 (2010). *

• Jazwinska EC, Olive C, Hogarth PM, Gatenby PA, Serjeantson SW. Fc gamma RII restriction fragment length polymorphism (RFLP): analysis in systemic lupus erythematosus and scleroderma and evidence of an alpha gene duplication. Clin. Exp. Immunol. 83: 47-51 (1991). *

• Jeninga EH, Gurnell M, Kalkhoven E. Functional implications of genetic variation in human PPARgamma. Trends Endocrinol. Metab. 20: 380-387 (2009). *

• Jetten AM. Retinoid-related orphan receptors (RORs): critical roles in development, immunity, circadian rhythm, and cellular metabolism. Nucl. Recept. Signal. 7: e003 (2009). *

• Jetten AM, Kurebayashi S, Ueda E. The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processes. Prog. Nucleic Acid Res. Mol. Biol. 69: 205-247 (2001).

• Ji-Rong Y, Bi-Rong D, Chang-Quan H, Zhen-Chan L, Hong-Mei W, Yan-Ling Z, Mattis TA. Pro12Ala polymorphism in PPARgamma2 associated with depression in Chinese nonagenarians/centenarians. Arch. Med. Res. 40: 411-415 (2009).

• Jiang Q, Yin X, Lill MA, Danielson ML, Freiser H, Huang J. Long-chain carboxychromanols, metabolites of vitamin E, are potent inhibitors of cyclooxygenases. Proc. Natl. Acad. Sci. U.S.A. 105: 20464-20469 (2008). *

• Jiang WG, Davies G, Kynaston H, Mason MD, Fodstad O. Does the PGC-1/PPARgamma pathway play a role in Com-1/p8 mediated cell growth inhibition in prostate cancer? Int. J. Mol. Med. 18: 1169-1175 (2006). *

• Jirsa M, Cebecauerova D, Budisova L, Chuzhanova N, Hrebicek M, Dvorakova L, Vitek L, Brodanova M, Hulek P, Taimr P. Indel in the FIC1/ATP8B1 gene - a novel rare type of mutation associated with benign recurrent intrahepatic cholestasis. Hepatol. Res. 30: 1-3 (2004).

• Johansen A, Jensen DP, Bergholdt R, Mortensen HB, Pociot F, Nerup J, Hansen T, Pedersen O; The Danish Society of Childhood Diabetes. IRS1, KCNJ11, PPARgamma2 and HNF-1alpha: do amino acid polymorphisms in these candidate genes support a shared aetiology between type 1 and type 2 diabetes? Diabetes Obes. Metab. 8: 75-82 (2006).

• Jonsen A, Bengtsson AA, Sturfelt G, Truedsson L. Analysis of HLA DR, HLA DQ, C4A, FcgammaRIIa, FcgammaRIIIa, MBL, and IL-1Ra allelic variants in Caucasian systemic lupus erythematosus patients suggests an effect of the combined FcgammaRIIa R/R and IL-1Ra 2/2 genotypes on disease susceptibility. Arthritis Res. Ther. 6: R557-R562 (2004). *

• Jonsen A, Gunnarsson I, Gullstrand B, Svenungsson E, Bengtsson AA, Nived O, Lundberg IE, Truedsson L, Sturfelt G. Association between SLE nephritis and polymorphic variants of the CRP and FcgammaRIIIa genes. Rheumatology (Oxford) 46: 1417-1421 (2007). *

• Jorge A, Findor J, Esley C, Bruch E. Primary sclerosing cholangitis. Z. Gastroenterol. 26: 322-330 (1988).

• Jorge AD, Esley C. Primary sclerosing cholangitis. Endoscopy 17: 11-14 (1985).

• Joshi GG, Thakur BS, Sircar S, Namdeo A, Jain AK. Role of intravenous naloxone in severe pruritus of acute cholestasis. Indian J. Gastroenterol. 28: 180-182 (2009). *

• Jun DW, Han JH, Jang EC, Kim SH, Kim SH, Jo YJ, Park YS, Chae JD. Polymorphisms of microsomal triglyceride transfer protein gene and phosphatidylethanolamine N-methyltransferase gene in alcoholic and nonalcoholic fatty liver disease in Koreans. Eur. J. Gastroenterol. Hepatol. 21: 667-672 (2009).

• Jun SY, Kim JS, Yu E. Primary sclerosing cholangitis - a report of two liver explants. Korean J. Pathol. 36: 420-424 (2002). *

• Kagalwalla AF, Al Amir AR, Khalifa A, Sylven M, Al Ajaji S, Kagalwalla YA. Progressive familial intrahepatic cholestasis (Byler's disease) in Arab children. Ann. Trop. Paediatr. 15: 321-327 (1995).

• Kakiuchi-Kiyota S, Vetro JA, Suzuki S, Varney ML, Han HY, Nascimento M, Pennington KL, Arnold LL, Singh RK, Cohen SM. Effects of the PPARgamma agonist troglitazone on endothelial cells in vivo and in vitro: differences between human and mouse. Toxicol. Appl. Pharmacol. 237: 83-90 (2009). *

• Kamata Y, Kamimura T, Yoshio T, Hirata D, Masuyama J, Isoda N, Kanai N, Minota S. Systemic lupus erythematosus with steroid induced non-alcoholic steatohepatitis: a case report. Ryumachi 43: 667-671 (2003).

• Kamimura T, Yoshida T, Ito S, Tashiro T. Primary biliary cirrhosis: symptoms, laboratory data and diagnosis. Nippon Rinsho 52: 246-250 (1994).

• Kampa IS, Jarzabek J, Clain J. The use of gamma-glutamyl transpeptidase in differentiating liver from bone isoenzymes of alkaline phosphatase. Clin. Biochem. 9: 234-236 (1976).

• Kang TJ, Yeum CE, Kim BC, You EY, Chae GT. Differential production of interleukin-10 and interleukin-12 in mononuclear cells from leprosy patients with a Toll-like receptor 2 mutation. Immunology 112: 674-680 (2004). *

• Kardorff R, Melter M, Rodeck B, Brodehl J. Long-term ursodeoxycholic acid treatment of cholestatic liver diseases in childhood - clinical and biochemical effects. Klin. Padiatr. 208: 118-122 (1996).

• Karvonen J, Kairisto V, Gronroos JM. Stone or stricture as a cause of extrahepatic cholestasis - do liver function tests predict the diagnosis? Clin. Chem. Lab. Med. 44: 1453-1456 (2006). *

• Kasai S, Inoue T, Yoshitomi H, Hihara T, Matsuura F, Harada H, Shinoda M, Tanaka I. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs. J. Pharmacol. Sci. 108: 40-48 (2008). *

• Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54: 117-121 (2005). *

• Keaveny AP, Karasik MS. Hepatobiliary and pancreatic infections in AIDS: part II. AIDS Patient Care STDS. 12: 451-456 (1998).

• Keeffe EB, Davis GL. Advances in liver disease: highlights from the 54th Annual Meeting of the American Association for the Study of Liver Diseases, October 24-28, 2003. Rev. Gastroenterol. Disord. 4: 36-42 (2004). *

• Keiding S, Hockerstedt K, Bjoro K, Bondesen S, Hjortrup A, Isoniemi H, Erichsen C, Soderdahl G, Ericzon BG. The Nordic multicenter double-blind randomized controlled trial of prophylactic ursodeoxycholic acid in liver transplant patients. Transplantation 63: 1591-1594 (1997).

• Kenngott S, Lohse P, Beuers U. Intrahepatic cholestasis in pregnancy. What to consider in jaundice and pruritus. MMW Fortschr. Med. 144: 41-44 (2002).

• Khan AA, Parveen N, Mahaboob VS, Rajendraprasad A, Ravindraprakash HR, Venkateswarlu J, Rao P, Pande G, Lakshmi Narusu M, Khaja MN, Pramila R, Habeeb A, Habibullah CM. Management of hyperbilirubinemia in biliary atresia by hepatic progenitor cell transplantation through hepatic artery: a case report. Transplant. Proc. 40: 1153-1155 (2008). *

• Khani-Hanjani A, Lacaille D, Hoar D, Chalmers A, Horsman D, Anderson M, Balshaw R, Keown PA. Association between dinucleotide repeat in non-coding region of interferon-gamma gene and susceptibility to, and severity of, rheumatoid arthritis. Lancet 356: 820-825 (2000). *

• Khoo SK, Hayden CM, Roberts M, Horak E, de Klerk N, Zhang G, Robertson CF, Goldblatt J, Le Souef P. Associations of the IL12B promoter polymorphism in longitudinal data from asthmatic patients 7 to 42 years of age. J. Allergy Clin. Immunol. 113: 475-481 (2004). *

• Kiaei M. Peroxisome proliferator-activated receptor-gamma in amyotrophic lateral sclerosis and Huntington's disease. PPAR Res. 2008: 418765 (2008). *

• Kilpealinen TO, Lakka TA, Laaksonen DE, Lindstorm J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Lindi V, Tuomilehto J, Uusitupa M, Laakso M. SNPs in PPARg associate with type 2 diabetes and interact with physical activity. Med. Sci. Sports Exerc. 40: 25-33 (2008).

• Kilroy GE, Zhang X, Floyd ZE. PPAR-gamma AF-2 domain functions as a component of a ubiquitin-dependent degradation signal. Obesity (Silver Spring) 17: 665-673 (2009). *

• Kim H, Oh BK, Roncalli M, Park C, Yoon SM, Yoo JE, Park YN. Large liver cell change in hepatitis B virus-related liver cirrhosis. Hepatology 50: 752-762 (2009).

• Kim JH, Kim BH, Kim YW, Park JC, Jung YH, Lee BO, Han YS, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R. Autoimmune cholangitis in a patient with thymoma. J. Gastroenterol. Hepatol. 19: 1324-1327 (2004). *

• Kiriyama K, Usui T, Takemura T, Ikeda K, Kishida H, Izumoto T, Kanayama Y, Hirota S. A case of rapid-onset antimitochondrial antibody-positive autoimmune hepatitis possibly triggered by a urinary tract infection. Nippon Shokakibyo Gakkai Zasshi 107: 270-277 (2010).

• Kita R, Kita-Sasai Y, Hanaoka I, Kimura T, Kokuryu H, Takamatsu S, Osaki Y, Tomono N, Hachiya T, Shimizu T. Beneficial effect of bezafibrate on primary sclerosing cholangitis (three case reports). Am. J. Gastroenterol. 97: 1849-1851 (2002). *

• Kita R, Takamatsu S, Kimura T, Kokuryu H, Osaki Y, Tomono N. Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels. J. Gastroenterol. 41: 686-692 (2006). *

• Kitaura Y, Jang IK, Wang Y, Han YC, Inazu T, Cadera EJ, Schlissel M, Hardy RR, Gu H. Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b. Immunity 26: 567-578 (2007). *

• Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, Adim SB, Yerci O, Memik F. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can. J. Gastroenterol. 17: 713-718 (2003). *

• Kleemann P, Papa D, Vigil-Cruz S, Seifert R. Functional reconstitution of the human chemokine receptor CXCR4 with G(i)/G (o)-proteins in Sf9 insect cells. Naunyn. Schmiedebergs. Arch. Pharmacol. 378: 261-274 (2008).

• Kluth D, Landes N, Pfluger P, Muller-Schmehl K, Weiss K, Bumke-Vogt C, Ristow M, Brigelius-Flohe R. Modulation of Cyp3a11 mRNA expression by alpha-tocopherol but not gamma-tocotrienol in mice. Free Radic. Biol. Med. 38: 507-514 (2005).

• Kneppelhout JC, Mulder CJ, van Berge Henegouwen GP, de Vries RA, Brandt KH. Ursodeoxycholic acid treatment in primary biliary cirrhosis with the emphasis on late stage disease. Neth. J. Med. 41: 11-16 (1992).

• Kobayashi M, Akuta N, Suzuki F, Hosaka T, Sezaki H, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Watahiki S, Mineta R, Iwasaki S, Miyakawa Y, Kumada H. Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b. J. Med. Virol. 82: 41-48 (2009). *

• Kodama Y, Hijikata M, Kageyama R, Shimotohno K, Chiba T. The role of notch signaling in the development of intrahepatic bile ducts. Gastroenterology 127: 1775-1786 (2004). *

• Kollerits B, Coassin S, Kiechl S, Hunt SC, Paulweber B, Willeit J, Brandstatter A, Adams TD, Kronenberg F. A common variant in the adiponutrin gene influences liver enzyme levels. J. Med. Genet. Jun 18 [Epub ahead of print] (2009).

• Konrad S, Engling L, Schmidt RE, Gessner JE. Characterization of the murine Fcgamma RIII and Fcgamma RIIB gene promoters: a single two-nucleotide difference determines their inverse responsiveness to C5A. J. Biol. Chem. 282: 37906-37912 (2007). *

• Korolenko TA, Savchenko NG, Yuz'ko JV, Alexeenko TV, Sorochinskaya NV. Activity of lysosomal enzymes in the bile and serum of mice with intrahepatic cholestasis. Bull. Exp. Biol. Med. 145: 560-563 (2008).

• Koshy A, Ramesh H, Mahadevan P, Mukkada RJ, Francis VJ, Chettupuzha AP, Mathew PG, Cyriac J, Augustine P. Progressive familial intrahepatic cholestasis: a case with improvement in liver tests and growth following partial external biliary diversion. Indian J. Gastroenterol. 28: 107-108 (2009). *

• Kotronen A, Yki-Jarvinen H, Aminoff A, Bergholm R, Pietilainen K, Westerbacka J, Talmud P, Humphries S, Hamsten A, Isomaa B, Groop L, Orho-Melander M, Ehrenborg E, Fisher R. Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. Eur. J. Endocrinol. 160: 593-602 (2009).

• Kozaiwa K, Tajiri H, Sawada A, Tada K, Etani Y, Miki K, Okada S. Three paediatric cases of primary sclerosing cholangitis treated with ursodeoxycholic acid and sulphasalazine. J. Gastroenterol. Hepatol. 13: 825-829 (1998).

• Kratz LE, Boughman JA, Pincus T, Cohen DI, Needleman BW. Association of scleroderma with a T cell antigen receptor gamma gene restriction fragment length polymorphism. Arthritis Rheum. 33: 569-573 (1990).

• Kreslavsky T, Gleimer M, von Boehmer H. alphabeta versus gammadelta lineage choice at the first TCR-controlled checkpoint. Curr. Opin. Immunol. Jan 12 [Epub ahead of print] (2010).

• Kuda O, Jelenik T, Jilkova Z, Flachs P, Rossmeisl M, Hensler M, Kazdova L, Ogston N, Baranowski M, Gorski J, Janovska P, Kus V, Polak J, Mohamed-Ali V, Burcelin R, Cinti S, Bryhn M, Kopecky J. n-3 Fatty acids and rosiglitazone improve insulin sensitivity through additive stimulatory effects on muscle glycogen synthesis in mice fed a high-fat diet. Diabetologia 52: 941-951 (2009). *

• Kurbegov AC, Setchell KD, Haas JE, Mierau GW, Narkewicz M, Bancroft JD, Karrer F, Sokol RJ. Biliary diversion for progressive familial intrahepatic cholestasis: improved liver morphology and bile acid profile. Gastroenterology 125: 1227-1234 (2003). *

• Kuroki K, Tsuchiya N, Tsao BP, Grossman JM, Fukazawa T, Hagiwara K, Kano H, Takazoe M, Iwata T, Hashimoto H, Tokunaga K. Polymorphisms of human CD19 gene: possible association with susceptibility to systemic lupus erythematosus in Japanese. Genes Immun. 3 Suppl. 1: S21-S30 (2002). *

• Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, Tamaki N, Hosokawa T, Ueda K, Tsuchiya K, Nakanishi H, Ikeda H, Itakura J, Takahashi Y, Asahina Y, Higaki M, Enomoto N, Izumi N. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol. Res. Jan 11 [Epub ahead of print] (2010). *

• Kuwano Y, Tominaga K, Kawahara T, Sasaki H, Takeo K, Nishida K, Masuda K, Kawai T, Teshima-Kondo S, Rokutan K. Tumor necrosis factor alpha activates transcription of the NADPH oxidase organizer 1 (NOXO1) gene and upregulates superoxide production in colon epithelial cells. Free Radic. Biol. Med. 45: 1642-1652 (2008).

• La Flamme AC, Harvie M, McNeill A, Goldsack L, Tierney JB, Backstrom BT. Fcgamma receptor-ligating complexes improve the course of experimental autoimmune encephalomyelitis by enhancing basal Th2 responses. Immunol. Cell. Biol. 84: 522-529 (2006). *

• Labrecque J, Wong RS, Fricker SP. A time-resolved fluorescent lanthanide (Eu)-GTP binding assay for chemokine receptors as targets in drug discovery. Methods Mol. Biol. 552: 153-169 (2009).

• Lachaux A, Loras-Duclaux I, Bouvier R, Fournier V, Regragui K, Hermier M. Benign recurrent cholestasis. Apropos of a case with normal serum gamma-glutamyl transpeptidase level. Pediatrie. 48: 163-165 (1993).

• Lagier AJ, Pober JS. Immune accessory functions of human endothelial cells are modulated by overexpression of B7-H1 (PDL1). Hum. Immunol. 67: 568-578 (2006).

• Lammert F, Marschall HU, Matern S. Intrahepatic cholestasis of pregnancy. Curr. Treat. Options Gastroenterol. 6: 123-132 (2003).

• Lammert F, Miquel JF. Gallstone disease: from genes to evidence-based therapy? J. Hepatol. 48: S124-S135 (2008). *

• Landowski P, Liberek A, Szlagatys-Sidorkiewicz A, Radys W, Brodzicki J, Szarszewski A, Marek A, Luczak G, Kaminska B. Inflammatory bowel disease in children - an analysis of the clinical symptoms and selected biochemical parameters. Med. Wieku. Rozwoj. 11: 401-407 (2007).

• Lang T, Prina E, Sibthorpe D, Blackwell JM. Nramp1 transfection transfers Ity/Lsh/Bcg-related pleiotropic effects on macrophage activation: influence on antigen processing and presentation. Infect. Immun. 65: 380-386 (1997). *

• Larsen LN, Granlund L, Holmeide AK, Skattebol L, Nebb HI, Bremer J. Sulfur-substituted and alpha-methylated fatty acids as peroxisome proliferator-activated receptor activators. Lipids 40: 49-57 (2005).

• Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, McGill DB. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 23: 1464-1467 (1996). *

• Lavaissiere L, Jia S, Nishiyama M, de la Monte S, Stern AM, Wands JR, Friedman PA. Overexpression of human aspartyl(asparaginyl)beta-hydroxylase in hepatocellular carcinoma and cholangiocarcinoma. J. Clin. Invest. 98: 1313-1323 (1996). *

• Lazaridis KN, Lindor KD. Primary biliary cirrhosis. Curr. Treat. Options Gastroenterol. 2: 473-480 (1999).

• Lazo M, Selvin E, Clark JM. Brief communication: clinical implications of short-term variability in liver function test results. Ann. Intern. Med. 148: 348-352 (2008). *

• Lecut C, Frederix K, Johnson DM, Deroanne C, Thiry M, Faccinetto C, Maree R, Evans RJ, Volders PG, Bours V, Oury C. P2X1 ion channels promote neutrophil chemotaxis through Rho kinase activation. J. Immunol. 183: 2801-2809 (2009).

• Lee BC, Doo HK, Ahn SY, Byun SH, Kim SI, Park HK, Hong M, Ha E, Yim SV, Yin C, Leem KH, Ahn YM. Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism is associated with the susceptibility to ischemic stroke in Taeeumin classified by Sasang medicine. Neurol. Res. 29 Suppl. 1: 32-37 (2007).

• Lee BC, Lee HJ, Chung JH. Peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism is associated with reduced risk for ischemic stroke with type 2 diabetes. Neurosci. Lett. 410: 141-145 (2006). *

• Lee BC, Lee KC, Lee H, Mach RH, Katzenellenbogen JA. Synthesis and binding affinity of a fluorine-substituted peroxisome proliferator-activated gamma (PPARgamma) ligand as a potential positron emission tomography (PET) imaging agent. Bioconjug. Chem. 18: 507-513 (2007). *

• Lee DH, Blomhoff R, Jacobs DR Jr. Is serum gamma glutamyltransferase a marker of oxidative stress? Free Radic. Res. 38: 535-539 (2004).

• Lee EB, Kim JY, Lee YJ, Park MH, Song YW. TNF and TNF receptor polymorphisms in Korean Behcet's disease patients. Hum. Immunol. 64: 614-620 (2003).

• Lee HM, Park SA, Chung SW, Woo JS, Chae SW, Lee SH, Kang HJ, Hwang SJ. Interleukin-18/-607 gene polymorphism in allergic rhinitis. Int. J. Pediatr. Otorhinolaryngol. 70: 1085-1088 (2006).

• Lee SJ, Qin H, Benveniste EN. The IFN-gamma-induced transcriptional program of the CIITA gene is inhibited by statins. Eur. J. Immunol. 38: 2325-2336 (2008). *

• Lee WS, Saw CB, Sarji SA. Autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome in a child: diagnostic usefulness of magnetic resonance cholangiopancreatography. J. Paediatr. Child. Health 41: 225-227 (2005).

• Lees JR, Cross AH. A little stress is good: IFN-gamma, demyelination, and multiple sclerosis. J. Clin. Invest. 117: 297-299 (2007). *

• Lefkowitch JH. Hepatobiliary pathology. Curr. Opin. Gastroenterol. 23: 221-231 (2007).

• Legrand F, Driss V, Woerly G, Loiseau S, Hermann E, Fournie JJ, Heliot L, Mattot V, Soncin F, Gougeon ML, Dombrowicz D, Capron M. A functional gammadeltaTCR/CD3 complex distinct from gammadelta T cells is expressed by human eosinophils. PLoS One 4: e5926 (2009). *

• Lemonde HA, Custard EJ, Bouquet J, Duran M, Overmars H, Scambler PJ, Clayton PT. Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid 5beta-reductase, in hepatitis and liver failure in infancy. Gut 52: 1494-1499 (2003). *

• Lenzi M, Bellentani S, Saccoccio G, Muratori P, Masutti F, Muratori L, Cassani F, Bianchi FB, Tiribelli C. Prevalence of non-organ-specific autoantibodies and chronic liver disease in the general population: a nested case-control study of the Dionysos cohort. Gut 45: 435-441 (1999). *

• Leslie EM, Haimeur A, Waalkes MP. Arsenic transport by the human multidrug resistance protein 1 (MRP1/ABCC1). Evidence that a tri-glutathione conjugate is required. J. Biol. Chem. 279: 32700-32708 (2004). *

• Leuschner M, Dietrich CF, You T, Seidl C, Raedle J, Herrmann G, Ackermann H, Leuschner U. Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut 46: 121-126 (2000). *

• Leuschner U. Primary biliary cirrhosis - presentation and diagnosis. Clin. Liver Dis. 7: 741-758 (2003).

• Leuschner U, Fischer H, Kurtz W, Guldutuna S, Hubner K, Hellstern A, Gatzen M, Leuschner M. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 97: 1268-1274 (1989).

• Levy C, Lindor KD. Current management of primary biliary cirrhosis and primary sclerosing cholangitis. J. Hepatol. 38: S24-S37 (2003). *

• Lewis JD, Lichtenstein GR, Stein RB, Deren JJ, Judge TA, Fogt F, Furth EE, Demissie EJ, Hurd LB, Su CG, Keilbaugh SA, Lazar MA, Wu GD. An open-label trial of the PPAR-gamma ligand rosiglitazone for active ulcerative colitis. Am. J. Gastroenterol. 96: 3323-3328 (2001). *

• Li CP, Tong MJ, Hwang SJ, Luo JC, Co RL, Tsay SH, Chang FY, Lee SD. Autoimmune cholangitis with features of autoimmune hepatitis: successful treatment with immunosuppressive agents and ursodeoxycholic acid. J. Gastroenterol. Hepatol. 15: 95-98 (2000). *

• Li L, Cheng LX, Nsenga R, He MA, Wu TC. Association between Pro12Ala polymorphism of peroxisome proliferator-activated receptor-gamma 2 and myocardial infarction in the Chinese Han population. Clin. Cardiol. 29: 300-304 (2006).

• Li L, Xu X, Lu F, Zhao N. Effects of ursodeoxycholic acid on intrahepatic cholestasis in rats. Chin. Med. J. (Engl.) 116: 1099-1103 (2003).

• Li LL, Ma XL, Ran JX, Sun XF, Xu LM, Ren J, Mao XM. Genetic polymorphism of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala on ethnic susceptibility to diabetes in Uygur, Kazak and Han subjects. Clin. Exp. Pharmacol Physiol. 35: 187-191 (2008).

• Li N, Zhang H, Wang S, Zhu W, Ren J, Li J. Laboratory investigation and clinical application of S-adenosyl-L-methionine in the treatment of cholestasis after total parenteral nutrition. Zhonghua Wai Ke Za Zhi 40: 407-410 (2002).

• Li N, Zhang HH, Wang SH, Zhu WM, Ren JA, Li JS. S-Adenosylmethionine in treatment of cholestasis after total parenteral nutrition: laboratory investigation and clinical application. Hepatobiliary Pancreat. Dis. Int. 1: 96-100 (2002). *

• Li Y, Kovach A, Suino-Powell K, Martynowski D, Xu HE. Structural and biochemical basis for the binding selectivity of PPARgamma to PGC-1alpha. J. Biol. Chem. 283: 19132-19139 (2008). *

• Liang Y, Yang Z, Li C, Zhu Y, Zhang L, Zhong R. Characterisation of TNF-related apoptosis-inducing ligand in peripheral blood in patients with primary biliary cirrhosis. Clin. Exp. Med. 8: 1-7 (2008). *

• Liao SY, Zeng ZR, Leung WK, Zhou SZ, Chen B, Sung JJ, Hu PJ. Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism, Helicobacter pylori infection and non-cardia gastric carcinoma in Chinese. Aliment. Pharmacol. Ther. 23: 289-294 (2006). *

• Lim AG, Jazrawi RP, Ahmed HA, Levy JH, Zuin M, Douds AC, Maxwell JD, Northfield TC. Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: relationship with disease stage, immune activity and cholestasis. Hepatology 20: 882-888 (1994).

• Lin CY, Lin LY, Chiang CK, Wang WJ, Su YN, Hung KY, Chen PC. Investigation of the associations between low-dose serum perfluorinated chemicals and liver enzymes in US adults. Am. J. Gastroenterol. Dec 14 [Epub ahead of print] (2009). *

• Lin JP, O'Donnell CJ, Fox CS, Cupples LA. Heritability of serum gamma-glutamyltransferase level: genetic analysis from the Framingham Offspring Study. Liver Int. 29: 776-777 (2009). *

• Lin LF, Huang PT, Ho KS, Tung JN. Autoimmune chronic pancreatitis. J. Chin. Med. Assoc. 71: 14-22 (2008).

• Lin SC, Shyur SD, Ma YC, Huang LH, Lee HC, Lee WI. Recurrent acalculous cholecystitis and sclerosing cholangitis in a patient with X-linked hyper-immunoglobulin M syndrome. J. Formos. Med. Assoc. 104: 421-426 (2005).

• Lin WT, Lin SJ, Ni YH, Chen HL, Wang HP, Chu JS, Chang MH. Primary sclerosing cholangitis in a child. J. Formos. Med. Assoc. 98: 209-213 (1999).

• Linhart P, Borner N, Leiss O. What is the onset of primary biliary liver cirrhosis? Z. Gastroenterol. 31 Suppl. 2: 94-95 (1993).

• Lintas C, Cappa M, Comparcola D, Nobili V, Fierabracci A. An 8-year-old boy with autoimmune hepatitis and Candida onychosis as the first symptoms of autoimmune polyglandular syndrome (APS1): identification of a new homozygous mutation in the autoimmune regulator gene (AIRE). Eur. J. Pediatr. 167: 949-953 (2008).

• Liu J, He YY, Chignell CF, Clark J, Myers P, Saavedra JE, Waalkes MP. Limited protective role of V-PYRRO/NO against cholestasis produced by alpha-naphthylisothiocyanate in mice. Biochem. Pharmacol. 70: 144-151 (2005). *

• Liu J, Manheimer E, Tsutani K, Gluud C. Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials. Am. J. Gastroenterol. 98: 538-544 (2003). *

• Liu LY, Wang XH, Wang ZL, Zhu QR, Wang JS. Characterization of ATP8B1 gene mutations and a hot-linked mutation found in Chinese children with progressive intrahepatic cholestasis and low GGT. J. Pediatr. Gastroenterol. Nutr. Dec 22 [Epub ahead of print] (2009).

• Liu LY, Wang ZL, Wang XH, Zhu QR, Wang JS. ABCB11 gene mutations in Chinese children with progressive intrahepatic cholestasis and low gamma glutamyltransferase. Liver Int. Oct 21 [Epub ahead of print] (2009). *

• Liu P, Lu M, Tian B, Li K, Garofalo RP, Prusak D, Wood TG, Brasier AR. Expression of an IKKgamma splice variant determines IRF3 and canonical NF-kappaB pathway utilization in ssRNA virus infection. PLoS One 4: e8079 (2009). *

• Liu X, Yang P, Lin X, Ren X, Zhou H, Huang X, Chi W, Kijlstra A, Chen L. Inhibitory effect of cyclosporin A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome. Clin. Immunol. 131: 333-342 (2009). *

• Ljubuncic P, Konikoff FM, Blendis LM, Bomzon A. Effect of interferon, ribavirin and ursodeoxycholic acid in patients with hepatitis C infection. Hepatogastroenterology 52: 1191-1196 (2005).

• Loguercio C, De Simone T, D'Auria MV, de Sio I, Federico A, Tuccillo C, Abbatecola AM, Del Vecchio Blanco C; Italian AISF Clinical Group. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Dig. Liver Dis. 36: 398-405 (2004).

• Lotterer E, Stiehl A, Raedsch R, Foelsch UR, Bircher J. Ursodeoxycholic acid in primary biliary cirrhosis: no evidence for toxicity in the stages I to III. J. Hepatol. 10: 284-290 (1990).

• Lu J, Chen M, Stanley SE, Li E. Effect of heterodimer partner RXRalpha on PPARgamma activation function-2 helix in solution. Biochem. Biophys. Res. Commun. 365: 42-46 (2008). *

• Lu M, Xia B, Ge L, Li Y, Zhao J, Chen F, Zhou F, Zhang X, Tan J. Role of major histocompatibility complex class I-related molecules A*A5.1 allele in ulcerative colitis in Chinese patients. Immunology 128: e230-e236 (2009). *

• Lu Z, Dong B, Mo X, Chen T, Wu H, Zhang Y, Xiao H. Pro12Ala polymorphism in PPAR gamma 2 associated with essential hypertension in Chinese nonagenarians/centenarians. Exp. Gerontol. 43: 1108-1113 (2008).

• Lucena JF, Herrero JI, Quiroga J, Sangro B, Garcia-Foncillas J, Zabalegui N, Sola J, Herraiz M, Medina JF, Prieto J. A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. Gastroenterology 124: 1037-1042 (2003). *

• Lukivskaya O, Zavodnik L, Knas M, Buko V. Antioxidant mechanism of hepatoprotection by ursodeoxycholic acid in experimental alcoholic steatohepatitis. Adv. Med. Sci. 51: 54-59 (2006).

• Luyendyk JP, Shores KC, Ganey PE, Roth RA. Bacterial lipopolysaccharide exposure alters aflatoxin B(1) hepatotoxicity: benchmark dose analysis for markers of liver injury. Toxicol. Sci. 68: 220-225 (2002). *

• Lykavieris P, Chardot C, Sokhn M, Gauthier F, Valayer J, Bernard O. Outcome in adulthood of biliary atresia: a study of 63 patients who survived for over 20 years with their native liver. Hepatology 41: 366-371 (2005). *

• Lykavieris P, Ducot B, Lachaux A, Dabadie A, Broue P, Sarles J, Bernard O, Jacquemin E. Liver disease associated with ZZ alpha1-antitrypsin deficiency and ursodeoxycholic acid therapy in children. J. Pediatr. Gastroenterol. Nutr. 47: 623-629 (2008). *

• Lykavieris P, van Mil S, Cresteil D, Fabre M, Hadchouel M, Klomp L, Bernard O, Jacquemin E. Progressive familial intrahepatic cholestasis type 1 and extrahepatic features: no catch-up of stature growth, exacerbation of diarrhea, and appearance of liver steatosis after liver transplantation. J. Hepatol. 39: 447-452 (2003). *

• Ma Y, Meregalli M, Hodges S, Davies N, Bogdanos DP, Fargion S, Fiorelli G, Vergani D. Alcohol dehydrogenase: an autoantibody target in patients with alcoholic liver disease. Int. J. Immunopathol. Pharmacol. 18: 173-182 (2005).

• Maestranzi S, Przemioslo R, Mitchell H, Sherwood RA. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann. Clin. Biochem. 35: 99-103 (1998).

• Maffei M, Hadengue A. Cholestasis of adult. 2. Clinical signs and symptomatic treatment. Rev. Med. Suisse. 2: 1965-1966, 1969-1971 (2006).

• Maggiore G, Bernard O, Hadchouel M, Lemonnier A, Alagille D. Diagnostic value of serum gamma-glutamyl transpeptidase activity in liver diseases in children. J. Pediatr. Gastroenterol. Nutr. 12: 21-26 (1991).

• Maggiore G, Sciveres M. Autoimmune hepatitis: a childhood disease. Current Pediatric Reviews 1: 73-90 (2005). *

• Magro F, Correia M, Moreira G, Dinis-Ribeiro M, Amandio V, Carneiro F, Ribeiro T. Adenocarcinoma of the cecum as the first manifestation of ulcerative colitis complicated by primary sclerosing cholangitis and endomyocardial fibrosis. Inflamm. Bowel Dis. 8: 287-290 (2002). *

• Mahl MA, von Schonfeld J, Uppenkamp M, Breuer N. Hemolytic anemia as cause of a marked bilirubin increase in primary biliary cirrhosis. Dtsch. Med. Wochenschr. 121: 1226-1228 (1996).

• Maier KP. Current diagnosis of chronic nonviral hepatitis. Schweiz. Rundsch. Med. Prax. 85: 1507-1512 (1996).

• Makino N, Maeda T, Oyama JI, Higuchi Y, Mimori K. Improving insulin sensitivity via activation of PPAR-gamma increases telomerase activity in the heart of OLETF rats. Am. J. Physiol. Heart Circ. Physiol. 297: H2188-H2195 (2009). *

• Malaguarnera M, Gargante MP, Russo C, Antic T, Vacante M, Malaguarnera M, Avitabile T, Li Volti G, Galvano F. L-Carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis - a randomized and controlled clinical trial. Am. J. Gastroenterol. Jan 12 [Epub ahead of print] (2010). *

• Malone DG, Dolan PW, Brown RR, Kalayoglu MV, Arend RA, Byrne GI, Ozaki Y. Interferon gamma induced production of indoleamine 2,3 dioxygenase in cultured human synovial cells. J. Rheumatol. 21: 1011-1019 (1994).

• Manns MP. Hepatotropic viruses and autoimmunity 1997. J. Viral Hepat. 4 Suppl. 1: 7-10 (1997).

• Manns MP, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology 26: 1054-1066 (1997). *

• Marchesini G, Suppini A, Forlani G. NAFLD treatment: cognitive-behavioral therapy has entered the arena. J. Hepatol. 43: 926-928 (2005). *

• Marra F, Defranco R, Robino G, Novo E, Efsen E, Pastacaldi S, Zamara E, Vercelli A, Lottini B, Spirli C, Strazzabosco M, Pinzani M, Parola M. Thiazolidinedione treatment inhibits bile duct proliferation and fibrosis in a rat model of chronic cholestasis. World J. Gastroenterol. 11: 4931-4938 (2005). *

• Marschall HU, Broome U, Einarsson C, Alvelius G, Thomas HG, Matern S. Isoursodeoxycholic acid: metabolism and therapeutic effects in primary biliary cirrhosis. J. Lipid Res. 42: 735-742 (2001). *

• Martin A, Romito G, Pepe I, De Vivo G, Merola MR, Limatola A, Gentile V. Transglutaminase-catalyzed reactions responsible for the pathogenesis of celiac disease and neurodegenerative diseases: from basic biochemistry to clinic. Curr. Med. Chem. 13: 1895-1902 (2006).

• Martinsson K, Carlsson L, Kleinau S, Hultman P. The effect of activating and inhibiting Fc-receptors on murine mercury-induced autoimmunity. J. Autoimmun. 31: 22-29 (2008).

• Maruta Y, Okayama N, Hiura M, Suehiro Y, Hirai H, Hinoda Y. Determination of ancestral allele for possible human cancer-associated polymorphisms. Cancer Genet. Cytogenet. 180: 24-29 (2008).

• Maton PN, Murphy GM, Dowling RH. Ursodeoxycholic acid treatment of gallstones. Dose-response study and possible mechanism of action. Lancet 2: 1297-1301 (1977).

• Matsuzaki Y, Doy M, Tanaka N, Shoda J, Osuga T, Nakano M, Aikawa T. Biochemical and histological changes after more than four years of treatment of ursodeoxycholic acid in primary biliary cirrhosis. J. Clin. Gastroenterol. 18: 36-41 (1994).

• Matsuzaki Y, Tanaka N, Osuga T, Aikawa T, Shoda J, Doi M, Nakano M. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am. J. Gastroenterol. 85: 15-23 (1990).

• Maver A, Medica I, Salobir B, Tercelj-Zorman M, Sabovic M, Petrovic D, Peterlin B. Peroxisome proliferator-activated receptor gamma/Pro12Ala polymorphism and peroxisome proliferator-activated receptor gamma coactivator-1 alpha/Gly482Ser polymorphism in patients with sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 25: 29-35 (2008).

• McClelland S, Shrivastava R, Medh JD. Regulation of translational efficiency by disparate 5' UTRs of PPARgamma splice variants. PPAR Res. 2009: 193413 (2009). *

• McColl GJ, Hammer J, Harrison LC. Absence of peripheral blood T cell responses to "shared epitope' containing peptides in recent onset rheumatoid arthritis. Ann. Rheum. Dis. 56: 240-246 (1997). *

• McPhie JL. Hepatic prolyl hydroxylase activity in human liver disease. Hepatogastroenterology 27: 277-282 (1980).

• Meier Y, Zodan T, Lang C, Zimmermann R, Kullak-Ublick GA, Meier PJ, Stieger B, Pauli-Magnus C. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World J. Gastroenterol. 14: 38-45 (2008). *

• Melter M, Rodeck B, Kardorff R, Hoyer PF, Petersen C, Ballauff A, Brodehl J. Progressive familial intrahepatic cholestasis: partial biliary diversion normalizes serum lipids and improves growth in noncirrhotic patients. Am. J. Gastroenterol. 95: 3522-3528 (2000). *

• Mentes BB, Tatlicioglu E, Akyol G, Uluoglu O, Sultan N, Yilmaz E, Celebi M, Taneri F, Ferahkose Z. Intestinal endotoxins as co-factors of liver injury in obstructive jaundice. HPB Surg. 9: 61-69 (1996). *

• Meredith D, Panchatcharam M, Miriyala S, Tsai YS, Morris AJ, Maeda N, Stouffer GA, Smyth SS. Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling. Arterioscler. Thromb. Vasc. Biol. 29: 465-471 (2009).

• Meyer JM, Han J, Moxley G. Tumor necrosis factor markers show sex-influenced association with rheumatoid arthritis. Arthritis Rheum. 44: 286-295 (2001). *

• Meyer S, Vogt T, Landthaler M, Berand A, Reichle A, Bataille F, Marx AH, Menz A, Hartmann A, Kunz-Schughart LA, Wild PJ. Cyclooxygenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma. PPAR Res. 2009: 848645 (2009). *

• Michaels A, Levy C. The medical management of primary sclerosing cholangitis. Medscape J. Med. 10: 61 (2008). *

• Michaels A, Levy C. Endoscopic and surgical management of primary sclerosing cholangitis. Medscape J. Med. 10: 242 (2008). *

• Mieli-Vergani G, Vergani D. Approach to a child with chronic liver disease. J. Gastroenterol. Hepatol. 19: S377-S378 (2004). *

• Milkiewicz P, Gallagher R, Chambers J, Eggington E, Weaver J, Elias E. Obstetric cholestasis with elevated gamma glutamyl transpeptidase: incidence, presentation and treatment. J. Gastroenterol. Hepatol. 18: 1283-1286 (2003). *

• Miloh T, Arnon R, Shneider B, Suchy F, Kerkar N. A retrospective single-center review of primary sclerosing cholangitis in children. Clin. Gastroenterol. Hepatol. 7: 239-245 (2009).

• Minervini MI, Ruppert K, Fontes P, Volpes R, Vizzini G, De Vera ME, Gruttadauria S, Miraglia R, Pipitone L, Marsh JW, Marcos A, Gridelli B, Demetris AJ. Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests? J. Hepatol. 50: 501-510 (2009).

• Minuk GY, Bohme CE, Burgess E, Hershfield NB, Kelly JK, Shaffer EA, Sutherland LR, Van Rosendaal G. Pilot study of cyclosporin A in patients with symptomatic primary biliary cirrhosis. Gastroenterology 95: 1356-1363 (1988).

• Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 121: 900-907 (2001). *

• Mitsui H, Miyauchi E, Miyahara J, Wada K, Yamakawa M, Kawata S. A case of primary biliary cirrhosis accompanied with fibrinogen storage disease. Pathol. Res. Pract. 201: 341-345 (2005).

• Miyachi K, Shibata M, Hasegawa C, Onozuka Y, Fritzler MJ. A case of primary biliary cirrhosis patient with anti-p97/VCP antibodies presenting a mild clinical course. Rinsho Byori 53: 19-23 (2005).

• Miyaguchi S, Ebinuma H, Imaeda H, Nitta Y, Watanabe T, Saito H, Ishii H. A novel treatment for refractory primary biliary cirrhosis? Hepatogastroenterology 47: 1518-1521 (2000).

• Miyaguchi S, Oda M, Saito H, Ishii H. Novel therapeutic approach to primary biliary cirrhosis patients: anti-eosinophil strategy. Hepatogastroenterology 45: 1457-1461 (1998).

• Mizukami Y, Ohhira M, Matsumoto A, Murazumi Y, Murazumi K, Ohta H, Ohhira M, Ono M, Miyake T, Maekawa I, Kohgo Y. Primary biliary cirrhosis associated with idiopathic thrombocytopenic purpura. J. Gastroenterol. 31: 284-288 (1996).

• Mizuno S, Hirano K, Tada M, Yamamoto K, Yashima Y, Yagioka H, Kawakubo K, Ito Y, Kogure H, Sasaki T, Arizumi T, Togawa O, Matsubara S, Nakai Y, Sasahira N, Tsujino T, Isayama H, Kawabe T, Omata M, Koike K. Bezafibrate for the treatment of primary sclerosing cholangitis. J. Gastroenterol. Feb 3 [Epub ahead of print] (2010). *

• Mo C, Chearwae W, O'Malley JT, Adams SM, Kanakasabai S, Walline CC, Stritesky GL, Good SR, Perumal NB, Kaplan MH, Bright JJ. Stat4 isoforms differentially regulate inflammation and demyelination in experimental allergic encephalomyelitis. J. Immunol. 181: 5681-5690 (2008). *

• Moibi JA, Gupta D, Jetton TL, Peshavaria M, Desai R, Leahy JL. Peroxisome proliferator-activated receptor-gamma regulates expression of PDX-1 and NKX6.1 in INS-1 cells. Diabetes 56: 88-95 (2007). *

• Monami M, Bardini G, Lamanna C, Pala L, Cresci B, Francesconi P, Buiatti E, Rotella CM, Mannucci E. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism 57: 387-392 (2008). *

• Mook-Kanamori DO, Steegers EA, Uitterlinden AG, Moll HA, van Duijn CM, Hofman A, Jaddoe VW. Breastfeeding modifies the association of PPARgamma-2 polymorphism Pro12Ala with growth in early life. Diabetes 58: 992-998 (2009). *

• Moras D. Structure of full-length PPARgamma-RXRalpha: a snapshot of a functional complex? Cell Metab. 9: 8-10 (2009). *

• Moreira AM, Carnevale FC, Tannuri U, Suzuki L, Gibelli N, Maksoud JG, Cerri GG. Long-term results of percutaneous bilioenteric anastomotic stricture treatment in liver-transplanted children. Cardiovasc. Intervent. Radiol. Jun 20 [Epub ahead of print] (2009).

• Morla D, Alazemi S, Lichtstein D. Stauffer's syndrome variant with cholestatic jaundice: a case report. J. Gen. Intern. Med. 21: C11-C13 (2006). *

• Morla D, Alazemi S, Lichtstein D. Stauffer's syndrome variant with cholestatic jaundice: a case report. J. Gen. Intern. Med. 21: 796 (2006). *

• Morton DH, Salen G, Batta AK, Shefer S, Tint GS, Belchis D, Shneider B, Puffenberger E, Bull L, Knisely AS. Abnormal hepatic sinusoidal bile acid transport in an Amish kindred is not linked to FIC1 and is improved by ursodiol. Gastroenterology 119: 188-195 (2000). *

• Muehlenberg K, Wiedmann K, Keppeler H, Sauerbruch T, Lammert F. Recurrent intrahepatic cholestasis of pregnancy and chain-like choledocholitiasis in a female patient with stop codon in the ABCB4-gene of the hepatobiliary phospholipid transporter. Z. Gastroenterol. 46: 48-53 (2008).

• Mullenbach R, Bennett A, Tetlow N, Patel N, Hamilton G, Cheng F, Chambers J, Howard R, Taylor-Robinson SD, Williamson C. ATP8B1 mutations in British cases with intrahepatic cholestasis of pregnancy. Gut 54: 829-834 (2005). *

• Munoz LE, Cordero P, Torres L, Sauceda AY, Flores JP, Segura JJ. Adipokines in a group of mexican patients with nonalcoholic steatohepatitis. Ann. Hepatol. 8: 123-128 (2009). *

• Muriel P, Suarez OR, Gonzalez P, Zuniga L. Protective effect of S-adenosyl-L-methionine on liver damage induced by biliary obstruction in rats: a histological, ultrastructural and biochemical approach. J. Hepatol. 21: 95-102 (1994).

• Muting D, Fischer R, Kalk JF, Kruck P. Chronic destructive non-suppurating cholangitis. Fortschr. Med. 100: 1179-1187 (1982).

• Myara A, Guechot J, Imbert-Bismut F, Lasnier E, Piton A, Voitot H, Ferard G. Harmonization of liver enzyme results: calibration for aminotransferases and gamma glutamyltransferase. J. Hepatol. 41: 501-502 (2004). *

• Naito H, Yamanoshita O, Kamijima M, Katoh T, Matsunaga T, Lee CH, Kim H, Aoyama T, Gonzalez FJ, Nakajima T. Association of V227A PPARalpha polymorphism with altered serum biochemistry and alcohol drinking in Japanese men. Pharmacogenet. Genomics 16: 569-577 (2006).

• Nakamura K, Aoshima M, Tani M, Kato T, Fugita M, Kimura A, Hasegawa T, Akiyama K, Makino I. Effect of ursodeoxycholic acid (UDCA) therapy for compensatory liver cirrhosis on liver function tests and serum bile acid metabolism. Nippon Shokakibyo Gakkai Zasshi 89: 2762-2770 (1992).

• Nakamura T, Higashi SI, Tomoda K, Tsukano M, Sugi K. Primary biliary cirrhosis (PBC)-CREST overlap syndrome with coexistence of Sjogren's syndrome and thyroid dysfunction. Clin. Rheumatol. 26: 596-600 (2007). *

• Nakamuta M, Enjoji M, Kotoh K, Shimohashi N, Tanabe Y. Long-term fibrate treatment for PBC. J. Gastroenterol. 40: 546-547 (2005). *

• Nakamuta M, Fujino T, Yada R, Yasutake K, Yoshimoto T, Harada N, Yada M, Higuchi N, Kato M, Kohjima M, Taketomi A, Maehara Y, Nishinakagawa T, Machida K, Matsunaga K, Nakashima M, Kotoh K, Enjoji M. Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway. Int. J. Clin. Pharmacol. Ther. 48: 22-28 (2010).

• Nakanishi N, Nakamura K, Nakajima K, Suzuki K, Tatara K. Coffee consumption and decreased serum gamma-glutamyltransferase: a study of middle-aged Japanese men. Eur. J. Epidemiol. 16: 419-423 (2000).

• Nakano T, Ishibashi H, Matsui M, Yasutake T, Ishii Y, Dohmen K, Nagasawa K, Niho Y. A case of primary biliary cirrhosis with negative anti-mitochondrial antibody anteceded by rheumatoid arthritis. Fukuoka Igaku Zasshi 83: 144-148 (1992).

• Nakashima T, Yoh T, Sumida Y, Kakisaka Y, Mitsuyoshi H. Differences in the efficacy of ursodeoxycholic acid and bile acid metabolism between viral liver diseases and primary biliary cirrhosis. J. Gastroenterol. Hepatol. 16: 541-547 (2001). *

• Narkewicz MR, Smith D, Gregory C, Lear JL, Osberg I, Sokol RJ. Effect of ursodeoxycholic acid therapy on hepatic function in children with intrahepatic cholestatic liver disease. J. Pediatr. Gastroenterol. Nutr. 26: 49-55 (1998). *

• Naveh Y, Bassan L, Rosenthal E, Berkowitz D, Jaffe M, Mandel H, Berant M. Progressive familial intrahepatic cholestasis among the Arab population in Israel. J. Pediatr. Gastroenterol. Nutr. 24: 548-554 (1997). *

• Nelson DE, Virok DP, Wood H, Roshick C, Johnson RM, Whitmire WM, Crane DD, Steele-Mortimer O, Kari L, McClarty G, Caldwell HD. Chlamydial IFN-gamma immune evasion is linked to host infection tropism. Proc. Natl. Acad. Sci. U.S.A. 102: 10658-10663 (2005). *

• Neugebauer P, Goldbergova-Pavkova M, Kala P, Bocek O, Jerabek P, Poloczek M, Vytiska M, Parenica J, Mikulik R, Jarkovsky J, Semrad B, Spinar J, Vasku A. Nuclear receptors gene polymorphisms and risk of restenosis and clinical events following coronary stenting. Vnitr. Lek. 55: 1135-1140 (2009).

• Neuhaus TJ, Stallmach T, Leumann E, Altorfer J, Braegger CP. Familial progressive tubulo-interstitial nephropathy and cholestatic liver disease - a newly recognized entity? Eur. J. Pediatr. 156: 723-726 (1997).

• Nicolas I, Pons JA, Vargas A, Gallardo F, Albaladejo A, Nicolas JM. Ursodeoxycholic acid treatment shortens the course of cholestasis in two patients with benign recurrent intrahepatic cholestasis. Gastroenterol. Hepatol. 26: 421-423 (2003).

• Niederau C, Lange S, Fruhauf M, Thiel A. Cutaneous signs of liver disease: value for prognosis of severe fibrosis and cirrhosis. Liver Int. 28: 659-666 (2008). *

• Nieto N, Fernandez MI, Torres MI, Rios A, Suarez MD, Gil A. Dietary monounsaturated n-3 and n-6 long-chain polyunsaturated fatty acids affect cellular antioxidant defense system in rats with experimental ulcerative colitis induced by trinitrobenzene sulfonic acid. Dig. Dis. Sci. 43: 2676-2687 (1998). *

• Nishio A, Bass NM, Luketic VA, Coppel RL, Gershwin ME. Primary biliary cirrhosis: from induction to destruction. Semin. Gastrointest. Dis. 12: 89-102 (2001).

• Nishio A, Keeffe EB, Gershwin ME. Primary biliary cirrhosis: lessons learned from an organ-specific disease. Clin. Exp. Med. 1: 165-178 (2001). *

• Nishio A, Keeffe EB, Ishibashi H, Gershwin EM. Diagnosis and treatment of primary biliary cirrhosis. Med. Sci. Monit. 6: 181-193 (2000). *

• Nishio A, Neuberger J, Gershwin ME. Management of patients with primary biliary cirrhosis: a practical guide. BioDrugs 12: 159-173 (1999).

• Nobili V, Marcellini M, Giovannelli L, Girolami E, Muratori F, Giannone G, Devito R, De Benedetti F. Association of serum interleukin-8 levels with the degree of fibrosis in infants with chronic liver disease. J. Pediatr. Gastroenterol. Nutr. 39: 540-544 (2004). *

• Nobuoka A, Takayama T, Miyanishi K, Sato T, Takanashi K, Hayashi T, Kukitsu T, Sato Y, Takahashi M, Okamoto T, Matsunaga T, Kato J, Oda M, Azuma T, Niitsu Y. Glutathione-S-transferase P1-1 protects aberrant crypt foci from apoptosis induced by deoxycholic acid. Gastroenterology 127: 428-443 (2004). *

• Nofziger C, Brown KK, Smith CD, Harrington W, Murray D, Bisi J, Ashton TT, Maurio FP, Kalsi K, West TA, Baines DL, Blazer-Yost BL. PPARgamma agonists inhibit vasopressin mediated anion transport in the MDCK-C7 cell line. Am. J. Physiol. Renal Physiol. 297: F55-F62 (2009). *

• Nong LG, Luo B, Zhang L, Nong HB. Interleukin-18 gene promoter polymorphism and the risk of nasopharyngeal carcinoma in a Chinese population. DNA Cell Biol. 28: 507-513 (2009).

• Noubade R, Milligan G, Zachary JF, Blankenhorn EP, Del Rio R, Rincon M, Teuscher C. Histamine receptor H(1) is required for TCR-mediated p38 MAPK activation and optimal IFN-gamma production in mice. J. Clin. Invest. 117: 3507-3518 (2007). *

• Nowak G, Ericzon BG, Nava S, Jaksch M, Westgren M, Sumitran-Holgersson S. Identification of expandable human hepatic progenitors which differentiate into mature hepatic cells in vivo. Gut 54: 972-979 (2005). *

• Nunes de Paiva MJ, Pereira Bastos de Siqueira ME. Increased serum bile acids as a possible biomarker of hepatotoxicity in Brazilian workers exposed to solvents in car repainting shops. Biomarkers 10: 456-463 (2005).

• O'Brien CB, Senior JR, Arora-Mirchandani R, Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 14: 838-847 (1991).

• Obermeier F, Kojouharoff G, Hans W, Scholmerich J, Gross V, Falk W. Interferon-gamma (IFN-gamma)- and tumour necrosis factor (TNF)-induced nitric oxide as toxic effector molecule in chronic dextran sulphate sodium (DSS)-induced colitis in mice. Clin. Exp. Immunol. 116: 238-245 (1999). *

• Oca F, Dreux S, Gerard B, Simon-Bouy B, de Becdelievre A, Ferec C, Girodon E, Muller F. Amniotic fluid digestive enzyme analysis is useful for identifying CFTR gene mutations of unclear significance. Clin. Chem. 55: 2214-2217 (2009). *

• Ohata M, Toda G. Gamma-glutamyltranspeptidase (gamma-GT). Rinsho Byori 116: S62-S71 (2001).

• Ohba K, Omagari K, Murase K, Hazama H, Masuda J, Kinoshita H, Isomoto H, Mizuta Y, Miyazaki M, Murata I, Kohno S. A possible mouse model for spontaneous cholangitis: serological and histological characteristics of MRL/lpr mice. Pathology 34: 250-256 (2002). *

• Ohhira M, Ohhira M, Matsumoto A, Ohta H, Okuno K, Okamoto M, Taya N, Namiki M. The development of serum alkaline phosphatase and gamma-glutamyl transpeptidase in early stages of primary biliary cirrhosis. Nippon Shokakibyo Gakkai Zasshi 92: 140-145 (1995).

• Oka H, Toda G, Ikeda Y, Hashimoto N, Hasumura Y, Kamimura T, Ohta Y, Tsuji T, Hattori N, Namihisa T, et al. A multi-center double-blind controlled trial of ursodeoxycholic acid for primary biliary cirrhosis. Gastroenterol. Jpn. 25: 774-780 (1990).

• Okolicsanyi L, Groppo M, Floreani A, Morselli-Labate AM, Rusticali AG, Battocchia A, Colombo M, Galatola G, Gasbarrini G, Podda M, Ricci G, Rosina F, Zuin M. Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey. Dig. Liver Dis. 35: 325-331 (2003).

• Omata M, Yoshida H, Toyota J, Tomita E, Nishiguchi S, Hayashi N, Iino S, Makino I, Okita K, Toda G, Tanikawa K, Kumada H. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 56: 1747-1753 (2007). *

• Onal IK, Ersoy O, Aydinli M, Yonem O, Harmanci O, Sokmensuer C, Bayraktar Y. Hepatic granuloma in Turkish adults: a report of 13 cases. Eur. J. Intern. Med. 19: 527-530 (2008).

• Ong JC, O'Loughlin EV, Kamath KR, Dorney SF, de Silva M, Gaskin KJ. Sclerosing cholangitis in children with inflammatory bowel disease. Aust. N. Z. J. Med. 24: 149-153 (1994).

• Ono M, Sekiya C, Ohhira M, Ohhira M, Namiki M, Endo Y, Suzuki K, Matsuda Y, Taniguchi N. Elevated level of serum Mn-superoxide dismutase in patients with primary biliary cirrhosis: possible involvement of free radicals in the pathogenesis in primary biliary cirrhosis. J. Lab. Clin. Med. 118: 476-483 (1991).

• Ostberg T, Svensson S, Selen G, Uppenberg J, Thor M, Sundbom M, Sydow-Backman M, Gustavsson AL, Jendeberg L. A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. J. Biol. Chem. 279: 41124-41130 (2004). *

• Ozes ON, Taylor MW. Reversal of interferon-gamma-resistant phenotype by poly(I:C): possible involvement of ISGF2 (IRF1) in interferon-gamma-mediated induction of the IDO gene. J. Interferon Res. 14: 25-32 (1994).

• Page ST, Plymate SR, Bremner WJ, Matsumoto AM, Hess DL, Lin DW, Amory JK, Nelson PS, Wu JD. Effect of medical castration on CD4+CD25+ T cells, CD8+T-cell IFN-gamma expression, and NK cells: a physiological role of testosterone and/or its metabolites. Am. J. Physiol. Endocrinol. Metab. 290: E856-E863 (2006). *

• Paine P, Hobday C, Keating JJ, Brown CM, Morris JA. Ulcerative pan-colitis and primary sclerosing cholangitis with hyposplenism complicated by fatal pneumococcal meningitis. CME Gastroenterology 4: 95-96 (2001). *

• Pan F, Tang X, Zhang K, Li X, Xu J, Chen H, Ye D. Genetic susceptibility and haplotype analysis between Fcgamma receptor IIB and IIIA gene with systemic lupus erythematosus in Chinese population. Lupus 17: 733-738 (2008). *

• Pan F, Ye D, Zhang K, Li X, Xu J, Chen H. Gln50Ter polymorphism of Fcgamma receptor IIB gene associated with genetic susceptibility to human systemic lupus erythematosus in Chinese populations. Arch. Dermatol. Res. 299: 47-51 (2007). *

• Pan F, Zhang K, Li X, Xu J, Hao J, Ye D. Association of Fcgamma receptor IIB gene polymorphism with genetic susceptibility to systemic lupus erythematosus in Chinese populations-A family-based association study. J. Dermatol. Sci. 43: 35-41 (2006).

• Pan X, Song X, Wang L, Li L, Ying B. Association of the Pro12Ala polymorphism in peroxisome proliferators activated receptor gamma gene with rheumatoid arthritis in Sichuan Province of China. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 26: 87-90 (2009).

• Panasiuk A, Zak J, Panasiuk B, Prokopowicz D. Increase in expression of monocytic tissue factor (CD142) with monocytes and blood platelet activation in liver cirrhosis. Blood Coagul. Fibrinolysis 18: 739-744 (2007).

• Pancani T, Phelps JT, Searcy JL, Kilgore MW, Chen KC, Porter NM, Thibault O. Distinct modulation of voltage-gated and ligand-gated Ca2+ currents by PPAR-gamma agonists in cultured hippocampal neurons. J. Neurochem. 109: 1800-1811 (2009).

• Pandey JP. Immunoglobulin GM genes and IgG antibodies to cytomegalovirus in patients with systemic sclerosis. Clin. Exp. Rheumatol. 22: S35-S37 (2004).

• Papachristou GI, Demetris AJ, Craig F, Lee KKW, Rabinovitz M. Cholestatic jaundice and bone lesions in an elderly woman. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 53-57 (2004). *

• Pares A, Caballeria L, Rodes J, Bruguera M, Rodrigo L, Garcia-Plaza A, Berenguer J, Rodriguez-Martinez D, Mercader J, Velicia R. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J. Hepatol. 32: 561-566 (2000). *

• Park JY, Kawada T, Han IS, Kim BS, Goto T, Takahashi N, Fushiki T, Kurata T, Yu R. Capsaicin inhibits the production of tumor necrosis factor alpha by LPS-stimulated murine macrophages, RAW 264.7: a PPARgamma ligand-like action as a novel mechanism. FEBS Lett. 572: 266-270 (2004). *

• Parlesak A, Schafer C, Bode C. IgA against gut-derived endotoxins: does it contribute to suppression of hepatic inflammation in alcohol-induced liver disease? Dig. Dis. Sci. 47: 760-766 (2002). *

• Patel DA, Srinivasan SR, Xu JH, Chen W, Berenson GS. Persistent elevation of liver function enzymes within the reference range is associated with increased cardiovascular risk in young adults: the Bogalusa Heart Study. Metabolism 56: 792-798 (2007). *

• Patkowski W, Zieniewicz K, Skalski M, Krawczyk M. Correlation between selected prognostic factors and postoperative course in liver transplant recipients. Transplant. Proc. 41: 3091-3102 (2009). *

• Patriquin H, Lenaerts C, Smith L, Perreault G, Grignon A, Filiatrault D, Boisvert J, Roy CC, Rasquin-Weber A. Liver disease in children with cystic fibrosis: US-biochemical comparison in 195 patients. Radiology 211: 229-232 (1999). *

• Patsenker E, Popov Y, Stickel F, Schneider V, Ledermann M, Sagesser H, Niedobitek G, Goodman SL, Schuppan D. Pharmacological inhibition of integrin alphavbeta3 aggravates experimental liver fibrosis and suppresses hepatic angiogenesis. Hepatology 50: 1501-1511 (2009).

• Patton H, Lavine JE, Van Natta ML, Schwimmer JB, Kleiner D, Molleston J; Nonalcoholic Steatohepatitis Clinical Research Network. Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. Gastroenterology 135: 1961-1971.e2 (2008). *

• Pedersen-Lane JH, Zurier RB, Lawrence DA. Analysis of the thiol status of peripheral blood leukocytes in rheumatoid arthritis patients. J. Leukoc. Biol. 81: 934-941 (2007). *

• Penalva Polo JC, Verdu Benavente C, Belda Abad G, Ruiz JA, Gaspar Martinez E, Correa Estan JA, Munoz Ramirez E, Martinez Prieto C. Persistent acute hepatitis in a patient with chronic hepatitis C. Gastroenterol. Hepatol. 29: 451-454 (2006).

• Peng WK, Sheikh Z, Paterson-Brown S, Nixon SJ. Role of liver function tests in predicting common bile duct stones in acute calculous cholecystitis. Br. J. Surg. 92: 1241-1247 (2005). *

• Pennington CR, Ross PE, Bouchier IA. Serum bile acids in the diagnosis of hepatobiliary disease. Gut 18: 903-908 (1977). *

• Perez-Aguilar F, Benlloch S, Berenguer M. Study of patients referred for elevated ferritin levels and/or transferrin saturation: significance of non-alcoholic fatty liver disease. Gastroenterol. Hepatol. 27: 508-514 (2004).

• Perez-Aguilar F, Ferrer-Calvete J, Nicolas D, Berenguer J, Ponce J. Digestive alterations in cystic fibrosis. Retrospective study of a series of 46 adult patients. Gastroenterol. Hepatol. 22: 72-78 (1999).

• Perra A, Kowalik MA, Pibiri M, Ledda-Columbano GM, Columbano A. Thyroid hormone receptor ligands induce regression of rat preneoplastic liver lesions causing their reversion to a differentiated phenotype. Hepatology 49: 1287-1296 (2009). *

• Pertovaara M, Hurme M, Antonen J, Pasternack A, Pandey JP. Immunoglobulin KM and GM gene polymorphisms modify the clinical presentation of primary Sjogren's syndrome. J. Rheumatol. 31: 2175-2180 (2004).

• PetitClerc C. Quantitative fractionation of alkaline phosphatase isoenzymes according to their thermostability. Clin. Chem. 22: 42-48 (1976).

• Pettersson J, Hindorf U, Persson P, Bengtsson T, Malmqvist U, Werkstrom V, Ekelund M. Muscular exercise can cause highly pathological liver function tests in healthy men. Br. J. Clin. Pharmacol. 65: 253-359 (2008). *

• Pfab T, Poralla C, Richter CM, Godes M, Slowinski T, Priem F, Halle H, Hocher B. Fetal and maternal peroxisome proliferator-activated receptor gamma2 Pro12Ala does not influence birth weight. Obesity (Silver Spring) 14: 1880-1885 (2006). *

• Phillips SM, Bhopale MK, Hilliard B, Zekavat SA, Ali MA, Rostami A. Suppression of murine experimental autoimmune encephalomyelitis by interleukin-2 receptor targeted fusion toxin, DAB(389)IL-2. Cell. Immunol. Dec 5 [Epub ahead of print] (2009). *

• Pianese P, Salvia G, Campanozzi A, D'Apolito O, Dello Russo A, Pettoello-Mantovani M, Corso G. Sterol profiling in red blood cell membranes and plasma of newborns receiving total parenteral nutrition. J. Pediatr. Gastroenterol. Nutr. 47: 645-651 (2008). *

• Piitulainen E, Carlson J, Ohlsson K, Sveger T. alpha1-Antitrypsin deficiency in 26-year-old subjects: lung, liver, and protease/protease inhibitor studies. Chest 128: 2076-2081 (2005). *

• Piperno A, Vergani A, Salvioni A, Trombini P, Vigano M, Riva A, Zoppo A, Boari G, Mancia G. Effects of venesections and restricted diet in patients with the insulin-resistance hepatic iron overload syndrome. Liver Int. 24: 471-476 (2004). *

• Pirenne J, Monbaliu D, Aerts R, Desschans B, Liu Q, Cassiman D, Laleman W, Verslype C, Magdy M, Van Steenbergen W, Nevens F. Biliary strictures after liver transplantation: risk factors and prevention by donor treatment with epoprostenol. Transplant. Proc. 41: 3399-3402 (2009). *

• Plesa A. Treatment of cholestatic liver disease. Rev. Med. Chir. Soc. Med. Nat. Iasi. 107: 733-736 (2003).

• Plonska-Ocypa K, Sicinski RR, Plum LA, Grzywacz P, Frelek J, Clagett-Dame M, Deluca HF. 13-Methyl-substituted des-C,D analogs of (20S)-1alpha,25-dihydroxy-2-methylene-19-norvitamin D(3) (2MD): synthesis and biological evaluation. Bioorg. Med. Chem. 17: 1747-1763 (2009). *

• Podojil JR, Miller SD. Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy. Immunol. Rev. 229: 337-355 (2009). *

• Pohl R, Junge U. Primary sclerosing cholangitis with chronic pancreatitis. Dtsch. Med. Wochenschr. 122: 778-782 (1997).

• Polzien F, Ramadori G. Increased intercellular adhesion molecule-1 serum concentration in cholestasis. J. Hepatol. 25: 877-886 (1996). *

• Ponsioen CY, Lam K, van Milligen de Wit AW, Huibregtse K, Tytgat GN. Four years experience with short term stenting in primary sclerosing cholangitis. Am. J. Gastroenterol. 94: 2403-2407 (1999). *

• Portincasa P, Vacca M, Moschetta A, Petruzzelli M, Palasciano G, van-Erpecum KJ, van-Berge-Henegouwen GP. Primary sclerosing cholangitis: updates in diagnosis and therapy. World J. Gastroenterol. 11: 7-16 (2005). *

• Poupon R, Chazouilleres O, Balkau B, Poupon RE. Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis. UDCA-PBC Group. J. Hepatol. 30: 408-412 (1999). *

• Poupon R, Chretien Y, Poupon RE, Ballet F, Calmus Y, Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet 1: 834-836 (1987).

• Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N. Engl. J. Med. 324: 1548-1554 (1991).

• Poupon RE, Eschwege E, Poupon R. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group. J. Hepatol. 11: 16-21 (1990).

• Poynard T, Zourabichvili O, Hilpert G, Naveau S, Poitrine A, Benatar C, Chaput JC. Prognostic value of total serum bilirubin/gamma-glutamyl transpeptidase ratio in cirrhotic patients. Hepatology 4: 324-327 (1984).

• Prasad KN, Saxena A, Ghoshal UC, Bhagat MR, Krishnani N. Analysis of Pro12Ala PPAR gamma polymorphism and Helicobacter pylori infection in gastric adenocarcinoma and peptic ulcer disease. Ann. Oncol. 19: 1299-1303 (2008).

• Pratt DS. Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 21: 270-274 (2005). *

• Preimel D, Sticht H. Molecular modeling of the interleukin-19 receptor complex. Novel aspects of receptor recognition in the interleukin-10 cytokine family. J. Mol. Model. 10: 290-296 (2004).

• Probstfield JL, Statland BE, Gorman L, Hunninghake DB. Alterations in human serum alkaline phosphatase and its isoenzymes by hypolipidemic agents: colestipol and clofibrate. Metabolism 32: 818-821 (1983).

• Qi PF, Wei YM, Ouellet T, Chen Q, Tan X, Zheng YL. The gamma-gliadin multigene family in common wheat (Triticum aestivum) and its closely related species. BMC Genomics 10: 168 (2009). *

• Qiao HL, Yang J, Zhang YW. Relationships between specific serum IgE, cytokines and polymorphisms in the IL-4, IL-4Ralpha in patients with penicillins allergy. Allergy 60: 1053-1059 (2005). *

• Qin B, Polansky MM, Harry D, Anderson RA. Green tea polyphenols improve cardiac muscle mRNA and protein levels of signal pathways related to insulin and lipid metabolism and inflammation in insulin-resistant rats. Mol. Nutr. Food Res. Jan 28 [Epub ahead of print] (2010). *

• Qiu DK, Li XM, Wei J, Ye LJ, Peng YS, Ma X. Clinical features of 107 autoimmune hepatitis patients and 30 of them with AIH-primary biliary cirrhosis overlap syndrome. Zhonghua Gan Zang Bing Za Zhi 16: 367-371 (2008).

• Quan Y, Moller T, Weinstein JR. Regulation of Fcgamma receptors and immunoglobulin G-mediated phagocytosis in mouse microglia. Neurosci. Lett. 464: 29-33 (2009).

• Quintanilla RA, Jin YN, Fuenzalida K, Bronfman M, Johnson GV. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J. Biol. Chem. 283: 25628-25637 (2008). *

• Radha V, Vimaleswaran KS, Babu HN, Abate N, Chandalia M, Satija P, Grundy SM, Ghosh S, Majumder PP, Deepa R, Rao SM, Mohan V. Role of genetic polymorphism peroxisome proliferator-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: evidence for heterogeneity. Diabetes Care 29: 1046-1051 (2006). *

• Radha V, Vimaleswaran KS, Babu S, Deepa R, Anjana M, Ghosh S, Majumder PP, Rao MR, Mohan V. Lack of association between serum adiponectin levels and the Pro12Ala polymorphism in Asian Indians. Diabet. Med. 24: 398-402 (2007). *

• Rahman SH, Srinivasan AR, Nicolaou A. Transsulfuration pathway defects and increased glutathione degradation in severe acute pancreatitis. Dig. Dis. Sci. 54: 675-682 (2009). *

• Rahmioglu N, Andrew T, Cherkas L, Surdulescu G, Swaminathan R, Spector T, Ahmadi KR. Epidemiology and genetic epidemiology of the liver function test proteins. PLoS ONE 4: e4435 (2009). *

• Rain F, Durieu I, Mackiewitz R, Levrat R. Dermatopolymyositis and primary biliary cirrhosis. A rare association. Presse. Med. 25: 581-582 (1996).

• Raina A, Greer JB, Whitcomb DC. Serology in autoimmune pancreatitis. Minerva Gastroenterol. Dietol. 54: 375-387 (2008).

• Rajendra S, Kutty K. Caecal tumour with hepatic metastases? Gut 54: 178 (2005). *

• Ramakers JD, Verstege MI, Thuijls G, Te Velde AA, Mensink RP, Plat J. The PPARgamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis. J. Clin. Immunol. 27: 275-283 (2007). *

• Ramasawmy R, Cunha-Neto E, Fae KC, Muller NG, Cavalcanti VL, Drigo SA, Ianni B, Mady C, Kalil J, Goldberg AC. BAT1, a putative anti-Inflammatory gene, is associated with chronic Chagas cardiomyopathy. J. Infect. Dis. 193: 1394-1399 (2006). *

• Ramos HJ, Davis AM, Cole AG, Schatzle JD, Forman J, Farrar JD. Reciprocal responsiveness to IL-12 and IFN-alpha specifies human CD8+ effector versus central memory T cell fates. Blood 113: 5516-5525 (2009). *

• Randy LH, Guoying B. Agonism of peroxisome proliferator receptor-gamma may have therapeutic potential for neuroinflammation and Parkinson's disease. Curr. Neuropharmacol. 5: 35-46 (2007).

• Rath HC, Caesar I, Roth M, Scholmerich J. Nutritional deficiencies and complications in chronic inflammatory bowel diseases. Med. Klin. (Munich) 93: 6-10 (1998).

• Razquin C, Alfredo Martinez J, Martinez-Gonzalez MA, Corella D, Santos JM, Marti A. The Mediterranean diet protects against waist circumference enlargement in 12Ala carriers for the PPARgamma gene: 2 years' follow-up of 774 subjects at high cardiovascular risk. Br. J. Nutr. 102: 672-679 (2009). *

• Reber SO, Obermeier F, Straub RH, Falk W, Neumann ID. Chronic intermittent psycho-social stress in mice increases the severity of an acute DSS-induced colitis and additionally impairs regeneration. Endocrinology 147: 4968-4976 (2006). *

• Reboredo M, Zabala M, Mauleon I, De Las Rivas J, Kreppel F, Kochanek S, Prieto J, Hernandez-Alcoceba R, Kramer MG. Interleukin-12 inhibits liver-specific drug-inducible systems in vivo. Gene Ther. 15: 277-288 (2008). *

• Redchenko I, Harrop R, Ryan MG, Hawkins RE, Carroll MW. Identification of a major histocompatibility complex class I-restricted T-cell epitope in the tumour-associated antigen, 5T4. Immunology 118: 50-57 (2006). *

• Reggiani A, Dizioli P, Quattrocchi D, Quinzani M, Marelli A, Bodini P. Intrahepatic cholestasis: clinical and nosological classification. Critical survey of personal experience. Minerva Gastroenterol. Dietol. 43: 71-81 (1997).

• Reichling JJ, Kaplan MM. Clinical use of serum enzymes in liver disease. Dig. Dis. Sci. 33: 1601-1614 (1988).

• Reifen R, Zaiger G, Uni Z. Effect of vitamin A on small intestinal brush border enzymes in a rat. Int. J. Vitam. Nutr. Res. 68: 281-286 (1998).

• Reuter S, Schnekenburger M, Cristofanon S, Buck I, Teiten MH, Daubeuf S, Eifes S, Dicato M, Aggarwal BB, Visvikis A, Diederich M. Tumor necrosis factor alpha induces gamma-glutamyltransferase expression via nuclear factor-kappaB in cooperation with Sp1. Biochem. Pharmacol. 77: 397-411 (2009). *

• Reyes-Gordillo K, Segovia J, Shibayama M, Vergara P, Moreno MG, Muriel P. Curcumin protects against acute liver damage in the rat by inhibiting NF-kappaB, proinflammatory cytokines production and oxidative stress. Biochim. Biophys. Acta 1770: 989-996 (2007). *

• Rezaei N, Aghamohammadi A, Shakiba Y, Mahmoudi M, Jalali A, Moradi B, Amirzargar AA. Cytokine gene polymorphisms in common variable immunodeficiency. Int. Arch. Allergy Immunol. 150: 1-7 (2009).

• Rhee EJ, Oh KW, Lee WY, Kim SY, Oh ES, Baek KH, Kang MI, Kim SW. Effects of two common polymorphisms of peroxisome proliferator-activated receptor-gamma gene on metabolic syndrome. Arch. Med. Res. 37: 86-94 (2006).

• Ribas F, Oliveira LA, Petzl-Erler ML, Bicalho MG. Major histocompatibility complex class I chain-related gene A polymorphism and linkage disequilibrium with HLA-B alleles in Euro-Brazilians. Tissue Antigens 72: 532-538 (2008). *

• Ribot JC, Debarros A, Pang DJ, Neves JF, Peperzak V, Roberts SJ, Girardi M, Borst J, Hayday AC, Pennington DJ, Silva-Santos B. CD27 is a thymic determinant of the balance between interferon-gamma- and interleukin 17-producing gammadelta T cell subsets. Nat. Immunol. 10: 427-436 (2009). *

• Rifle G, Mousson C, Hillon P, Marceau M, Chalopin JM, Tanter Y. Primary biliary cirrhosis: therapeutic trial using plasma exchange and immunosuppression. Preliminary results. Ann. Med. Interne (Paris) 139 Suppl. 1: 32-34 (1988).

• Rigato I, Cravatari M, Avellini C, Ponte E, Croce SL, Tiribelli C. Drug-induced acute cholestatic liver damage in a patient with mutation of UGT1A1. Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 403-408 (2007). *

• Risques RA, Lai LA, Brentnall TA, Li L, Feng Z, Gallaher J, Mandelson MT, Potter JD, Bronner MP, Rabinovitch PS. Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. Gastroenterology 135: 410-418 (2008). *

• Ritzel U, Leonhardt U, Nather M, Schafer G, Armstrong VW, Ramadori G. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J. Hepatol. 36: 454-458 (2002). *

• Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes. J. Cardiovasc. Pharmacol. Ther. 7: 219-226 (2002).

• Rodriguez-Ortigosa CM, Cincu RN, Sanz S, Ruiz F, Quiroga J, Prieto J. Effect of ursodeoxycholic acid on methionine adenosyltransferase activity and hepatic glutathione metabolism in rats. Gut 50: 701-706 (2002). *

• Rolandi E, Franceschini R, Cataldi A, Cicchetti V, Carati L, Barreca T. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study. Eur. J. Clin. Pharmacol. 40: 473-476 (1991).

• Rollins MD, Sudarshan S, Firpo MA, Etherington BH, Hart BJ, Jackson HH, Jackson JD, Emerson LL, Yang DT, Mulvihill SJ, Glasgow RE. Anti-inflammatory effects of PPAR-gamma agonists directly correlate with PPAR-gamma expression during acute pancreatitis. J. Gastrointest. Surg. 10: 1120-1130 (2006).

• Roschmann E, Wienker TF, Gerok W, Volk BA. T-cell receptor variable genes and genetic susceptibility to celiac disease: an association and linkage study. Gastroenterology 105: 1790-1796 (1993).

• Rosmorduc O, Poupon R. Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene. Orphanet J. Rare Dis. 2: 29 (2007). *

• Rossi M, Vajro P, Iorio R, Battagliese A, Brunetti-Pierri N, Corso G, Di Rocco M, Ferrari P, Rivasi F, Vecchione R, Andria G, Parenti G. Characterization of liver involvement in defects of cholesterol biosynthesis: long-term follow-up and review. Am. J. Med. Genet. 132A: 144-151 (2005). *

• Roth M, Black JL. Transcription factors in asthma: are transcription factors a new target for asthma therapy? Curr. Drug Targets 7: 589-595 (2006).

• Rottman M, Soudais C, Vogt G, Renia L, Emile JF, Decaluwe H, Gaillard JL, Casanova JL. IFN-gamma mediates the rejection of haematopoietic stem cells in IFN-gammaR1-deficient hosts. PLoS Med. 5: e26 (2008). *

• Rudi J, Schonig T, Stremmel W. Therapy with ursodeoxycholic acid in primary biliary cirrhosis in pregnancy. Z. Gastroenterol. 34: 188-191 (1996).

• Ruedig C, Dringen R. TNFalpha increases activity of gamma-glutamyl transpeptidase in cultured rat astroglial cells. J. Neurosci. Res. 75: 536-543 (2004). *

• Ruegg R, Matter L, Schopfer K, Grob PJ. Clinical significance of antimitochondrial antibodies. Schweiz. Med. Wochenschr. 115: 290-296 (1985).

• Ruhl CE, Everhart JE. Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population. Gastroenterology 136: 477-485.e11 (2009). *

• Ruiz-Herrera J, Iranzo M, Elorza MV, Sentandreu R, Mormeneo S. Involvement of transglutaminase in the formation of covalent cross-links in the cell wall of Candida albicans. Arch. Microbiol. 164: 186-193 (1995).

• Ruppin DC, Frydman MI, Lunzer MR. Value of serum gamma-glutamyltransferase activity in the diagnosis of hepatobiliary disease. Med. J. Aust. 1: 421-424 (1982).

• Rutherford AE, Pratt DS. Cholestasis and cholestatic syndromes. Curr. Opin. Gastroenterol. 22: 209-214 (2006). *

• Sa EH, Jin UH, Kim DS, Kang BS, Ha KT, Kim JK, Park WH, Kim CH. Herbal medicine Gamgungtang down-regulates autoimmunity through induction of TH2 cytokine production by lymphocytes in experimental thyroiditis model. J. Ethnopharmacol. 109: 472-479 (2007). *

• Saka B, Kalayoglu-Besisik S, Ozturk GB, Dogan O, Erten N. Primary biliary cirrhosis and IgG-kappa type multiple myeloma both respond well to vincristine, adriamycin and dexamethasone: is there a pathogenic relationship? J. Formos. Med. Assoc. 107: 185-190 (2008). *

• Sakauchi F, Mori M, Zeniya M, Toda G. Antimitochondrial antibody negative primary biliary cirrhosis in Japan: utilization of clinical data when patients applied to receive public financial aid. J. Epidemiol. 16: 30-34 (2006). *

• Sakauchi F, Oura A, Ohnishi H, Mori M. Comparison of the clinical features of Japanese patients with primary biliary cirrhosis in 1999 and 2004: utilization of clinical data when patients applied to receive public financial aid. J. Epidemiol. 17: 210-214 (2007). *

• Sakugawa H, Nakasone H, Nakayoshi T, Yamashiro T, Maeshiro T, Kobashigawa K, Kinjo F, Saito A, Zukeran H, Nakanuma Y, Ohba K. Epidemiology of primary biliary cirrhosis among women with elevated gamma-glutamyl transpeptidase levels in Okinawa, Japan. Hepatol. Res. 26: 330-336 (2003).

• Salaspuro MP, Sipponen P, Ikkala E, Kolho L, Makkonen HM, Miettinen TA, Rasanen JA, Siurala M. Clinical correlations and significance of orceinpositivity in chronic active hepatitis and primary biliary cirrhosis. Ann. Clin. Res. 8: 206-215 (1976).

• Salla C, Chatzipantelis P, Konstantinou P, Karoumpalis I, Pantazopoulou A, Tsiotos G. EUS-FNA contribution in the identification of autoimmune pancreatitis: a case report. JOP 8: 598-604 (2007). *

• Sanchez-Campos S, Lopez-Acebo R, Gonzalez P, Culebras JM, Tuñon MJ, Gonzalez-Gallego J. Cholestasis and alterations of glutathione metabolism induced by tacrolimus (FK506) in the rat. Transplantation 66: 84-88 (1998).

• Sandhir R, Gill KD. Hepatoprotective effects of Liv-52 on ethanol induced liver damage in rats. Indian J. Exp. Biol. 37: 762-766 (1999).

• Sandhu BS, Luketic VA. Management of primary sclerosing cholangitis. Gastroenterology & Hepatology 2: 843-849 (2006). *

• Sanghera DK, Ortega L, Han S, Singh J, Ralhan SK, Wander GS, Mehra NK, Mulvihill JJ, Ferrell RE, Nath SK, Kamboh MI. Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant risk. BMC Med. Genet. 9: 59 (2008). *

• Sangorrin Iranzo A, Iriondo Sanz M, Alvarez Garcia L, Jara Vega P, Martin de Carpi J. Progressive familial intrahepatic cholestasis presenting as liver failure. An. Pediatr. (Barc.) 71: 510-513 (2009).

• Sano M, Izumi Y, Helenius K, Asakura M, Rossi DJ, Xie M, Taffet G, Hu L, Pautler RG, Wilson CR, Boudina S, Abel ED, Taegtmeyer H, Scaglia F, Graham BH, Kralli A, Shimizu N, Tanaka H, Makela TP, Schneider MD. Menage-a-trois 1 is critical for the transcriptional function of PPARgamma coactivator 1. Cell. Metab. 5: 129-142 (2007). *

• Sapey T, Mendler MH, Guyader D, Morio O, Corbinais S, Deugnier Y, Brissot P. Respective value of alkaline phosphatase, gamma-glutamyl transpeptidase and 5' nucleotidase serum activity in the diagnosis of cholestasis: a prospective study of 80 patients. J. Clin. Gastroenterol. 30: 259-263 (2000).

• Sarruf DA, Yu F, Nguyen HT, Williams DL, Printz RL, Niswender KD, Schwartz MW. Expression of PPARgamma in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology 150: 707-712 (2009). *

• Sato N, Ohira H, Orikasa H, Shinzawa J, Suzuki T, Tojo J, Miyata M, Nishimaki T, Kasukawa R. Primary biliary cirrhosis associated with painless thyroiditis. Intern. Med. 38: 244-248 (1999). *

• Sato S, Miyake T, Tobita H, Oshima N, Ishine J, Hanaoka T, Amano Y, Kinoshita Y. A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients. World J. Gastroenterol. 15: 2782-2786 (2009). *

• Sato Y, Harada K, Sudo Y, Watanabe K, Nakahama T, Morimoto H, Nakanuma Y. Autoimmune hepatitis associated with bile duct injury resembling chronic non-suppurative destructive cholangitis. Pathol. Int. 52: 478-482 (2002). *

• Sauma L, Franck N, Paulsson JF, Westermark GT, Kjolhede P, Stralfors P, Soderstrom M, Nystrom FH. Peroxisome proliferator activated receptor gamma activity is low in mature primary human visceral adipocytes. Diabetologia 50: 195-201 (2007). *

• Sauna ZE, Kim IW, Nandigama K, Kopp S, Chiba P, Ambudkar SV. Catalytic cycle of ATP hydrolysis by P-glycoprotein: evidence for formation of the E.S reaction intermediate with ATP-gamma-S, a nonhydrolyzable analogue of ATP. Biochemistry 46: 13787-13799 (2007). *

• Savkur RS, Bramlett KS, Stayrook KR, Nagpal S, Burris TP. Coactivation of the human vitamin D receptor by the peroxisome proliferator-activated receptor gamma coactivator-1 alpha. Mol. Pharmacol. 68: 511-517 (2005). *

• Savkur RS, Thomas JS, Bramlett KS, Gao Y, Michael LF, Burris TP. Ligand-dependent coactivation of the human bile acid receptor FXR by the peroxisome proliferator-activated receptor gamma coactivator-1alpha. J. Pharmacol. Exp. Ther. 312: 170-178 (2005). *

• Sawada S. Comment to: regulation of various genes in human leukocytes acutely exposed to morphine: expression microarray analysis. Med. Sci. Monit. 11: LE19-LE20 (2005). *

• Saxon A, Sidell N, Zhang K. B cells from subjects with CVI can be driven to Ig production in response to CD40 stimulation. Cell. Immunol. 144: 169-181 (1992).

• Sbragia L, Schmidt AF, Moraes S, Bittencourt DG, Goncalves FL, Pereira LA, Velloso LA. Inflammatory response in a rat model of gastroschisis is associated with an increase of NF-kappaB. Braz. J. Med. Biol. Res. Jan 22 [Epub ahead of print] (2010). *

• Schaiff WT, Bildirici I, Cheong M, Chern PL, Nelson DM, Sadovsky Y. PPARgamma and RXR signaling regulate fatty acid uptake by primary human placental trophoblasts. J. Clin. Endocrinol. Metab. 90: 4267-4275 (2005). *

• Schaiff WT, Knapp FF Jr, Barak Y, Biron-Shental T, Nelson DM, Sadovsky Y. Ligand-activated PPARgamma alters placental morphology and placental fatty acid uptake in mice. Endocrinology 148: 3625-3634 (2007). *

• Schedel J, Mayer S, Woenckhaus M, Kiss E, Scholmerich J, Rogler G. Autoimmune cholangitis with vasculitic ulcers, rheumatoid arthritis and IgA glomerulonephritis. Dtsch. Med. Wochenschr. 129: 2409-2412 (2004).

• Schiedermaier P, Hansen S, Asdonk D, Brensing K, Sauerbruch T. Effects of ursodeoxycholic acid on splanchnic and systemic hemodynamics. A double-blind, cross-over, placebo-controlled study in healthy volunteers. Digestion 61: 107-112 (2000).

• Schiemann U, Ferhat A, Gotzberger M, Kaiser C, Stief J, Landgraf R, Dieterle C. Prevalence of cholecystolithiasis and its management among kidney/pancreas-transplanted type 1 (insulin-dependent) diabetic patients. Eur. J. Med. Res. 13: 127-130 (2008).

• Schlaeger R, Haux P, Kattermann R. Studies on the mechanism of the increase in serum alkaline phosphatase activity in cholestasis: significance of the hepatic bile acid concentration for the leakage of alkaline phosphatase from rat liver. Enzyme 28: 3-13 (1982).

• Schneider G, Paus TC, Kullak-Ublick GA, Meier PJ, Wienker TF, Lang T, van de Vondel P, Sauerbruch T, Reichel C. Linkage between a new splicing site mutation in the MDR3 alias ABCB4 gene and intrahepatic cholestasis of pregnancy. Hepatology 45: 150-158 (2007). *

• Schneider JG, Schiekofer S, Eynatten MV, Schlimmer P, Dugi KA. The proline 12 alanine substitution in the PPARgamma2 gene is associated with increased extent of coronary artery disease in men. Exp. Clin. Endocrinol. Diabetes 117: 519-521 (2009).

• Schoenborn JR, Dorschner MO, Sekimata M, Santer DM, Shnyreva M, Fitzpatrick DR, Stamatoyonnapoulos JA, Wilson CB. Comprehensive epigenetic profiling identifies multiple distal regulatory elements directing transcription of the gene encoding interferon-gamma. Nat. Immunol. 8: 732-742 (2007). *

• Schoenborn JR, Wilson CB. Regulation of interferon-gamma during innate and adaptive immune responses. Adv. Immunol. 96: 41-101 (2007).

• Schoniger-Hekele M, Ramskogler K, Hartl D, Lesch OM, Muller C. Exclusion of trisialo-transferrin from carbohydrate-deficient transferrin measurement: advantage in patients with chronic liver disease? Wien. Med. Wochenschr. 156: 216-222 (2006).

• Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37: 907-925 (1996). *

• Schreiber S, Hamling J, Zehnter E, Howaldt S, Daerr W, Raedler A, Kruis W. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut 40: 761-766 (1997). *

• Schroecksnadel K, Zangerle R, Bellmann-Weiler R, Garimorth K, Weiss G, Fuchs D. Indoleamine-2, 3-dioxygenase and other interferon-gamma-mediated pathways in patients with human immunodeficiency virus infection. Curr. Drug Metab. 8: 225-236 (2007).

• Schulte DJ, Yilmaz A, Shimada K, Fishbein MC, Lowe EL, Chen S, Wong M, Doherty TM, Lehman T, Crother TR, Sorrentino R, Arditi M. Involvement of innate and adaptive immunity in a murine model of coronary arteritis mimicking Kawasaki disease. J. Immunol. 183: 5311-5318 (2009).

• Schuppan D. Markers of progression. Falk Symposium 137. XII FALK LIVER WEEK 2003 (Part II) In honour of Hans Popper’s 100th Birthday. Liver Diseases: Advances in Treatment and Prevention. Freiburg (Germany). p. 37. October 17 - 19 (2003). *

• Scola L, Vaglica M, Crivello A, Palmeri L, Forte GI, Macaluso MC, Giacalone A, Noto LD, Bongiovanni A, Raimondi C, Accardo A, Verna R, Candore G, Caruso C, Lio D, Palmeri S. Cytokine gene polymorphisms and breast cancer susceptibility. Ann. N. Y. Acad. Sci. 1089: 104-109 (2006). *

• Scully C, Potts AJ, Hamburger J, Wiesenfeld D, McKee JI, el Kom M. Lichen planus and liver disease: how strong is the association? J. Oral. Pathol. 14: 224-226 (1985).

• Sekimata M, Perez-Melgosa M, Miller SA, Weinmann AS, Sabo PJ, Sandstrom R, Dorschner MO, Stamatoyannopoulos JA, Wilson CB. CCCTC-binding factor and the transcription factor T-bet orchestrate T helper 1 cell-specific structure and function at the interferon-gamma locus. Immunity 31: 551-564 (2009). *

• Selinger MJ, Matloff DS, Kaplan MM. gamma-Glutamyl transpeptidase activity in liver disease: serum elevation is independent of hepatic GGTP activity. Clin. Chim. Acta 125: 283-290 (1982).

• Seminari E, Gentilini G, Galli L, Hasson H, Danise A, Carini E, Dorigatti F, Soldarini A, Lazzarin A, Castagna A. Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients. J. Antimicrob. Chemother. 56: 790-792 (2005). *

• Sen M, Inan A, Yenidunya S, Ergin M, Dener C. Effect of vitamin A on the CD44 expression in the small intestine of rats with obstructive jaundice. Eur. Surg. Res. 38: 347-352 (2006).

• Sepodes B, Maio R, Pinto R, Sharples E, Oliveira P, McDonald M, Yaqoob M, Thiemermann C, Mota-Filipe H. Recombinant human erythropoietin protects the liver from hepatic ischemia-reperfusion injury in the rat. Transpl. Int. 19: 919-926 (2006). *

• Sevastos N, Savvas SP, Rafailidis PI, Manesis EK. Cholestasis in acute stroke: an investigation on its prevalence and etiology. Scand. J. Gastroenterol. 40: 862-866 (2005). *

• Shah Y, Morimura K, Gonzalez F. Expression of peroxisome proliferator-activated receptor-gamma in macrophage suppresses experimentally-induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G657-G666 (2007). *

• Sheehan M, Haythorn P. Predictive values of various liver function tests with respect to the diagnosis of liver disease. Clin. Biochem. 12: 262-263 (1979).

• Shen P, Liu MH, Ng TY, Chan YH, Yong EL. Differential effects of isoflavones, from Astragalus membranaceus and Pueraria thomsonii, on the activation of PPARalpha, PPARgamma, and adipocyte differentiation in vitro. J. Nutr. 136: 899-905 (2006). *

• Sheng X, Zhang Y, Gong Z, Huang C, Zang YQ. Improved insulin resistance and lipid metabolism by cinnamon extract through activation of peroxisome proliferator-activated receptors. PPAR Res. 2008: 581348 (2008). *

• Shenkar R, Shi C, Check IJ, Lipton HL, Awad IA. Concepts and hypotheses: inflammatory hypothesis in the pathogenesis of cerebral cavernous malformations. Neurosurgery 61: 693-702 (2007).

• Sherlock S. Ludwig Symposium on biliary disorders. Autoimmune cholangitis: a unique entity? Mayo Clin. Proc. 73: 184-190 (1998). *

• Sherwood P, Lyburn I, Brown S, Ryder S. How are abnormal results for liver function tests dealt with in primary care? Audit of yield and impact. BMJ 322: 276-278 (2001). *

• Shi M, Lin TH, Appell KC, Berg LJ. Cell cycle progression following naive T cell activation is independent of Jak3/common gamma-chain cytokine signals. J. Immunol. 183: 4493-4501 (2009).

• Shi X, Zhang C, Jia J, Zhang F, Qian L, Wang B. Histopathological features of 27 cases of primary biliary cirrhosis. Zhonghua Gan Zang Bing Za Zhi 10: 338-340 (2002).

• Shibata J, Fujiyama S, Honda Y, Sato T. Combination therapy with ursodeoxycholic acid and colchicine for primary biliary cirrhosis. J. Gastroenterol. Hepatol. 7: 277-282 (1992).

• Shim J, Byun HO, Lee YD, Lee ES, Sohn S. Interleukin-6 small interfering RNA improved the herpes simplex virus-induced systemic inflammation in vivo Behcet's disease-like mouse model. Gene Ther. 16: 415-425 (2009).

• Shimizu Y, Margenthaler JA, Landeros K, Otomo N, Doherty G, Flye MW. The resistance of P. acnes-primed interferon gamma-deficient mice to low-dose lipopolysaccharide-induced acute liver injury. Hepatology 35: 805-814 (2002). *

• Shiraoku H, Hokamura M, Sagara K, Fujiyama S. A case of primary sclerosing cholangitis. Gastroenterol. Jpn. 20: 368-373 (1985).

• Shnyreva M, Weaver WM, Blanchette M, Taylor SL, Tompa M, Fitzpatrick DR, Wilson CB. Evolutionarily conserved sequence elements that positively regulate IFN-gamma expression in T cells. Proc. Natl. Acad. Sci. U.S.A. 101: 12622-12627 (2004). *

• Si Y, Ciccone S, Yang FC, Yuan J, Zeng D, Chen S, van de Vrugt HJ, Critser J, Arwert F, Haneline LS, Clapp DW. Continuous in vivo infusion of interferon-gamma (IFN-gamma) enhances engraftment of syngeneic wild-type cells in Fanca-/- and Fancg-/- mice. Blood 108: 4283-4287 (2006). *

• Siciliano M, Milani A, Marra L, Arringoli D, Rossi L. Serum bile acids in cirrhosis: correlation with liver function parameters and with the severity of the disease. Quad. Sclavo. Diagn. 22: 355-361 (1986).

• Sijens PE, Alkefaji H, Lunsing RJ, van Spronsen FJ, Meiners LC, Oudkerk M, Verkade HJ. Quantitative multivoxel (1)H MR spectroscopy of the brain in children with acute liver failure. Eur. Radiol. 18: 2601-2609 (2008).

• Sillanpaa M, Kaukinen P, Melen K, Julkunen I. Hepatitis C virus proteins interfere with the activation of chemokine gene promoters and downregulate chemokine gene expression. J. Gen. Virol. 89: 432-443 (2008). *

• Silva-Santos B, Pennington DJ, Hayday AC. Lymphotoxin-mediated regulation of gammadelta cell differentiation by alphabeta T cell progenitors. Science 307: 925-928 (2005). *

• Singla A, Kaur J, Mahmood A. Alterations in the expression of intestinal enzymes in rats exposed to nickel. J. Appl. Toxicol. 26: 397-401 (2006). *

• Siracusa MC, Overstreet MG, Housseau F, Scott AL, Klein SL. 17beta-Estradiol alters the activity of conventional and IFN-producing killer dendritic cells. J. Immunol. 180: 1423-1431 (2008). *

• Sisley AC, Desai TR, Hynes KL, Gewertz BL, Dudeja PK. Decrease in mucosal alkaline phosphatase: a potential marker of intestinal reperfusion injury. J. Lab. Clin. Med. 133: 335-341 (1999). *

• Smith MA, Moylan JS, Smith JD, Li W, Reid MB. IFN-gamma does not mimic the catabolic effects of TNF-alpha. Am. J. Physiol. Cell Physiol. 293: C1947-C1952 (2007). *

• Snyder JM, Jenkins-Moore M, Jackson SK, Goss KL, Dai HH, Bangsund PJ, Giguere V, McGowan SE. Alveolarization in retinoic acid receptor-beta-deficient mice. Pediatr. Res. 57: 384-391 (2005). *

• Sokolovic D, Bjelakovic G, Nikolic J, Djindjic B, Pavlovic D, Kocic G, Stojanovic I, Pavlovic V. Effect of L-arginine on metabolism of polyamines in rat's brain with extrahepatic cholestasis. Amino Acids Mar 13 [Epub ahead of print] (2009). *

• Sokolovic D, Bjelakovic G, Nikolic J, Djindjic B, Pavlovic D, Kocic G, Stojanovic I, Pavlovic V. Effect of L-arginine on metabolism of polyamines in rat's brain with extrahepatic cholestasis. Amino Acids Jan 29 [Epub ahead of print] (2008). *

• Sorda J, Findor J. Methotrexate therapy in primary biliary cirrhosis. Acta Gastroenterol. Latinoam. 30: 221-225 (2000).

• Sorrentino P, Tarantino G, Perrella A, Micheli P, Perrella O, Conca P. A clinical-morphological study on cholestatic presentation of nonalcoholic fatty liver disease. Dig. Dis. Sci. 50: 1130-1135 (2005). *

• Soyland E, Funk J, Rajka G, Sandberg M, Thune P, Rustad L, Helland S, Middelfart K, Odu S, Falk ES, Solvoll K, Bjorneboe GA, Drevon CA. Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis. N. Engl. J. Med. 328: 1812-1816 (1993).

• Spagnuolo MI, Iorio R, Vegnente A, Guarino A. Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study. Gastroenterology 111: 716-719 (1996). *

• Spooner RJ, Smith DH, Bedford D, Beck PR. Serum gamma-glutamyltransferase and alkaline phosphatase in rheumatoid arthritis. J. Clin. Pathol. 35: 638-641 (1982). *

• Sprong T, Jack DL, Klein NJ, Turner MW, Van Der Ley P, Steeghs L, Jacobs L, Van Der Meer JW, Van Deuren M. Mannose binding lectin enhances IL-1beta and IL-10 induction by non-lipopolysaccharide (LPS) components of Neisseria meningitidis. Cytokine 28: 59-66 (2004).

• Stapelbroek JM, van Erpecum KJ, Klomp LW, Houwen RH. Liver disease associated with canalicular transport defects: current and future therapies. J. Hepatol. 52: 258-271 (2010). *

• Stauber DJ, Debler EW, Horton PA, Smith KA, Wilson IA. Crystal structure of the IL-2 signaling complex: paradigm for a heterotrimeric cytokine receptor. Proc. Natl. Acad. Sci. U.S.A. 103: 2788-2793 (2006). *

• Stefanski A, Majkowska L, Ciechanowicz A, Frankow M, Safranow K, Parczewski M, Moleda P, Pilarska K. Association between the Pro12Ala variant of the peroxisome proliferator-activated receptor-gamma2 gene and increased 24-h diastolic blood pressure in obese patients with type II diabetes. J. Hum. Hypertens. 20: 684-692 (2006).

• Stiehl A. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis. Ann. Med. 26: 345-349 (1994).

• Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J. Hepatol. 20: 57-64 (1994).

• Stipsanelli K, Koutsikos J, Papantoniou V, Arka A, Palestidis C, Tsiouris S, Manolaki A, Zerva C. Hepatobiliary scintigraphy and gamma-GT levels in the differential diagnosis of extrahepatic biliary atresia. Q. J. Nucl. Med. Mol. Imaging 51: 74-81 (2007).

• Stojakovic T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Stadlbauer V, Gurakuqi G, Stauber RE, Marz W, Trauner M. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 46: 776-784 (2007). *

• Stokkers PC, de Heer K, Leegwater AC, Reitsma PH, Tytgat GN, van Deventer SJ. Inflammatory bowel disease and the genes for the natural resistance-associated macrophage protein-1 and the interferon-gamma receptor 1. Int. J. Colorectal Dis. 14: 13-17 (1999). *

• Stonehouse W, Kruger A, Smuts CM, Loots DT, Wentzel-Viljoen E, Vorster HH. Plasma polyunsaturated fatty acids and liver enzymes in HIV-infected subjects: the Prospective Urban and Rural Epidemiology (PURE) study. Am. J. Clin. Nutr. Jan 13 [Epub ahead of print] (2010). *

• Strandvik B, Hjelte L, Gabrielsson N, Glaumann H. Sclerosing cholangitis in cystic fibrosis. Scand. J. Gastroenterol. Suppl. 143: 121-124 (1988). *

• Strassburg CP. Autoimmune liver diseases. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 66-70 (2005). *

• Strassburg CP, Manns MP. Primary biliary cirrhosis and overlap syndromes. Diagnosis and therapy. Internist (Berl.) 45: 16-26 (2004).

• Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, Sokal E, Dahan K, Childs S, Ling V, Tanner MS, Kagalwalla AF, Nemeth A, Pawlowska J, Baker A, Mieli-Vergani G, Freimer NB, Gardiner RM, Thompson RJ. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat. Genet. 20: 233-238 (1998). *

• Strazzabosco M, Joplin R, Zsembery A, Wallace L, Spirli C, Fabris L, Granato A, Rossanese A, Poci C, Neuberger JM, Okolicsanyi L, Crepaldi G. Na(+)-dependent and -independent Cl-/HCO3- exchange mediate cellular HCO3- transport in cultured human intrahepatic bile duct cells. Hepatology 25: 976-985 (1997). *

• Stuve O, Cravens PD, Eagar TN. DNA-based vaccines: the future of multiple sclerosis therapy? Expert Rev. Neurother. 8: 351-360 (2008).

• Sugimoto M, Sadamoto T, Nonaka H. Clinical and pathological differences between alcoholic hepatitis and non-alcoholic steatohepatitis. Nihon Arukoru Yakubutsu Igakkai Zasshi 38: 34-45 (2003).

• Sukhumavasi W, Egan CE, Warren AL, Taylor GA, Fox BA, Bzik DJ, Denkers EY. TLR adaptor MyD88 is essential for pathogen control during oral toxoplasma gondii infection but not adaptive immunity induced by a vaccine strain of the parasite. J. Immunol. 181: 3464-3473 (2008). *

• Sundaram SS, Bove KE, Lovell MA, Sokol RJ. Mechanisms of disease: inborn errors of bile acid synthesis. Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 456-468 (2008).

• Sundaram SS, Sokol RJ. The multiple facets of ABCB4 (MDR3) deficiency. Curr. Treat. Options Gastroenterol. 10: 495-503 (2007).

• Surrenti C, Pozzi M, Biagini MR, Franco C, Lombardo R, Avanzi G. Effects of plasma exchange (PE) in primary biliary cirrhosis (PBC). A pilot study. Hepatogastroenterology 37: 128-130 (1990).

• Suwazono Y, Kobayashi E, Uetani M, Miura K, Morikawa Y, Ishizaki M, Kido T, Nakagawa H, Nogawa K. The -1438A/G polymorphism in the 5-hydroxytryptamine receptor 2A gene is related to hyperuricemia, increased gamma-glutamyl transpeptidase and decreased high-density lipoprotein cholesterol level in the Japanese population. Int. J. Mol. Med. 17: 77-82 (2006). *

• Suzuki K, Kawauchi Y, Palaniyandi SS, Veeraveedu PT, Fujii M, Yamagiwa S, Yoneyama H, Han GD, Kawachi H, Okada Y, Ajioka Y, Watanabe K, Hosono M, Asakura H, Aoyagi Y, Narumi S. Blockade of interferon-gamma-inducible protein-10 attenuates chronic experimental colitis by blocking cellular trafficking and protecting intestinal epithelial cells. Pathol. Int. 57: 413-420 (2007).

• Suzuki S, Arnold LL, Pennington KL, Kakiuchi-Kiyota S, Wei M, Wanibuchi H, Cohen SM. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol. Sci. 113: 349-357 (2010). *

• Svenberg T, Hammarstrom S, Andersson G, Johansson C, Samuelson K, Wahren B. Serum level of biliary glycoprotein I, a determinant of cholestasis, of similar use as gamma-glutamyltranspeptidase. Scand. J. Gastroenterol. 16: 817-824 (1981).

• Syversen U, Stunes AK, Gustafsson BI, Obrant KJ, Nordsletten L, Berge R, Thommesen L, Reseland JE. Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPAR gamma agonist pioglitazone. BMC Endocr. Disord. 9: 10 (2009). *

• Szeto CC, Chow KM, Poon PY, Kwan BC, Li PK. Peroxisome proliferator-activated receptor-gamma gene polymorphism and risk of cardiovascular disease in patients with diabetic nephropathy. Am. J. Nephrol. 28: 715-722 (2008).

• Tabata R, Tabata C, Okamoto T, Omori K, Terada M, Nagai T. Autoimmune pancreatitis associated with myelodysplastic syndrome. Int. Arch. Allergy Immunol. 151: 168-172 (2009).

• Tachi Y, Katano Y, Honda T, Hayashi K, Ishigami M, Itoh A, Hirooka Y, Nakano I, Samejima Y, Goto H. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. Liver Int. Nov 27 [Epub ahead of print] (2009). *

• Taguchi M, Aridome G, Abe S, Kume K, Tashiro M, Yamamoto M, Kihara Y, Nakamura H, Otsuki M. Autoimmune pancreatitis with IgG4-positive plasma cell infiltration in salivary glands and biliary tract. World J. Gastroenterol. 11: 5577-5581 (2005). *

• Tahan G, Tarcin O, Tahan V, Eren F, Gedik N, Sahan E, Biberoglu N, Guzel S, Bozbas A, Tozun N, Yucel O. The effects of N-acetylcysteine on bile duct ligation-induced liver fibrosis in rats. Dig. Dis. Sci. 52: 3348-3354 (2007). *

• Tahan V, Canbakan B, Balci H, Dane F, Akin H, Can G, Hatemi I, Olgac V, Sonsuz A, Ozbay G, Yurdakul I, Senturk H. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk. Hepatogastroenterology 55: 1433-1438 (2008).

• Takada I, Kato S. PPARs target genes. Nippon Rinsho 63: 573-577 (2005).

• Takagi T, Naito Y, Tomatsuri N, Handa O, Ichikawa H, Yoshida N, Yoshikawa T. Pioglitazone, a PPAR-gamma ligand, provides protection from dextran sulfate sodium-induced colitis in mice in association with inhibition of the NF-kappaB-cytokine cascade. Redox. Rep. 7: 283-289 (2002). *

• Takigawa T, Hibino Y, Kimura S, Yamauchi H, Wang B, Wang D, Ogino K. Association between serum gamma-glutamyltransferase and oxidative stress related factors. Hepatogastroenterology 55: 50-53 (2008).

• Talar-Wojnaroska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E. Tumor necrosis factor alpha and interferon gamma genes polymorphisms and serum levels in pancreatic adenocarcinoma. Neoplasma 56: 56-62 (2009).

• Taniguchi E, Matsunami M, Kimura T, Yonezawa D, Ishiki T, Sekiguchi F, Nishikawa H, Maeda Y, Ishikura H, Kawabata A. Rhodanese, but not cystathionine-gamma-lyase, is associated with dextran sulfate sodium-evoked colitis in mice: a sign of impaired colonic sulfide detoxification? Toxicology 264: 96-103 (2009). *

• Tavares V, Hirata RD, Rodrigues AC, Monte O, Salles JE, Scalissi N, Speranza AC, Hirata MH. Association between Pro12Ala polymorphism of the PPAR-gamma2 gene and insulin sensitivity in Brazilian patients with type-2 diabetes mellitus. Diabetes Obes. Metab. 7: 605-611 (2005).

• Tavian D, Degiorgio D, Roncaglia N, Vergani P, Cameroni I, Colombo R, Coviello DA. A new splicing site mutation of the ABCB4 gene in intrahepatic cholestasis of pregnancy with raised serum gamma-GT. Dig. Liver Dis. 41: 671-675 (2009).

• Taylor GA, Feng CG, Sher A. p47 GTPases: regulators of immunity to intracellular pathogens. Nat. Rev. Immunol. 4: 100-109 (2004). *

• Taylor PA, Ehrhardt MJ, Lees CJ, Panoskaltsis-Mortari A, Krieg AM, Sharpe AH, Murphy WJ, Serody JS, Hemmi H, Akira S, Levy RB, Blazar BR. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood 112: 3508-3516 (2008). *

• Taylor SL, Dean PJ, Riely CA. Primary autoimmune cholangitis. An alternative to antimitochondrial antibody-negative primary biliary cirrhosis. Am. J. Surg. Pathol. 18: 91-99 (1994).

• Teare JP, Sherman D, Greenfield SM, Simpson J, Bray G, Catterall AP, Murray-Lyon IM, Peters TJ, Williams R, Thompson RP. Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 342: 895-898 (1993).

• Terekhina NA, Zarivchatskii MF, Soldatenko NV. Analysis of tear enzymes in the diagnosis of obstructive jaundice of subhepatic cholestasis. Klin. Lab. Diagn. 11: 13-15 (2008).

• Tervaert JW, Van Hoek B, Koek G. Antineutrophil cytoplasmic antibodies in small-duct primary sclerosing cholangitis. Gastroenterology 136: 364 (2009). *

• Terzic D, Dupanovic B, Mugosa B, Draskovic N, Svirtlih N. Acute hepatitis E in Montenegro: epidemiology, clinical and laboratory features. Ann. Hepatol. 8: 203-206 (2009).

• Theal RM, Scott K. Evaluating asymptomatic patients with abnormal liver function test results. Am. Fam. Physician 53: 2111-2119 (1996).

• Thimme R, Opitz OG, Blum HE, Kreisel W. Cholestatic liver diseases. Ther. Umsch. 61: 521-527 (2004).

• Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S. Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res. 62: 5196-5203 (2002). *

• Toblli JE, Ferrini MG, Cao G, Vernet D, Angerosa M, Gonzalez-Cadavid NF. Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol. Dial. Transplant. 24: 2384-2391 (2009).

• Tok EC, Ertunc D, Bilgin O, Erdal EM, Kaplanoglu M, Dilek S. PPAR-gamma2 Pro12Ala polymorphism is associated with weight gain in women with gestational diabetes mellitus. Eur. J. Obstet. Gynecol. Reprod. Biol. 129: 25-30 (2006).

• Tolstrup JS, Gronbaek M, Tybjaerg-Hansen A, Nordestgaard BG. Alcohol intake, alcohol dehydrogenase genotypes, and liver damage and disease in the Danish general population. Am. J. Gastroenterol. 104: 2182-2188 (2009).

• Tominaga T, Suzuki H, Mizuno H, Kouno M, Suzuki M, Kato Y, Sato A, Okabe K, Miyashita M. Clinical significance of measuring plasma concentrations of glutamine and glutamate in alcoholic liver diseases. Alcohol Alcohol Suppl. 1A: 103-109 (1993).

• Tommasi AM, Fabris P, Carderi I, Baragiotta A, Baldo V, Venturi C, Giordani MT, Tositti G, Floreani A. Lack of higher frequency of the chemokine receptor 5-Delta32/Delta32 genotype in hepatitis C. J. Clin. Gastroenterol. 40: 440-443 (2006).

• Trauner M, Boyer JL. Cholestatic syndromes. Curr. Opin. Gastroenterol. 20: 220-230 (2004). *

• Treepongkaruna S, Gaensan A, Pienvichit P, Luksan O, Knisely AS, Sornmayura P, Jirsa M. Novel ABCB11 mutations in a Thai infant with progressive familial intrahepatic cholestasis. World J. Gastroenterol. 15: 4339-3242 (2009). *

• Trentini EA, Crema E, Llanos JC, Lerco MM, Magna LA, Leonardi LS. Biliary tract reconstruction using jejunal tube: an experimental study in dogs. Hepatobiliary Pancreat. Dis. Int. 8: 179-185 (2009). *

• Tsuda H, Masui T, Imaida K, Fukushima S, Ito N. Promotive effect of primary and secondary bile acids on the induction of gamma-glutamyl transpeptidase-positive liver cell foci as a possible endogenous factor for hepatocarcinogenesis in rats. Gann. 75: 871-875 (1984).

• Tunheim G, Schjetne KW, Rasmussen IB, Sollid LM, Sandlie I, Bogen B. Recombinant antibodies for delivery of antigen: a single loop between beta-strands in the constant region can accommodate long, complex and tandem T cell epitopes. Int. Immunol. 20: 295-306 (2008). *

• Ueda Y, Takada Y, Marusawa H, Haga H, Sato T, Tanaka Y, Egawa H, Uemoto S, Chiba T. Clinical features of biochemical cholestasis in patients with recurrent hepatitis C after living-donor liver transplantation. J. Viral. Hepat. Oct 4 [Epub ahead of print] (2009).

• Ukarapol N, Wongsawasdi L, Ong-Chai S, Riddhiputra P, Kongtawelert P. Hyaluronic acid: additional biochemical marker in the diagnosis of biliary atresia. Pediatr. Int. 49: 608-611 (2007). *

• Uppington H, Menager N, Boross P, Wood J, Sheppard M, Verbeek S, Mastroeni P. Effect of immune serum and role of individual Fcgamma receptors on the intracellular distribution and survival of Salmonella enterica serovar Typhimurium in murine macrophages. Immunology 119: 147-158 (2006). *

• Uraz S, Tahan V, Aygun C, Eren F, Unluguzel G, Yuksel M, Senturk O, Avsar E, Haklar G, Celikel C, Hulagu S, Tozun N. Role of ursodeoxycholic acid in prevention of methotrexate-induced liver toxicity. Dig. Dis. Sci. 53: 1071-1077 (2008). *

• Valente AI, Almeida A, Gouveia A, Serejo F, Ramalho F, Baptista A, Saragoca A, Moura MC. Prevalence of chronic hepatic disease in Portugal. Apropos of a review carried out in a hepatology unit. Acta Med. Port. 9: 197-202 (1996).

• Valimaki MJ, Harju KJ, Ylikahri RH. Decreased serum selenium in alcoholics - a consequence of liver dysfunction. Clin. Chim. Acta 130: 291-296 (1983).

• van Beelen AJ, Teunissen MB, Kapsenberg ML, de Jong EC. Interleukin-17 in inflammatory skin disorders. Curr. Opin. Allergy Clin. Immunol. 7: 374-381 (2007). *

• van Buuren HR. Ursodeoxycholic acid: high-dose, mono- or combination therapy? Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 83. October 15-16 (2003). *

• van de Meeberg PC, Houwen RH, Sinaasappel M, Heijerman HG, Bijleveld CM, Vanberge-Henegouwen GP. Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up. Scand. J. Gastroenterol. 32: 369-373 (1997).

• van der Straaten R, Wessels JA, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Allaart CF, Bogaartz J, Tiller M, Huizinga TW, Guchelaar HJ. Exploratory analysis of four polymorphisms in human GGH and FPGS genes and their effect in methotrexate-treated rheumatoid arthritis patients. Pharmacogenomics 8: 141-150 (2007).

• van der Velden AM, Claessen AM, van Velzen-Blad H, Biesma DH, Rijkers GT. Development of T cell-mediated immunity after autologous stem cell transplantation: prolonged impairment of antigen-stimulated production of gamma-interferon. Bone Marrow Transplant. 40: 261-266 (2007).

• van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, Clevers H. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 435: 959-963 (2005). *

• Van Hoogstraten HJ, De Smet MB, Renooij W, Breed JG, Engels LG, Den Ouden-Muller JW, Rijk MC, Smit AM, Zwertbroek R, Hop WC, van Berge Henegouwen GP, Schalm SW, van Buuren HR. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group. Aliment. Pharmacol. Ther. 12: 965-971 (1998). *

• van Hoogstraten HJ, Vleggaar FP, Boland GJ, van Steenbergen W, Griffioen P, Hop WC, van Hattum J, van Berge Henegouwen GP, Schalm SW, van Buuren HR. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am. J. Gastroenterol. 95: 2015-2022 (2000). *

• van Hoogstraten HJ, Wolfhagen FH, verg PC, Kuiper H, Nix GA, Becx MC, Hoek AC, van Houte DP, Rijk MC, Salemans JM, Scherpenisse J, Schrijver M, Smit AM, Spoelstra P, Stadhouders PH, Tan TG, Hop WC, ten Kate FJ, vanBerge-Henegouwen GP, et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J. Hepatol. 29: 417-423 (1998). *

• Van Steenbergen W, Sciot R, Van Eyken P, Desmet V, Fevery J. Combined treatment with methotrexate and ursodeoxycholic acid in non-cirrhotic primary biliary cirrhosis. Acta Clin. Belg. 51: 8-18 (1996).

• Vanhoutte F, Paget C, Breuilh L, Fontaine J, Vendeville C, Goriely S, Ryffel B, Faveeuw C, Trottein F. Toll-like receptor (TLR)2 and TLR3 synergy and cross-inhibition in murine myeloid dendritic cells. Immunol. Lett. 116: 86-94 (2008).

• Vantourout P, Mookerjee-Basu J, Rolland C, Pont F, Martin H, Davrinche C, Martinez LO, Perret B, Collet X, Perigaud C, Peyrottes S, Champagne E. Specific requirements for Vgamma9Vdelta2 T cell stimulation by a natural adenylated phosphoantigen. J. Immunol. 183: 3848-3857 (2009).

• Velicia Llames MR, Gonzalez Hernandez JM, Fernandez Orcajo P, Sanz Santacruz C. Symptomatic primary biliary stenosis without cholestasis. Gastroenterol. Hepatol. 18: 330-331 (1995).

• Velsor LW, van Heeckeren A, Day BJ. Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 281: L31-L38 (2001). *

• Venkatesh J, Kawabata D, Kim S, Xu X, Chinnasamy P, Paul E, Diamond B, Grimaldi CM. Selective regulation of autoreactive B cells by FcgammaRIIB. J. Autoimmun. 32: 149-157 (2009).

• Verma A, Jazrawi RP, Ahmed HA, Davis T, Bland JM, Benson M, Orchard RT, Theodossi A, Maxwell JD, Northfield TC. Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 11: 1069-1076 (1999).

• Vermeulen T, Marquardt T, Haberle J. Pseudodeficiency of glutamine in infant liver disease. Amino Acids 37: 435-437 (2009). *

• Vierling JM. Is primary sclerosing cholangitis an autoimmune disease? Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 67-69. October 15-16 (2003). *

• Viguier M, Allez M, Zagdanski AM, Bertheau P, de Kerviler E, Rybojad M, Morel P, Dubertret L, Lemann M, Bachelez H. High frequency of cholestasis in generalized pustular psoriasis: evidence for neutrophilic involvement of the biliary tract. Hepatology 40: 452-458 (2004). *

• Villanueva SS, Ruiz ML, Soroka CJ, Cai SY, Luquita MG, Torres AM, Sanchez Pozzi EJ, Pellegrino JM, Boyer JL, Catania VA, Mottino AD. Hepatic and extrahepatic synthesis and disposition of dinitrophenyl-S-glutathione in bile duct ligated rats. Drug Metab. Dispos. 34: 1301-1309 (2006). *

• Vimaleswaran KS, Radha V, Anjana M, Deepa R, Ghosh S, Majumder PP, Rao MR, Mohan V. Effect of polymorphisms in the PPARGC1A gene on body fat in Asian Indians. Int. J. Obes. (Lond.) 30: 884-891 (2006). *

• Vimaleswaran KS, Radha V, Deepa R, Mohan V. Absence of association of metabolic syndrome with PPARGC1A, PPARG and UCP1 gene polymorphisms in Asian Indians. Metab. Syndr. Relat. Disord. 5: 153-162 (2007).

• Vimaleswaran KS, Radha V, Jayapriya MG, Ghosh S, Majumder PP, Rao MR, Mohan V. Evidence for an association with type 2 diabetes mellitus at the PPARG locus in a South Indian population. Metabolism Oct 19 [Epub ahead of print] (2009). *

• Vincze A, Patty I, Javor T, Par A. Clinical evidence of hepatoprotection induced by ursodeoxycholic acid. Acta Physiol. Hung. 80: 369-374 (1992).

• Virovic L, Supanc V, Duvnjak M. Primary sclerosing cholangitis - diagnosis and therapy. Acta Med. Croatica 57: 207-219 (2003).

• Vleggaar FP, Monkelbaan JF, van Erpecum KJ. Probiotics in primary sclerosing cholangitis: a randomized placebo-controlled crossover pilot study. Eur. J. Gastroenterol. Hepatol. 20: 688-692 (2008). *

• Vleggaar FP, van Buuren HR, van Berge Henegouwen GP, Hop WC, van Erpecum KJ. No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study. Eur. J. Gastroenterol. Hepatol. 13: 171-175 (2001).

• Vogelsang H, Hamwi A, Ferenci P. Elevated liver isoenzymes of alkaline phosphatase and disease activity in patients with Crohn's disease. Digestion 57: 11-15 (1996).

• Volate SR, Muga SJ, Issa AY, Nitcheva D, Smith T, Wargovich MJ. Epigenetic modulation of the retinoid X receptor alpha by green tea in the azoxymethane-Apc(Min/+) mouse model of intestinal cancer. Mol. Carcinog. 48: 920-933 (2009). *

• von Schonfeld J, Breuer N, Zotz RB, Beste M, Goebell H. Serial quantitative liver function tests in patients with primary biliary cirrhosis: a prospective long-term study. Digestion 58: 396-401 (1997).

• von Schonfeld J, Zotz R, Mahl M, Beste M, Breuer N, Goebell H. Primary sclerosing cholangitis: conventional and quantitative liver function tests during long-term therapy with ursodeoxycholic acid. Z. Gastroenterol. 34: 123-127 (1996).

• Vuoristo M, Farkkila M, Karvonen AL, Leino R, Lehtola J, Makinen J, Mattila J, Friman C, Seppala K, Tuominen J, et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid. Gastroenterology 108: 1470-1478 (1995). *

• Wagner S, Gebel M, Meier P, Trautwein C, Bleck J, Nashan B, Manns MP. Endoscopic management of biliary tract strictures in primary sclerosing cholangitis. Endoscopy 28: 546-551 (1996).

• Waku T, Shiraki T, Oyama T, Fujimoto Y, Maebara K, Kamiya N, Jingami H, Morikawa K. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids. J. Mol. Biol. 385: 188-199 (2009). *

• Wallis RS. Reactivation of latent tuberculosis by TNF blockade: the role of interferon gamma. J. Investig. Dermatol. Symp. Proc. 12: 16-21 (2007). *

• Wang CP, Hung WC, Yu TH, Chiu CA, Lu LF, Chung FM, Hung CH, Shin SJ, Chen HJ, Lee YJ. Genetic variation in the G-50T polymorphism of the cytochrome P450 epoxygenase CYP2J2 gene and the risk of younger onset type 2 diabetes among Chinese population: potential interaction with body mass index and family history. Exp. Clin. Endocrinol. Diabetes Feb 5 [Epub ahead of print] (2010).

• Wang F, Tahara T, Arisawa T, Sakata M, Takahama K, Watanabe M, Hirata I, Nakano H. Polymorphism of peroxisome proliferator-activated receptor gamma is not associated to Japanese ulcerative colitis. Hepatogastroenterology 55: 73-75 (2008).

• Wang J, Jiang W, Gao H, He B, Liu W. Clinical and pathological characteristics of primary biliary cirrhosis. Zhonghua Gan Zang Bing Za Zhi 10: 334-337 (2002).

• Wang NY, Zhang D, Zhao W, Fang GX, Shi YL, Duan MH. Clinical application of an enzyme-linked immunosorbent assay detecting hepatoma-specific gamma-glutamyltransferase. Hepatol. Res. 39: 979-987 (2009). *

• Wang TN, Chu YT, Chen WY, Feng WW, Shih NH, Hsiang CH, Ko YC. Association of interferon-gamma and interferon regulatory factor 1 polymorphisms with asthma in a family-based association study in Taiwan. Clin. Exp. Allergy 36: 1147-1152 (2006). *

• Wang Y, Feng D, Liu G, Luo Q, Xu Y, Lin S, Fei J, Xu L. gamma-Aminobutyric acid transporter 1 negatively regulates T cell-mediated immune responses and ameliorates autoimmune inflammation in the CNS. J. Immunol. 181: 8226-8236 (2008). *

• Wang ZJ, Liu Q, Li PP, Zou CH, Shen ZF. Effect of GCP-02, a PPARalpha/gamma dual activator, on glucose and lipid metabolism in insulin-resistant mice. Eur. J. Pharmacol. 580: 277-283 (2008). *

• Wannamethee SG, Shaper AG, Lennon L, Whincup PH. Hepatic enzymes, the metabolic syndrome, and the risk of type 2 diabetes in older men. Diabetes Care 28: 2913-2918 (2005). *

• Wannamethee SG, Whincup PH, Rumley A, Lowe GD. Interrelationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J. Thromb. Haemost. 5: 1637-1643 (2007). *

• Wanty C, Joomye R, Van Hoorebeek N, Paul K, Otte JB, Reding R, Sokal EM. Fifteen years single center experience in the management of progressive familial intrahepatic cholestasis of infancy. Acta Gastroenterol. Belg. 67: 313-319 (2004).

• Washington K, Stenzel TT, Buckley RH, Gottfried MR. Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia. Am. J. Surg. Pathol. 20: 1240-1252 (1996).

• Watanabe Y, Mori S, Fujiyama S, Sato T, Mori M. Clinical evaluation of serum ornithine carbamoyltransferase by enzyme-linked immunosorbent assay in patients with liver diseases. Enzyme Protein 48: 18-26 (1995).

• Waterman EA, Gawkrodger DJ, Watson PF, Weetman AP, Kemp EH. Autoantigens in vitiligo identified by the serological selection of a phage-displayed melanocyte cDNA expression library. J. Invest. Dermatol. 130: 230-240 (2010). *

• Watine J, Friedberg B. Laboratory variables and stratification of metastatic colorectal cancer patients: recommendations for therapeutic trials and for clinical practice guidelines. Clin. Chim. Acta 345: 1-15 (2004). *

• Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, Oliver WR Jr, Willson TM, Kliewer SA, Hotamisligil GS. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J. Biol. Chem. 276: 25651-2563 (2001). *

• Way JM, Harrington WW, Brown KK, Gottschalk WK, Sundseth SS, Mansfield TA, Ramachandran RK, Willson TM, Kliewer SA. Comprehensive messenger ribonucleic acid profiling reveals that peroxisome proliferator-activated receptor gamma activation has coordinate effects on gene expression in multiple insulin-sensitive tissues. Endocrinology 142: 1269-1277 (2001). *

• Wei YS, Lan Y, Luo B, Lu D, Nong HB. Association of variants in the interleukin-27 and interleukin-12 gene with nasopharyngeal carcinoma. Mol. Carcinog. 48: 751-757 (2009). *

• Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 15: 465-489 (2001).

• Whitaker KB, Costa D, Moss DW. Selective effects of clofibrate on alkaline phosphatase isoenzymes in serum. Clin. Chim. Acta 94: 191-196 (1979).

• Whitfield JB, Zhu G, Nestler JE, Heath AC, Martin NG. Genetic covariation between serum gamma-glutamyltransferase activity and cardiovascular risk factors. Clin. Chem. 48: 1426-1431 (2002). *

• Whitington PF, Freese DK, Alonso EM, Schwarzenberg SJ, Sharp HL. Clinical and biochemical findings in progressive familial intrahepatic cholestasis. J. Pediatr. Gastroenterol. Nutr. 18: 134-141 (1994).

• Williams JM, Ben-Smith A, Hewins P, Dove SK, Hughes P, McEwan R, Wakelam MJ, Savage CO. Activation of the G(i) heterotrimeric G protein by ANCA IgG F(ab')2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG. J. Am. Soc. Nephrol. 14: 661-669 (2003). *

• Willot S, Uhlen S, Michaud L, Briand G, Bonnevalle M, Sfeir R, Gottrand F. Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia. Pediatrics 122: e1236-e1241 (2008). *

• Wirth HP, Zala G, Meyenberger C, Ammann R. Significance of subtype pattern of antimitochondrial antibodies in primary biliary cirrhosis for prognostic parameters and response to ursodeoxycholic acid. Schweiz. Med. Wochenschr. 125: 750-754 (1995).

• Wodzinska JM. Transglutaminases as targets for pharmacological inhibition. Mini. Rev. Med. Chem. 5: 279-292 (2005).

• Wohlfert EA, Nichols FC, Nevius E, Clark RB. Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J. Immunol. 178: 4129-4135 (2007). *

• Wolk K, Witte E, Warszawska K, Schulze-Tanzil G, Witte K, Philipp S, Kunz S, Docke WD, Asadullah K, Volk HD, Sterry W, Sabat R. The Th17 cytokine IL-22 induces IL-20 production in keratinocytes: a novel immunological cascade with potential relevance in psoriasis. Eur. J. Immunol. 39: 3570-3581 (2009). *

• Wright DC, Geiger PC, Han DH, Jones TE, Holloszy JO. Calcium induces increases in peroxisome proliferator-activated receptor gamma coactivator-1alpha and mitochondrial biogenesis by a pathway leading to p38 mitogen activated protein kinase activation. J. Biol. Chem. 282: 18793-18799 (2007). *

• Wright KL, Chin KC, Linhoff M, Skinner C, Brown JA, Boss JM, Stark GR, Ting JP. CIITA stimulation of transcription factor binding to major histocompatibility complex class II and associated promoters in vivo. Proc. Natl. Acad. Sci. U.S.A. 95: 6267-6272 (1998). *

• Wu F, Qu Y, Tang Y, Cao D, Sun P, Xia Z. Lack of association between cytokine gene polymorphisms and silicosis and pulmonary tuberculosis in Chinese iron miners. J. Occup. Health 50: 445-454 (2008). *

• Wu J, Alizadeh BZ, Veen TV, Meijer JW, Mulder CJ, Pena AS. Association of FAS (TNFRSF6)-670 gene polymorphism with villous atrophy in coeliac disease. World J. Gastroenterol. 10: 717-720 (2004). *

• Wu X, Liu X, Tang J. The effect of vitamin A on secretion of IFN-gamma and IL-4 in A549 cells induced by Mycoplasma pneumoniae. J. Huazhong Univ. Sci. Technolog. Med. Sci. 28: 649-652 (2008).

• Xu Y, Chen ZQ, Li YM, Gong JQ, Li AS, Chen M, Liu J. Correlation between some Th1 and Th2 cytokine receptor gene polymorphisms and systemic lupus erythematosus in Chinese patients. Int. J. Dermatol. 46: 1129-1135 (2007). *

• Yabu K, Kiyosawa K, Akahane Y, Shimakura K, Nagata A, Furuta S. A case of asymptomatic primary biliary cirrhosis with an initial presenting feature of localized gastric varices. Gastroenterol. Jpn. 18: 384-390 (1983).

• Yan HP, Zhuang H, Liu YM, Feng X, Tan YF, Liu Y, Zhang X, Zhao CH. Immunological characteristics of primary biliary cirrhosis patients. Zhonghua Gan Zang Bing Za Zhi 13: 12-16 (2005).

• Yang J, Williams RS, Kelly DP. Bcl3 interacts cooperatively with peroxisome proliferator-activated receptor gamma (PPARgamma) coactivator 1alpha to coactivate nuclear receptors estrogen-related receptor alpha and PPARalpha. Mol. Cell Biol. 29: 4091-4102 (2009). *

• Yang K, Wen J, Liu X, Kijlstra A, Chen L, Chi W, Zhou H, Huang X, Yang P. Inhibitory effect of rapamycin and dexamethasone on production of IL-17 and IFN-gamma in Vogt-Koyanagi-Harada patients. Br. J. Ophthalmol. 93: 249-253 (2009).

• Yang L, Chan CC, Kwon OS, Liu S, McGhee J, Stimpson S, Chen L, Harrington WW, Symonds W, Rockey DC. Regulation of peroxisome proliferator-activated receptor-gamma in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 291: G902-G911 (2006). *

• Yang T, Michele DE, Park J, Smart AM, Lin Z, Brosius FC 3rd, Schnermann JB, Briggs JP. Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney. Am. J. Physiol. 277: F966-F973 (1999). *

• Yao D, Xie W, Wang L. Clinical analysis of 22 patients with primary biliary cirrhosis. Zhonghua Gan Zang Bing Za Zhi 10: 344-345 (2002).

• Yao L, Li K, Zhang L, Yao S, Piao Z, Song L. Influence of the Pro12Ala polymorphism of PPAR-gamma on age at onset and sRAGE levels in Alzheimer's disease. Brain Res. 1291: 133-139 (2009).

• Yao X, Chen ZQ, Gong JQ, Chen M, Li AS, Liu J. The interferon-gamma receptor gene polymorphisms (Val14Met and Gln64Arg) are not associated with systemic lupus erythematosus in Chinese patients. Arch. Dermatol. Res. 299: 367-371 (2007). *

• Yao X, Li Y, Hu Z, Li W, Chen Z. Polymorphisms within the interferon-gamma receptor associated with systemic lupus erythematosus. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 22: 320-323 (2005).

• Yao Y, Xu ZY, Gao JP, Chen XP, Shen LJ, Yang LH, You LY, Yang JH. Liver histopathology, clinical features and prognostic factors of primary biliary cirrhosis: an analysis of 60 cases. Zhonghua Gan Zang Bing Za Zhi 16: 457-460 (2008).

• Ye D, Pan F, Zhang K, Li X, Xu J, Hao J. A novel single-nucleotide polymorphism of the Fcgamma receptor IIIa gene is associated with genetic susceptibility to systemic lupus erythematosus in Chinese populations: a family-based association study. Clin. Exp. Dermatol. 31: 553-557 (2006). *

• Ye J. Regulation of PPARgamma function by TNF-alpha. Biochem. Biophys. Res. Commun. 374: 405-408 (2008). *

• Yerushalmi B, Sokol RJ, Narkewicz MR, Smith D, Karrer FM. Use of rifampin for severe pruritus in children with chronic cholestasis. J. Pediatr. Gastroenterol. Nutr. 29: 442-447 (1999). *

• Yilmaz M, Ali Ergun M, Karakoc A, Yurtcu E, Cakir N, Arslan M. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome. Gynecol. Endocrinol. 22: 336-342 (2006).

• Yilmaz M, Ara C, Isik B, Karadag N, Yilmaz S, Polat A, Coban S, Duzova H. The effect of aminoguanidine against cholestatic liver injury in rats. Cell. Biochem. Funct. 25: 625-632 (2007). *

• Yilmaz M, Ergun MA, Karakoc A, Yurtcu E, Yetkin I, Ayvaz G, Cakir N, Arslan M. Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma gene in first-degree relatives of subjects with polycystic ovary syndrome. Gynecol. Endocrinol. 21: 206-210 (2005).

• Yilmaz V, Demirbilek V, Gurses C, Yentur SP, Uysal S, Yapici Z, Yilmaz G, Muncey A, Cokar O, Onal E, Gokyigit A, Saruhan-Direskeneli G. Interleukin (IL)-12, IL-2, interferon-gamma gene polymorphisms in subacute sclerosing panencephalitis patients. J. Neurovirol. 13: 410-415 (2007).

• Yin Y, Russell RG, Dettin LE, Bai R, Wei ZL, Kozikowski AP, Kopleovich L, Glazer RI. Peroxisome proliferator-activated receptor delta and gamma agonists differentially alter tumor differentiation and progression during mammary carcinogenesis. Cancer Res. 65: 3950-3957 (2005). *

• Yokomuro S, Arima Y, Mizuguchi Y, Shimizu T, Kawahigashi Y, Kannda T, Arai M, Uchida E, Akimaru K, Tajiri T. Mucin-producing bile duct carcinoma arising from primary sclerosing cholangitis: a case report. J. Nippon Med. Sch. 74: 61-64 (2007). *

• Yokoyama H. Gamma glutamyl transpeptidase (gammaGTP) in the era of metabolic syndrome. Nihon Arukoru Yakubutsu Igakkai Zasshi 42: 110-124 (2007).

• Yoneda M, Hotta K, Nozaki Y, Endo H, Uchiyama T, Mawatari H, Iida H, Kato S, Hosono K, Fujita K, Yoneda K, Takahashi H, Kirikoshi H, Kobayashi N, Inamori M, Abe Y, Kubota K, Saito S, Maeyama S, Wada K, Nakajima A. Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol. 8: 27 (2008). *

• Yu S, Viswakarma N, Batra SK, Sambasiva Rao M, Reddy JK. Identification of promethin and PGLP as two novel up-regulated genes in PPARgamma1-induced adipogenic mouse liver. Biochimie 86: 743-761 (2004).

• Yuan X, Waterworth D, Perry JR, Lim N, Song K, Chambers JC, Zhang W, Vollenweider P, Stirnadel H, Johnson T, Bergmann S, Beckmann ND, Li Y, Ferrucci L, Melzer D, Hernandez D, Singleton A, Scott J, Elliott P, Waeber G, Cardon L, Frayling TM, et al. Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes. Am. J. Hum. Genet. 83: 520-528 (2008). *

• Yun JW, Cho YK, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI, Son BH, Shin JH. Hepatic steatosis and fibrosis in young men with treatment-naive chronic hepatitis B. Liver Int. 29: 878-883 (2009). *

• Zachou K, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzem S, Bozkaya H, Schlaphoff V, Dienes HP, Bock TC, Manns MP, Wedemeyer H; for HIDT-1 Study Group. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int. 30: 430-437 (2010). *

• Zaima N, Sugawara T, Goto D, Hirata T. Trans geometric isomers of eicosapentaenoic acid lower LXRalpha-induced cellular triacylglycerol via suppression of sterol regulatory element binding protein-1c and peroxisome-proliferator-activated receptor-gamma co-activator 1beta. J. Lipid Res. 47: 2712-2717 (2006). *

• Zaman K, Carraro S, Doherty J, Henderson EM, Lendermon E, Liu L, Verghese G, Zigler M, Ross M, Park E, Palmer L, Doctor A, Stamler J, Gaston B. S-Nitrosylating agents: a novel class of compounds that increase cystic fibrosis transmembrane conductance regulator expression and maturation in epithelial cells. Mol. Pharmacol. 70: 1435-1442 (2006). *

• Zaripheh S, Nara TY, Nakamura MT, Erdman JW Jr. Dietary lycopene downregulates carotenoid 15,15'-monooxygenase and PPAR-gamma in selected rat tissues. J. Nutr. 136: 932-938 (2006). *

• Zavadinack Netto M, Fagundes DJ, Bandeira CO. Effects of structural injure in the bile bacterial contamination after balloon transduodenal sphincteroplasty (papillary dilation) in dogs. Acta Cir. Bras. 21: 348-353 (2006).

• Zhai D, Zhao Y, Chen X, Guo J, He H, Yu Q, Yang J, Davey AK, Wang J. Protective effect of glycyrrhizin, glycyrrhetic acid and matrine on acute cholestasis induced by alpha-naphthyl isothiocyanate in rats. Planta Med. 73: 128-133 (2007).

• Zhang A, Zhang M, Zhang J, Yu Y, Xie J. The influence of the Pro12Ala mutation of PPARgamma2 receptor gene on beta-cells restoration and insulin resistance in type 2 diabetes with hypertension. J. Huazhong Univ. Sci. Technolog. Med. Sci. 25: 648-650 (2005).

• Zhang F, Jia J, Cui R, Wang B, Wang H. Clinical features of forty patients with primary biliary cirrhosis. Chin. Med. J. (Engl.) 115: 904-908 (2002).

• Zhang F, Jia J, Wang B, Qian L, Yin S, Wang Y, Cui Y, You H, Ma H, Wang H, Zhang C. Clinical characteristics of primary biliary cirrhosis: a report of 45 cases. Zhonghua Nei Ke Za Zhi 41: 163-167 (2002).

• Zhang SL, Lu WS, Yan L, Wu MC, Xu MT, Chen LH, Cheng H. Association between peroxisome proliferator-activated receptor-gamma coactivator-1alpha gene polymorphisms and type 2 diabetes in southern Chinese population: role of altered interaction with myocyte enhancer factor 2C. Chin. Med. J. (Engl.) 120: 1878-1885 (2007).

• Zhao B, Meng LQ, Huang HN, Pan Y, Xu QQ. A novel functional polymorphism, 16974 A/C, in the interleukin-12-3' UTR is associated with risk of glioma. DNA Cell Biol. 28: 335-341 (2009).

• Zheng MQ, Tang K, Zimmerman MC, Liu L, Xie B, Rozanski GJ. Role of gamma-glutamyl transpeptidase in redox regulation of K+ channel remodeling in post-myocardial infarction rat hearts. Am. J. Physiol. Cell Physiol. 297: C253-C262 (2009). *

• Zhou C, Tabb MM, Sadatrafiei A, Grun F, Blumberg B. Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selectively regulate expression of its target genes. Drug Metab. Dispos. 32: 1075-1082 (2004). *

• Zhou GD, Li MR, Zhang J, Pan D, Zhao SX, Yang JF, Yu J, Zhao JM. Chitosan ameliorates the severity of steatohepatitis induced by high fat diet in rats. Scand. J. Gastroenterol. 43: 1371-1377 (2008). *

• Zhou L, Tang YP, Gao L, Fan XS, Liu CM, Wu DK. Separation, characterization and dose-effect relationship of the PPARgamma-activating bio-active constituents in the Chinese herb formulation 'San-Ao decoction'. Molecules 14: 3942-3951 (2009).

• Zhu DY, Wu JY, Li H, Yan JP, Guo MY, Wo YB, Lou YJ. PPAR-beta facilitating maturation of hepatic-like tissue derived from mouse embryonic stem cells accompanied by mitochondriogenesis and membrane potential retention. J. Cell. Biochem. Dec 8 [Epub ahead of print] (2009). *

• Zhu FS, Liu S, Chen XM, Huang ZG, Zhang DW. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J. Gastroenterol. 14: 6395-6400 (2008). *

• Zhu S, Liu Y, Wang X, Wu X, Zhu X, Li J, Ma J, Gu HF, Liu Y. Evaluation of the association between the PPARGC1A genetic polymorphisms and type 2 diabetes in Han Chinese population. Diabetes Res. Clin. Pract. 86: 168-172 (2009).

• Zieleniak A, Wojcik M, Wozniak LA. Structure and physiological functions of the human peroxisome proliferator-activated receptor gamma. Arch. Immunol. Ther. Exp. (Warsz.) 56: 331-345 (2008).

• Zilkens C, Friese J, Koller M, Muhr G, Schinkel C. Hepatic failure after injury - a common pathogenesis with sclerosing cholangitis? Eur. J. Med. Res. 13: 309-313 (2008).

• Zivna H, Zivny P, Palicka V, Nozicka J. The differences in selected biochemical markers and histological findings after bile duct ligation in male and female rats. Adv. Clin. Path. 5: 147-153 (2001).

• Zoepf T, Maldonado-Lopez EJ, Hilgard P, Dechene A, Malago M, Broelsch CE, Schlaak J, Gerken G. Diagnosis of biliary strictures after liver transplantation: which is the best tool? World J. Gastroenterol. 11: 2945-2948 (2005). *

Number of references = 985

www psc-literature.org